drTarget portfolio target-disease associations. Other diseases. DrTarget’s AI-Powered Indication Expansion for Other Therapeutic Areas

Expanding AI-Driven Drug Discovery Across Diverse Diseases

DrTarget’s advanced AI models and data-driven methodologies uncover novel disease-target associations beyond conventional therapeutic areas. By integrating machine learning, bioinformatics, and public repositories, we provide insights for:

✔ Rare Diseases – Identifying new therapeutic options where limited treatment exists.
✔ Multi-System Disorders – Targeting conditions with complex pathophysiology.
✔ Undiagnosed Syndromes – Leveraging AI to predict genetic and molecular associations.
✔ Emerging Therapeutic Areas – Exploring new targets for regenerative medicine, aging, and inflammation-driven diseases.

Target-disease associations for additional therapeutic areas.

Check best scored target-disease associations in table:

BioAssay Name	program	gene	assayType	diseaseName	therArea	isTherapeuticArea	associationScore	numberOfEvidences	testedCompounds	activeCompounds
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	injury	otherPhenotypes	False	0.499391027345525	20	290355	265
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	injury	otherPhenotypes	False	0.483086989535937	47	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	injury	otherPhenotypes	False	0.483086989535937	47	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	injury	otherPhenotypes	False	0.21123986929058	24	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	injury	otherPhenotypes	False	0.63920957677244	77	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	injury	otherPhenotypes	False	0.63920957677244	77	335239	695
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	injury	otherPhenotypes	False	0.568124714348561	40	339297	1446
Thrombin 1536 HTS	F2_modulation	F2	targetBased	injury	otherPhenotypes	False	0.286101829824846	27	217233	557
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	injury	otherPhenotypes	False	0.607137392360614	85	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	injury	otherPhenotypes	False	0.639553777527006	41	339772	8480
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	preeclampsia	pregnancyPerinatal	False	0.637771450291283	22	335531	328
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	preeclampsia	pregnancyPerinatal	False	0.611191772523636	20	339297	1446
Thrombin 1536 HTS	F2_modulation	F2	targetBased	preeclampsia	pregnancyPerinatal	False	0.296119827236208	95	217233	557
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	preeclampsia	pregnancyPerinatal	False	0.434804579211044	14	316642	617
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	preeclampsia	pregnancyPerinatal	False	0.301027375817204	33	343468	734
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	Sjogren syndrome	visualSystem	False	0.549959690731184	17	343468	734
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	skin disease	dermatology	False	0.245178714581563	126	376029	3978
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	skin disease	dermatology	False	0.265359438075048	119	280024	1717
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	skin disease	dermatology	False	0.279455780203757	199	217959	2390
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	skin disease	dermatology	False	0.236960469214688	50	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	skin disease	dermatology	False	0.236960469214688	50	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	DICER1	targetBased	skin disease	dermatology	False	0.219420555037864	40	46715	2829
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	skin disease	dermatology	False	0.270361455969788	266	324747	7988
qHTS of IL-2 Activators	IL2	IL2	targetBased	skin disease	dermatology	False	0.210979205308151	542	364617	238
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	skin disease	dermatology	False	0.320146194922594	300	394050	3624
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	skin disease	dermatology	False	0.303529161049536	424	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	skin disease	dermatology	False	0.303529161049536	424	195980	695
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	skin disease	dermatology	False	0.282345316069955	41	362098	692
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	skin disease	dermatology	False	0.212288110609512	95	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	skin disease	dermatology	False	0.212288110609512	95	403871	1243
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	skin disease	dermatology	False	0.213105685245471	1238	362051	17187
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	skin disease	dermatology	False	0.299211816294707	376	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	skin disease	dermatology	False	0.299211816294707	376	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	skin disease	dermatology	False	0.299211816294707	376	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	skin disease	dermatology	False	0.299211816294707	376	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	skin disease	dermatology	False	0.299211816294707	376	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	skin disease	dermatology	False	0.299211816294707	376	196177	519
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	skin disease	dermatology	False	0.243751119482949	36	369953	2294
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	skin disease	dermatology	False	0.297626545785912	1606	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	skin disease	dermatology	False	0.297626545785912	1606	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	skin disease	dermatology	False	0.297626545785912	1606	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	skin disease	dermatology	False	0.297626545785912	1606	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	skin disease	dermatology	False	0.297626545785912	1606	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	targetBased	skin disease	dermatology	False	0.308471257825776	923	356517	1139
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	skin disease	dermatology	False	0.329587928513535	6998	322361	619
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	skin disease	dermatology	False	0.266879515478918	274	369953	3080
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	skin disease	dermatology	False	0.276361079676474	12	335531	328
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	skin disease	dermatology	False	0.274700686125318	342	330392	1295
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	skin disease	dermatology	False	0.242447551201795	111	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	NOD2	targetBased	skin disease	dermatology	False	0.220631627505394	84	292323	1836
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	STAT3	pathwayBased	skin disease	dermatology	False	0.247250029172752	568	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	STAT3	pathwayBased	skin disease	dermatology	False	0.247250029172752	568	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	skin disease	dermatology	False	0.225902565308712	26	339297	1446
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	skin disease	dermatology	False	0.322939019644328	285	194628	267
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	skin disease	dermatology	False	0.308674607649173	1277	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	skin disease	dermatology	False	0.308674607649173	1277	331360	2760
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	MDM4	targetBased	skin disease	dermatology	False	0.407486117916616	18	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	skin disease	dermatology	False	0.263907930792131	431	43989	342
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	age-related macular degeneration	visualSystem	False	0.607810318811785	669	343467	1710
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	kidney disease	urinarySystem	False	0.210050553657487	16	290355	265
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	kidney disease	urinarySystem	False	0.33128920364024	487	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	kidney disease	urinarySystem	False	0.33128920364024	487	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	kidney disease	urinarySystem	False	0.248480980277369	205	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	kidney disease	urinarySystem	False	0.248480980277369	205	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	kidney disease	urinarySystem	False	0.311044934163617	155	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	targetBased	kidney disease	urinarySystem	False	0.206580836280916	43	359207	1432
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	kidney disease	urinarySystem	False	0.558942391032917	360	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	kidney disease	urinarySystem	False	0.255594330580829	21	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	kidney disease	urinarySystem	False	0.255594330580829	21	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	targetBased	kidney disease	urinarySystem	False	0.204780075373914	348	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	targetBased	kidney disease	urinarySystem	False	0.204780075373914	348	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	targetBased	kidney disease	urinarySystem	False	0.204780075373914	348	405130	6428
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	targetBased	kidney disease	urinarySystem	False	0.251922377193279	427	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	kidney disease	urinarySystem	False	0.251403089372962	212	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	kidney disease	urinarySystem	False	0.251403089372962	212	403871	1243
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	kidney disease	urinarySystem	False	0.284520337143029	309	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	kidney disease	urinarySystem	False	0.284520337143029	309	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	kidney disease	urinarySystem	False	0.284520337143029	309	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	kidney disease	urinarySystem	False	0.284520337143029	309	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	kidney disease	urinarySystem	False	0.284520337143029	309	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	kidney disease	urinarySystem	False	0.284520337143029	309	196177	519
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	kidney disease	urinarySystem	False	0.421177682283902	457	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	kidney disease	urinarySystem	False	0.421177682283902	457	305610	3253
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	kidney disease	urinarySystem	False	0.311143870587084	1063	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	kidney disease	urinarySystem	False	0.311143870587084	1063	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	kidney disease	urinarySystem	False	0.311143870587084	1063	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	kidney disease	urinarySystem	False	0.311143870587084	1063	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	kidney disease	urinarySystem	False	0.311143870587084	1063	124022	1156
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	targetBased	kidney disease	urinarySystem	False	0.408642687321529	5	292323	567
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	kidney disease	urinarySystem	False	0.251892827593123	137	125268	2463
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	kidney disease	urinarySystem	False	0.529475545353634	15	335531	328
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	kidney disease	urinarySystem	False	0.555299935898777	14	324747	813
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	kidney disease	urinarySystem	False	0.205663152563528	428	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	kidney disease	urinarySystem	False	0.264881684155334	112	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	kidney disease	urinarySystem	False	0.204797424325113	4	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	kidney disease	urinarySystem	False	0.204797424325113	4	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	kidney disease	urinarySystem	False	0.204797424325113	4	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	kidney disease	urinarySystem	False	0.204797424325113	4	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	kidney disease	urinarySystem	False	0.204797424325113	4	359207	4555
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	targetBased	kidney disease	urinarySystem	False	0.302211498367216	27	76168	1231
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	kidney disease	urinarySystem	False	0.234561533736864	139	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	kidney disease	urinarySystem	False	0.234561533736864	139	331360	2760
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	kidney disease	urinarySystem	False	0.396107483527554	49	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	kidney disease	urinarySystem	False	0.422679013753302	4	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	kidney disease	urinarySystem	False	0.298220076983693	1437	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	kidney disease	urinarySystem	False	0.229785704629033	171	343468	734
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	pregnancy	pregnancyPerinatal	False	0.613137664988923	15	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	pregnancy	pregnancyPerinatal	False	0.613137664988923	15	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	pregnancy	pregnancyPerinatal	False	0.408268776218017	9	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	pregnancy	pregnancyPerinatal	False	0.612682141130405	20	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	pregnancy	pregnancyPerinatal	False	0.612682141130405	20	335239	695
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	targetBased	pregnancy	pregnancyPerinatal	False	0.507859445482339	5	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	targetBased	pregnancy	pregnancyPerinatal	False	0.507859445482339	5	255537	2141
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	pregnancy	pregnancyPerinatal	False	0.416461875296342	6	86095	1114
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	pregnancy	pregnancyPerinatal	False	0.586792686121393	9	339297	1446
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	pregnancy	pregnancyPerinatal	False	0.612946296670552	11	324747	1043
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	pregnancy	pregnancyPerinatal	False	0.308385093781704	5	343468	734
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	FUS	targetBased	essential tremor	otherPhenotypes	False	0.749984466437818	387	385746	932
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	essential tremor	otherPhenotypes	False	0.501948282330665	41	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	essential tremor	otherPhenotypes	False	0.501948282330665	41	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	essential tremor	otherPhenotypes	False	0.501948282330665	41	407539	2380
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	Behcet's syndrome	urinarySystem	False	0.326047900071041	95	362051	17187
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ERAP1	targetBased	Behcet's syndrome	urinarySystem	False	0.360867786402803	86	335777	499
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	NOD2	targetBased	Behcet's syndrome	urinarySystem	False	0.542016081643006	30	292323	1836
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	skin pigmentation	dermatology	False	0.406474501033405	5	324747	7988
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.406014828741173	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.406014828741173	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.406014828741173	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.406014828741173	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.406014828741173	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.406014828741173	5	196177	519
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.588528225678562	8	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	ischemia reperfusion injury	otherPhenotypes	False	0.588528225678562	8	339674	2841
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	chronic kidney disease	urinarySystem	False	0.515099145760397	31	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	chronic kidney disease	urinarySystem	False	0.451939008581856	6	363803	2412
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	chronic kidney disease	urinarySystem	False	0.680879493325072	458	394050	3624
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	targetBased	chronic kidney disease	urinarySystem	False	0.289080046978868	543	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	targetBased	chronic kidney disease	urinarySystem	False	0.289080046978868	543	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	targetBased	chronic kidney disease	urinarySystem	False	0.289080046978868	543	405130	6428
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	chronic kidney disease	urinarySystem	False	0.208129806265218	202	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	chronic kidney disease	urinarySystem	False	0.208129806265218	202	403871	1243
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	chronic kidney disease	urinarySystem	False	0.434801794661345	502	362051	17187
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	chronic kidney disease	urinarySystem	False	0.597603837168746	188	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	chronic kidney disease	urinarySystem	False	0.597603837168746	188	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	chronic kidney disease	urinarySystem	False	0.597603837168746	188	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	chronic kidney disease	urinarySystem	False	0.597603837168746	188	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	chronic kidney disease	urinarySystem	False	0.597603837168746	188	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	chronic kidney disease	urinarySystem	False	0.597603837168746	188	196177	519
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	vitamin D deficiency	otherPhenotypes	False	0.66393764534113	198	394050	3624
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	chronic kidney disease	urinarySystem	False	0.487216813178942	7	335531	328
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	chronic kidney disease	urinarySystem	False	0.308260134404771	7	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	chronic kidney disease	urinarySystem	False	0.511240366697604	5	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	chronic kidney disease	urinarySystem	False	0.511240366697604	5	339674	2841
Thrombin 1536 HTS	F2_modulation	F2	targetBased	chronic kidney disease	urinarySystem	False	0.45043778054873	48	217233	557
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	chronic kidney disease	urinarySystem	False	0.436837560487006	6	195821	1625
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	chronic kidney disease	urinarySystem	False	0.510228231583128	12	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	chronic kidney disease	urinarySystem	False	0.510228231583128	12	335239	695
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	calcification	otherPhenotypes	False	0.42817028375832	14	394050	3624
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	acne	dermatology	False	0.659027038178219	60	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	acne	dermatology	False	0.659027038178219	60	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	acne	dermatology	False	0.521174640201791	8	394050	3624
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	acne	dermatology	False	0.272196880839052	162	362051	17187
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	eye disease	visualSystem	False	0.492174955124587	33	326271	221
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	eye disease	visualSystem	False	0.283713647233715	69	59788	212
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	premature birth	otherPhenotypes	False	0.419955493885449	5	394050	3624
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	premature birth	otherPhenotypes	False	0.62556973411477	24	335531	328
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	premature birth	otherPhenotypes	False	0.616021785259648	29	324747	1043
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	eye disease	visualSystem	False	0.518999582067646	50	92518	501
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	eye disease	visualSystem	False	0.498151084007504	174	339297	1446
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	eye disease	visualSystem	False	0.313185436329951	371	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	eye disease	visualSystem	False	0.313185436329951	371	314998	380
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	Keloid	dermatology	False	0.31909131377967	65	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Keloid	dermatology	False	0.31909131377967	65	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Keloid	dermatology	False	0.31909131377967	65	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Keloid	dermatology	False	0.31909131377967	65	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Keloid	dermatology	False	0.31909131377967	65	124022	1156
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	hair color	otherPhenotypes	False	0.439799357823719	5	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	hair color	otherPhenotypes	False	0.439799357823719	5	331360	2760
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	nephrolithiasis	urinarySystem	False	0.602212906787968	11	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	nephrolithiasis	urinarySystem	False	0.602212906787968	11	335239	695
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	nephrolithiasis	urinarySystem	False	0.416529493720648	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	nephrolithiasis	urinarySystem	False	0.416529493720648	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	nephrolithiasis	urinarySystem	False	0.416529493720648	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	nephrolithiasis	urinarySystem	False	0.416529493720648	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	nephrolithiasis	urinarySystem	False	0.416529493720648	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	nephrolithiasis	urinarySystem	False	0.416529493720648	6	196177	519
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	nephrolithiasis	urinarySystem	False	0.5424462695145	8	335531	328
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	nephrolithiasis	urinarySystem	False	0.502807214536861	17	195560	517
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	NFKB1	pathwayBased	membranous glomerulonephritis	urinarySystem	False	0.395701976206895	19	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	NFKB1	pathwayBased	membranous glomerulonephritis	urinarySystem	False	0.395701976206895	19	359244	3094
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	open-angle glaucoma	visualSystem	False	0.616661170668676	21	59788	212
Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression	VCAM1_expression	VCAM1	targetBased	open-angle glaucoma	visualSystem	False	0.313671851271754	6	94498	457
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	nephrotic syndrome	urinarySystem	False	0.564523814927137	122	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	nephrotic syndrome	urinarySystem	False	0.564523814927137	122	305610	3253
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	focal segmental glomerulosclerosis	urinarySystem	False	0.875186084052801	548	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	focal segmental glomerulosclerosis	urinarySystem	False	0.875186084052801	548	305610	3253
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	open-angle glaucoma	visualSystem	False	0.569561257660925	6	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	open-angle glaucoma	visualSystem	False	0.569561257660925	6	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	open-angle glaucoma	visualSystem	False	0.569561257660925	6	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	open-angle glaucoma	visualSystem	False	0.569561257660925	6	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	open-angle glaucoma	visualSystem	False	0.569561257660925	6	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	open-angle glaucoma	visualSystem	False	0.668093484041488	190	339297	1446
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	alopecia areata	dermatology	False	0.554940346190329	45	217959	2390
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	IGA glomerulonephritis	urinarySystem	False	0.488162761969075	9	394050	3624
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	IGA glomerulonephritis	urinarySystem	False	0.596885730731305	83	343468	734
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	NCOA1	targetBased	anthropometric measurement	otherPhenotypes	False	0.209862339615588	12	359206	428
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	anthropometric measurement	otherPhenotypes	False	0.42473309618221	80	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	anthropometric measurement	otherPhenotypes	False	0.42473309618221	80	86095	1151
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	CCNA2	targetBased	anthropometric measurement	otherPhenotypes	False	0.252453860982828	30	93798	679
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	anthropometric measurement	otherPhenotypes	False	0.708890420062797	443	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	anthropometric measurement	otherPhenotypes	False	0.708890420062797	443	356160	1703
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	anthropometric measurement	otherPhenotypes	False	0.338436938689333	28	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	anthropometric measurement	otherPhenotypes	False	0.338436938689333	28	330107	7652
Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide	UHRF1	UHRF1	targetBased	anthropometric measurement	otherPhenotypes	False	0.245713130983075	19	369953	2779
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist circumference	otherPhenotypes	False	0.427609784030175	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist circumference	otherPhenotypes	False	0.427609784030175	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist circumference	otherPhenotypes	False	0.427609784030175	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist circumference	otherPhenotypes	False	0.427609784030175	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist circumference	otherPhenotypes	False	0.427609784030175	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist circumference	otherPhenotypes	False	0.427609784030175	5	196177	519
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	waist circumference	otherPhenotypes	False	0.758230714129653	50	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	waist circumference	otherPhenotypes	False	0.758230714129653	50	356160	1703
Cell-based high throughput primary assay to identify activators of GPR151	GPR151	GPR151	targetBased	waist circumference	otherPhenotypes	False	0.385834311096996	8	642701	6746
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	waist circumference	otherPhenotypes	False	0.352889989684614	6	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	waist circumference	otherPhenotypes	False	0.352889989684614	6	362577	2709
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	waist-hip ratio	otherPhenotypes	False	0.229674411112822	10	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	waist-hip ratio	otherPhenotypes	False	0.229674411112822	10	296501	2737
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	targetBased	waist-hip ratio	otherPhenotypes	False	0.259831276343779	7	336894	489
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	NRP1	targetBased	waist-hip ratio	otherPhenotypes	False	0.480602875747564	6	363840	3086
qHTS for Inhibitors of Glutaminase (GLS)	GLS	GLS	targetBased	waist-hip ratio	otherPhenotypes	False	0.37441933722049	4	405291	844
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	NR5A2	targetBased	waist-hip ratio	otherPhenotypes	False	0.488929950377878	6	363803	458
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	waist-hip ratio	otherPhenotypes	False	0.322500483281187	14	305610	2592
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	PLCG1	targetBased	waist-hip ratio	otherPhenotypes	False	0.293181918989857	5	369953	3123
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist-hip ratio	otherPhenotypes	False	0.468346669186239	23	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist-hip ratio	otherPhenotypes	False	0.468346669186239	23	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist-hip ratio	otherPhenotypes	False	0.468346669186239	23	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist-hip ratio	otherPhenotypes	False	0.468346669186239	23	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist-hip ratio	otherPhenotypes	False	0.468346669186239	23	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	waist-hip ratio	otherPhenotypes	False	0.468346669186239	23	196177	519
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).	PLCB3	PLCB3	targetBased	waist-hip ratio	otherPhenotypes	False	0.271569644168848	4	369953	662
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	waist-hip ratio	otherPhenotypes	False	0.340417628874346	6	369953	3080
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	waist-hip ratio	otherPhenotypes	False	0.430819372521604	12	325630	216
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	waist-hip ratio	otherPhenotypes	False	0.482227844758901	8	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	waist-hip ratio	otherPhenotypes	False	0.482227844758901	8	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	waist-hip ratio	otherPhenotypes	False	0.220168671034291	8	88033	251
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	waist-hip ratio	otherPhenotypes	False	0.272237742541252	8	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	waist-hip ratio	otherPhenotypes	False	0.272237742541252	8	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	waist-hip ratio	otherPhenotypes	False	0.272237742541252	8	271402	1048
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	HTT	targetBased	waist-hip ratio	otherPhenotypes	False	0.342422286774199	6	189882	6790
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	HTT	targetBased	waist-hip ratio	otherPhenotypes	False	0.342422286774199	6	48068	449
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	HTT	targetBased	waist-hip ratio	otherPhenotypes	False	0.342422286774199	6	220571	2380
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	HTT	targetBased	waist-hip ratio	otherPhenotypes	False	0.342422286774199	6	223611	305
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	birth weight	otherPhenotypes	False	0.381643322384267	5	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	birth weight	otherPhenotypes	False	0.381643322384267	5	305610	1082
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	birth weight	otherPhenotypes	False	0.52265879869217	12	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	birth weight	otherPhenotypes	False	0.52265879869217	12	86095	1151
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	targetBased	birth weight	otherPhenotypes	False	0.475269165175059	12	363840	2624
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	birth weight	otherPhenotypes	False	0.469747634643608	5	639428	9218
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	birth weight	otherPhenotypes	False	0.339610170197929	8	369953	3080
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	HKDC1	targetBased	birth weight	otherPhenotypes	False	0.48638866094119	9	340696	540
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	targetBased	birth weight	otherPhenotypes	False	0.399498159724504	8	405685	308
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	birth weight	otherPhenotypes	False	0.316180877610397	6	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	birth weight	otherPhenotypes	False	0.316180877610397	6	330107	7652
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	NR2F2	targetBased	birth weight	otherPhenotypes	False	0.301281731857956	5	369953	2602
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	birth weight	otherPhenotypes	False	0.238565971737545	9	358434	2554
Inhibitors of USP1/UAF1: Primary Screen	USP1	USP1	targetBased	corneal topography	otherPhenotypes	False	0.26186294664875	5	389569	904
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.26750126300484	8	324747	7988
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	TDP2	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.511944395493285	5	369953	1241
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	PAFAH1B2	targetBased	soluble transferrin receptor measurement	otherPhenotypes	False	0.304687693242986	5	335239	4158
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	TACC3	targetBased	body height	otherPhenotypes	False	0.282405443518858	9	391179	2589
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	SLC12A5	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.259967171669807	5	189132	4127
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	body height	otherPhenotypes	False	0.289819120098109	20	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	body height	otherPhenotypes	False	0.289819120098109	20	305610	1082
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	targetBased	body height	otherPhenotypes	False	0.363645034990115	6	305610	1552
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	targetBased	body height	otherPhenotypes	False	0.363645034990115	6	343666	1267
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	targetBased	body height	otherPhenotypes	False	0.363645034990115	6	342084	3260
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.23963930667702	15	359244	2975
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.363946594349883	27	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.363946594349883	27	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.363946594349883	27	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.363946594349883	27	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.363946594349883	27	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.363946594349883	27	196177	519
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	body height	otherPhenotypes	False	0.551680303826237	14	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	body height	otherPhenotypes	False	0.551680303826237	14	64908	278
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.501543697849377	18	639428	9218
HTS Assay for Activators of Cytochrome P450 2A9	CYP2C9_activators	CYP2C9	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.316806639668977	6	95858	1368
CYP2C9 Assay	CYP2C9_inhibitors	CYP2C9	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.316806639668977	6	95858	18730
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7)	SENP7	SENP7	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.390079826677083	6	331670	4902
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	NCOA2	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.465682566865133	14	368927	620
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	alkaline phosphatase measurement	otherPhenotypes	False	0.360723659254914	5	320682	7575
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.367184847098743	6	325630	216
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.347724109587598	12	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.347724109587598	12	218234	1620
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.791261379108031	93	195560	517
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.436440300111088	138	330392	1295
CYP2C19 Assay	CYP2C19_inhibitors	CYP2C19	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.229850902481426	8	95857	20295
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.372307020947339	9	55710	315
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	NR2F2	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.265159703547402	6	369953	2602
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	alkaline phosphatase measurement	otherPhenotypes	False	0.201329560813219	29	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.201329560813219	29	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	alkaline phosphatase measurement	otherPhenotypes	False	0.201329560813219	29	271402	1048
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.279712056633989	11	358434	2554
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	body height	otherPhenotypes	False	0.206988883368495	5	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	body height	otherPhenotypes	False	0.206988883368495	5	316970	306
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	NCOA1	targetBased	body height	otherPhenotypes	False	0.206487618158866	8	359206	428
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	ABCB1	targetBased	body height	otherPhenotypes	False	0.351486743306197	5	396029	13426
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	ABCB1	targetBased	body height	otherPhenotypes	False	0.351486743306197	5	395981	5516
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	body height	otherPhenotypes	False	0.399290669777748	11	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	body height	otherPhenotypes	False	0.399290669777748	11	337446	1356
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.413205988434338	9	96879	447
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	alkaline phosphatase measurement	otherPhenotypes	False	0.413205988434338	9	96879	207
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	body height	otherPhenotypes	False	0.633664584736138	47	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	body height	otherPhenotypes	False	0.633664584736138	47	86095	1151
Identification of CBX7 inhibitors - Primary Alpha Screen	Chromobox protein homolog 7 inhibitors	CBX7	targetBased	body height	otherPhenotypes	False	0.362174025094543	6	64999	724
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	DICER1	targetBased	body height	otherPhenotypes	False	0.42809604506904	5	46715	2829
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	KLF5	targetBased	body height	otherPhenotypes	False	0.288625732058329	6	290726	671
USP10 deubiquitinase inhibition: Primary qHTS	USP10	USP10	targetBased	body height	otherPhenotypes	False	0.391193531299214	8	47480	509
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	ABCC1	targetBased	body height	otherPhenotypes	False	0.460371702635348	5	138717	842
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	targetBased	body height	otherPhenotypes	False	0.408729989189979	26	57013	201
Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity	KDM4C	KDM4C	targetBased	body height	otherPhenotypes	False	0.459495502799262	9	326066	228
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	CBX1	targetBased	body height	otherPhenotypes	False	0.26694440126891	9	383363	2142
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)	SENP6	SENP6	targetBased	body height	otherPhenotypes	False	0.397002160132385	6	330392	5817
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	body height	otherPhenotypes	False	0.313505400493152	9	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	body height	otherPhenotypes	False	0.313505400493152	9	195980	695
qHTS for Inhibitors of Glutaminase (GLS)	GLS	GLS	targetBased	body height	otherPhenotypes	False	0.46718958810713	9	405291	844
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	body height	otherPhenotypes	False	0.29068369423624	8	362098	692
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	NR5A2	targetBased	body height	otherPhenotypes	False	0.483163495277179	9	363803	458
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	body height	otherPhenotypes	False	0.487203901025279	12	305610	2592
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	PLCG1	targetBased	body height	otherPhenotypes	False	0.355540411174992	8	369953	3123
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	SMARCA4	targetBased	body height	otherPhenotypes	False	0.301333573679696	6	344733	7043
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	targetBased	body height	otherPhenotypes	False	0.224781597622353	8	359244	2975
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	body height	otherPhenotypes	False	0.490917915199672	15	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	body height	otherPhenotypes	False	0.490917915199672	15	335180	1022
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	body height	otherPhenotypes	False	0.409799828070667	5	59788	212
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	LDHA	targetBased	body height	otherPhenotypes	False	0.30716873157764	5	476056	732
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	telomere length	otherPhenotypes	False	0.650168587201349	33	322361	619
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7)	SENP7	SENP7	targetBased	body height	otherPhenotypes	False	0.28896229714988	5	331670	4902
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	body height	otherPhenotypes	False	0.448609778245131	5	86095	1114
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	body height	otherPhenotypes	False	0.267296663157418	5	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	body height	otherPhenotypes	False	0.267296663157418	5	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	body height	otherPhenotypes	False	0.267296663157418	5	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	body height	otherPhenotypes	False	0.267296663157418	5	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	body height	otherPhenotypes	False	0.267296663157418	5	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	targetBased	body height	otherPhenotypes	False	0.229707598384022	5	356517	1139
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	CCNA2	targetBased	body height	otherPhenotypes	False	0.340187030292205	8	93798	679
Primary qHTS for Inhibitors of N-terminal methyltransferase 1 (NTMT1): MTaseGlo Assay	NTMT1	NTMT1	targetBased	body height	otherPhenotypes	False	0.295885349005016	5	56440	1336
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	PIP4K2A	targetBased	body height	otherPhenotypes	False	0.413714917755547	9	328860	4078
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	targetBased	body height	otherPhenotypes	False	0.338503166872432	6	276265	806
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	body height	otherPhenotypes	False	0.301420576664249	6	369953	3080
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	body height	otherPhenotypes	False	0.203677581945685	9	125268	2463
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	body height	otherPhenotypes	False	0.427052842582739	6	325630	216
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)	ASAP1_inhibitors	ASAP1	targetBased	body height	otherPhenotypes	False	0.377969595468088	6	362577	680
Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	MMP14	targetBased	body height	otherPhenotypes	False	0.414458918129891	5	86733	537
uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	MMP14	targetBased	body height	otherPhenotypes	False	0.414458918129891	5	361500	222
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	targetBased	body height	otherPhenotypes	False	0.400291250375212	8	405685	308
Luminescent assay for HTS discovery of chemical activators of placental alkaline phosphatase	ALPG_activators	ALPG	targetBased	body height	otherPhenotypes	False	0.23186507485734	17	95729	1178
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	DAGLB	targetBased	body height	otherPhenotypes	False	0.399140657132645	5	343468	202
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	body height	otherPhenotypes	False	0.631175554191538	20	343467	1710
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	body height	otherPhenotypes	False	0.423518135232559	18	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	body height	otherPhenotypes	False	0.423518135232559	18	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	body height	otherPhenotypes	False	0.515300145843167	11	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	body height	otherPhenotypes	False	0.310656586390291	6	193542	587
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	EIF2AK3	targetBased	body height	otherPhenotypes	False	0.41891335484819	15	217959	370
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	ID4	targetBased	body height	otherPhenotypes	False	0.54316419394014	12	31324	362
uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1	PHOSPHO1	PHOSPHO1	targetBased	body height	otherPhenotypes	False	0.373433345846849	6	288321	3164
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	body height	otherPhenotypes	False	0.460359973950866	18	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	body height	otherPhenotypes	False	0.460359973950866	18	330107	7652
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	urate measurement	urinarySystem	False	0.323381753133334	6	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	urate measurement	urinarySystem	False	0.323381753133334	6	337446	1356
qHTS Assay for Inhibitors of BAZ2B	BAZ2B_modulators	BAZ2B	targetBased	urate measurement	urinarySystem	False	0.343601388924461	5	356826	15709
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	PAX8	targetBased	urate measurement	urinarySystem	False	0.479177834478971	8	353950	4145
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urate measurement	urinarySystem	False	0.446913690432228	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urate measurement	urinarySystem	False	0.446913690432228	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urate measurement	urinarySystem	False	0.446913690432228	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urate measurement	urinarySystem	False	0.446913690432228	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urate measurement	urinarySystem	False	0.446913690432228	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urate measurement	urinarySystem	False	0.446913690432228	6	196177	519
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	body height	otherPhenotypes	False	0.202046298683697	6	43989	342
Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype	MAP3K3	MAP3K3	targetBased	body height	otherPhenotypes	False	0.292623151629551	20	289573	4159
Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide	UHRF1	UHRF1	targetBased	body height	otherPhenotypes	False	0.362022074991953	14	369953	2779
uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1_inhibitors	ACP1	targetBased	body height	otherPhenotypes	False	0.324465474216306	9	363840	817
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	urate measurement	urinarySystem	False	0.370800502630873	6	324747	2221
uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1_inhibitors	ACP1	targetBased	urate measurement	urinarySystem	False	0.229645962740979	5	363840	817
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	MARVELD2	targetBased	urate measurement	urinarySystem	False	0.422917733589784	5	362274	1085
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	urate measurement	urinarySystem	False	0.398537681319208	8	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	urate measurement	urinarySystem	False	0.398537681319208	8	356160	1703
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.471784808986777	5	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.471784808986777	5	316970	306
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.303004536253504	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.303004536253504	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.303004536253504	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.303004536253504	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.303004536253504	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.303004536253504	5	196177	519
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	apolipoprotein B measurement	otherPhenotypes	False	0.229581560386425	5	358434	2554
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	urate measurement	urinarySystem	False	0.328301608992151	15	358434	2554
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	urate measurement	urinarySystem	False	0.328569110008753	11	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	urate measurement	urinarySystem	False	0.328569110008753	11	127961	1153
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.654585106434475	18	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.654585106434475	18	316970	306
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	NRP1	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.448700168606194	8	363840	3086
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3)	NCOA3	NCOA3	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.384104962843479	5	359207	620
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	cystatin C measurement	otherPhenotypes	False	0.377205114163867	5	324747	7988
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	NCOA2	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.329845184244016	5	368927	620
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.302574256980887	6	356517	1139
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	DAGLB	targetBased	apolipoprotein A 1 measurement	otherPhenotypes	False	0.372445718206003	5	343468	202
Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity	SELE	SELE	targetBased	e-selectin measurement	otherPhenotypes	False	0.27028209986146	5	257988	963
Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression	E-selectinExpression	SELE	targetBased	e-selectin measurement	otherPhenotypes	False	0.27028209986146	5	118096	843
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	cystatin C measurement	otherPhenotypes	False	0.467022760566957	6	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	cystatin C measurement	otherPhenotypes	False	0.467022760566957	6	331360	2760
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	cystatin C measurement	otherPhenotypes	False	0.343940466578324	6	358434	2554
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	liver enzyme measurement	otherPhenotypes	False	0.47097039899895	33	195560	517
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	cystatin C measurement	otherPhenotypes	False	0.346889329846495	5	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	cystatin C measurement	otherPhenotypes	False	0.346889329846495	5	127961	1153
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	vitamin B6 measurement	otherPhenotypes	False	0.488835659326561	12	195560	517
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	IGF-1 measurement	otherPhenotypes	False	0.429070650212345	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	IGF-1 measurement	otherPhenotypes	False	0.429070650212345	5	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	IGF-1 measurement	otherPhenotypes	False	0.742703261668942	36	217959	2390
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	IGF-1 measurement	otherPhenotypes	False	0.348320321180894	8	217819	5697
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	age at menarche	otherPhenotypes	False	0.254504575602592	5	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	age at menarche	otherPhenotypes	False	0.254504575602592	5	64908	278
Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity	KDM4C	KDM4C	targetBased	age at menarche	otherPhenotypes	False	0.481575508911808	6	326066	228
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	NR5A2	targetBased	age at menarche	otherPhenotypes	False	0.291008607453221	5	363803	458
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	NR5A1	targetBased	age at menarche	otherPhenotypes	False	0.268716350172229	5	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	NR5A1	targetBased	age at menarche	otherPhenotypes	False	0.268716350172229	5	64908	359
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	age at menarche	otherPhenotypes	False	0.392464566642137	5	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	age at menarche	otherPhenotypes	False	0.392464566642137	5	305610	3253
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	age at menarche	otherPhenotypes	False	0.476394265806183	5	305610	3794
Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).	NPBWR1	NPBWR1	targetBased	age at menarche	otherPhenotypes	False	0.358776742604709	5	290726	3127
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	uric acid measurement	urinarySystem	False	0.344877688561562	8	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	uric acid measurement	urinarySystem	False	0.344877688561562	8	337446	1356
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	IGF-1 measurement	otherPhenotypes	False	0.424857285873739	5	88033	251
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	IGF-1 measurement	otherPhenotypes	False	0.427094318536056	6	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	IGF-1 measurement	otherPhenotypes	False	0.427094318536056	6	369953	498
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	visceral adipose tissue measurement	otherPhenotypes	False	0.440575741841394	6	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	visceral adipose tissue measurement	otherPhenotypes	False	0.440575741841394	6	356160	1703
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	IGF-1 measurement	otherPhenotypes	False	0.293709516999477	5	96879	447
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	IGF-1 measurement	otherPhenotypes	False	0.293709516999477	5	96879	207
QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2)	PLA2G3	PLA2G3	targetBased	vitamin D measurement	otherPhenotypes	False	0.44691847836184	11	369953	2089
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype	RAB2A	RAB2A	targetBased	vitamin D measurement	otherPhenotypes	False	0.359539364526578	8	194628	365
Inhibitors of USP1/UAF1: Primary Screen	USP1	USP1	targetBased	vitamin D measurement	otherPhenotypes	False	0.209501594131452	9	389569	904
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	phospholipid measurement	otherPhenotypes	False	0.36986139083754	7	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	phospholipid measurement	otherPhenotypes	False	0.36986139083754	7	316970	306
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	age at onset	otherPhenotypes	False	0.44781143655288	6	75924	1804
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	phosphorus measurement	otherPhenotypes	False	0.41476574098901	5	195560	517
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.454582421665771	5	75924	1804
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.235218663090971	5	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.235218663090971	5	335180	1022
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.414227834727566	5	325630	216
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)	ASAP1_inhibitors	ASAP1	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.457926694171772	5	362577	680
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.426239704054639	8	343467	1710
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.496675835911215	6	88033	251
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.466546651948365	5	339297	1446
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Otitis media	pregnancyPerinatal	False	0.509737735046375	4	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Otitis media	pregnancyPerinatal	False	0.509737735046375	4	335239	695
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	targetBased	TPE interval measurement	otherPhenotypes	False	0.370315846531369	5	305610	1552
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	targetBased	TPE interval measurement	otherPhenotypes	False	0.370315846531369	5	343666	1267
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	targetBased	TPE interval measurement	otherPhenotypes	False	0.370315846531369	5	342084	3260
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	TPE interval measurement	otherPhenotypes	False	0.324623694723435	8	305610	2592
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	wet macular degeneration	visualSystem	False	0.248205364788668	68	343467	1710
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	ID4	targetBased	FEV/FVC ratio	otherPhenotypes	False	0.440553636602286	5	31324	362
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	breast size	otherPhenotypes	False	0.435010076613255	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	breast size	otherPhenotypes	False	0.435010076613255	8	86095	1151
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.612103153859535	24	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.577168330395272	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.577168330395272	6	335239	695
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.644129386558569	38	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.644129386558569	38	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.644129386558569	38	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.644129386558569	38	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.644129386558569	38	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.644129386558569	38	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.602553424206921	21	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.602553424206921	21	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.602553424206921	21	407539	2380
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.515680643226986	9	335239	2035
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.515680643226986	9	335239	279
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.612946296670552	11	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.612946296670552	11	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.612946296670552	11	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.612946296670552	11	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.612946296670552	11	359207	4555
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.515680643226986	9	64908	446
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.515680643226986	9	64908	641
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.551811421280784	5	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.551811421280784	5	339674	2841
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.519892362582376	12	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	targetBased	post operative nausea and vomiting	otherPhenotypes	False	0.519892362582376	12	61606	416
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	PABPC1	targetBased	calcium measurement	otherPhenotypes	False	0.315418551709661	5	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	PABPC1	targetBased	calcium measurement	otherPhenotypes	False	0.315418551709661	5	359244	1307
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	PAX8	targetBased	calcium measurement	otherPhenotypes	False	0.460667955309126	6	353950	4145
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	calcium measurement	otherPhenotypes	False	0.465830388828053	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	calcium measurement	otherPhenotypes	False	0.465830388828053	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	calcium measurement	otherPhenotypes	False	0.465830388828053	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	calcium measurement	otherPhenotypes	False	0.465830388828053	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	calcium measurement	otherPhenotypes	False	0.465830388828053	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	calcium measurement	otherPhenotypes	False	0.465830388828053	6	196177	519
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	calcium measurement	otherPhenotypes	False	0.295276423272554	5	86095	1114
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	calcium measurement	otherPhenotypes	False	0.44310639506669	5	125268	2463
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	calcium measurement	otherPhenotypes	False	0.59105234661804	15	195560	517
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	NR2F2	targetBased	calcium measurement	otherPhenotypes	False	0.244940624733462	5	369953	2602
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	eye measurement	visualSystem	False	0.30387673673336	18	217819	5697
High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment	PTBP1	PTBP1	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.367654316666045	11	139718	4338
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.314842730589119	9	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.314842730589119	9	64908	278
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	pathwayBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.307102870257535	5	403345	4970
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	TNFRSF10B	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.326987071799773	5	363840	3764
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	TNFSF10	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.522832199327453	11	217035	883
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.293660907122885	6	305610	2592
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.243562271154209	12	359244	2975
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.515407329254512	20	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.515407329254512	20	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.515407329254512	20	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.515407329254512	20	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.515407329254512	20	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.515407329254512	20	196177	519
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.405130482732993	5	320682	7575
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	hip circumference	otherPhenotypes	False	0.257392946763728	4	305610	2592
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hip circumference	otherPhenotypes	False	0.329066243071309	4	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hip circumference	otherPhenotypes	False	0.329066243071309	4	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hip circumference	otherPhenotypes	False	0.329066243071309	4	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hip circumference	otherPhenotypes	False	0.329066243071309	4	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hip circumference	otherPhenotypes	False	0.329066243071309	4	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hip circumference	otherPhenotypes	False	0.329066243071309	4	196177	519
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	HKDC1	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.489310468007523	9	340696	540
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	hip circumference	otherPhenotypes	False	0.376725013311045	7	320682	7575
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.43732774077386	9	330392	1295
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	DAGLB	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.34114145357088	5	343468	202
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	hip circumference	otherPhenotypes	False	0.266751004985796	5	325630	216
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.413724302881525	5	55710	315
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	hip circumference	otherPhenotypes	False	0.764439035227678	48	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	hip circumference	otherPhenotypes	False	0.764439035227678	48	356160	1703
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	NFKB1	pathwayBased	albumin:globulin ratio measurement	otherPhenotypes	False	0.291691262658331	6	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	NFKB1	pathwayBased	albumin:globulin ratio measurement	otherPhenotypes	False	0.291691262658331	6	359244	3094
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.277753403334271	9	358434	2554
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.415231618685321	12	96879	447
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	serum alanine aminotransferase measurement	otherPhenotypes	False	0.415231618685321	12	96879	207
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	TACC3	targetBased	appendicular lean mass	otherPhenotypes	False	0.228570828202111	5	391179	2589
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	appendicular lean mass	otherPhenotypes	False	0.449999559301538	14	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	appendicular lean mass	otherPhenotypes	False	0.449999559301538	14	305610	1082
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	appendicular lean mass	otherPhenotypes	False	0.315891160551468	5	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	appendicular lean mass	otherPhenotypes	False	0.315891160551468	5	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	appendicular lean mass	otherPhenotypes	False	0.490960063593444	12	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	appendicular lean mass	otherPhenotypes	False	0.490960063593444	12	86095	1151
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	targetBased	appendicular lean mass	otherPhenotypes	False	0.32333735950445	9	57013	201
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	renal system measurement	urinarySystem	False	0.281453832549736	13	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	renal system measurement	urinarySystem	False	0.281453832549736	13	337446	1356
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	PAX8	targetBased	renal system measurement	urinarySystem	False	0.382131583310538	12	353950	4145
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	lipoprotein-associated phospholipase A(2) measurement	otherPhenotypes	False	0.456842320523008	5	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	lipoprotein-associated phospholipase A(2) measurement	otherPhenotypes	False	0.456842320523008	5	316970	306
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	PLA2G7	targetBased	lipoprotein-associated phospholipase A(2) measurement	otherPhenotypes	False	0.446324331481006	8	326024	4934
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	appendicular lean mass	otherPhenotypes	False	0.409915119554358	5	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	appendicular lean mass	otherPhenotypes	False	0.409915119554358	5	403871	1243
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	appendicular lean mass	otherPhenotypes	False	0.490876025088761	9	305610	2592
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	appendicular lean mass	otherPhenotypes	False	0.439230586099382	14	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	appendicular lean mass	otherPhenotypes	False	0.439230586099382	14	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	appendicular lean mass	otherPhenotypes	False	0.445727375154298	8	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	appendicular lean mass	otherPhenotypes	False	0.445727375154298	8	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	appendicular lean mass	otherPhenotypes	False	0.445727375154298	8	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	appendicular lean mass	otherPhenotypes	False	0.445727375154298	8	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	appendicular lean mass	otherPhenotypes	False	0.445727375154298	8	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	appendicular lean mass	otherPhenotypes	False	0.445727375154298	8	196177	519
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7)	SENP7	SENP7	targetBased	appendicular lean mass	otherPhenotypes	False	0.329201021929686	5	331670	4902
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	appendicular lean mass	otherPhenotypes	False	0.301283746338818	9	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	appendicular lean mass	otherPhenotypes	False	0.301283746338818	9	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	appendicular lean mass	otherPhenotypes	False	0.301283746338818	9	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	appendicular lean mass	otherPhenotypes	False	0.301283746338818	9	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	appendicular lean mass	otherPhenotypes	False	0.301283746338818	9	124022	1156
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	MCL1	targetBased	appendicular lean mass	otherPhenotypes	False	0.204991466708098	5	314998	2139
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	MCL1	targetBased	appendicular lean mass	otherPhenotypes	False	0.204991466708098	5	218602	2129
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	MCL1	targetBased	appendicular lean mass	otherPhenotypes	False	0.204991466708098	5	217330	3334
uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1_inhibitors	ACP1	targetBased	appendicular lean mass	otherPhenotypes	False	0.243635839886729	6	363840	817
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	CCNA2	targetBased	appendicular lean mass	otherPhenotypes	False	0.220596777199403	5	93798	679
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	targetBased	appendicular lean mass	otherPhenotypes	False	0.369222257567349	6	276265	806
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	appendicular lean mass	otherPhenotypes	False	0.316841457806623	5	325630	216
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	appendicular lean mass	otherPhenotypes	False	0.666466888144041	17	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	appendicular lean mass	otherPhenotypes	False	0.666466888144041	17	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	appendicular lean mass	otherPhenotypes	False	0.412495308743252	5	88033	251
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	ID4	targetBased	appendicular lean mass	otherPhenotypes	False	0.483181233817563	5	31324	362
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	appendicular lean mass	otherPhenotypes	False	0.384191203393108	6	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	appendicular lean mass	otherPhenotypes	False	0.384191203393108	6	330107	7652
Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide	UHRF1	UHRF1	targetBased	appendicular lean mass	otherPhenotypes	False	0.256210885394125	5	369953	2779
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	glomerular filtration rate	otherPhenotypes	False	0.277887839658936	17	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	glomerular filtration rate	otherPhenotypes	False	0.277887839658936	17	305610	1082
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	glomerular filtration rate	otherPhenotypes	False	0.344025305981226	8	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	glomerular filtration rate	otherPhenotypes	False	0.344025305981226	8	337446	1356
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	glomerular filtration rate	otherPhenotypes	False	0.432836338967004	12	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	glomerular filtration rate	otherPhenotypes	False	0.432836338967004	12	403871	1243
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	PAX8	targetBased	glomerular filtration rate	otherPhenotypes	False	0.415290776181947	11	353950	4145
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	glomerular filtration rate	otherPhenotypes	False	0.42089745344178	5	88033	251
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	ATXN2	targetBased	glomerular filtration rate	otherPhenotypes	False	0.267342427352067	5	358434	2554
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	central corneal thickness	otherPhenotypes	False	0.470286209574352	6	88033	251
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	microphthalmia	visualSystem	False	0.510387699900412	12	362098	692
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.395229930503431	10	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.621738874881876	17	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.621738874881876	17	335239	695
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.404254517072409	15	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.404254517072409	15	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.404254517072409	15	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.404254517072409	15	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.404254517072409	15	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.404254517072409	15	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.392635629924812	9	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.392635629924812	9	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.392635629924812	9	407539	2380
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.221138697926778	7	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.221138697926778	7	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.221138697926778	7	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.221138697926778	7	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.221138697926778	7	359207	4555
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.541614541812703	9	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.541614541812703	9	339674	2841
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	post-operative sign or symptom	otherPhenotypes	False	0.553175059504274	7	339772	8480
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	white matter microstructure measurement	otherPhenotypes	False	0.319963694599238	17	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	white matter microstructure measurement	otherPhenotypes	False	0.319963694599238	17	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	white matter microstructure measurement	otherPhenotypes	False	0.319963694599238	17	271402	1048
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	urticaria	dermatology	False	0.487064432146504	7	394050	3624
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	urticaria	dermatology	False	0.235426510552419	51	362051	17187
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	urticaria	dermatology	False	0.546000964662808	58	217430	649
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	urticaria	dermatology	False	0.27602123406572	59	330392	1295
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	urticaria	dermatology	False	0.598573318267027	11	339297	1446
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	angioedema	dermatology	False	0.38677486134443	6	218707	302
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	angioedema	dermatology	False	0.594448014117014	64	217430	649
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	vitamin deficiency	otherPhenotypes	False	0.508869431197495	75	394050	3624
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	FEV change measurement	otherPhenotypes	False	0.257415110273261	6	217819	5697
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	cycloplegia	visualSystem	False	0.631704381295873	17	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	cycloplegia	visualSystem	False	0.631704381295873	17	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	cycloplegia	visualSystem	False	0.631704381295873	17	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	cycloplegia	visualSystem	False	0.631704381295873	17	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	cycloplegia	visualSystem	False	0.631704381295873	17	359207	4555
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	mammographic density measurement	otherPhenotypes	False	0.422058813153847	4	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	mammographic density measurement	otherPhenotypes	False	0.422058813153847	4	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	mammographic density measurement	otherPhenotypes	False	0.422058813153847	4	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	mammographic density measurement	otherPhenotypes	False	0.422058813153847	4	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	mammographic density measurement	otherPhenotypes	False	0.422058813153847	4	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	mammographic density measurement	otherPhenotypes	False	0.422058813153847	4	196177	519
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	autoimmune thrombocytopenic purpura	urinarySystem	False	0.414854529001918	8	394050	3624
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	targetBased	autoimmune thrombocytopenic purpura	urinarySystem	False	0.30655979076627	11	359244	2975
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	autoimmune thrombocytopenic purpura	urinarySystem	False	0.430864599673371	5	195821	1625
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	autoimmune thrombocytopenic purpura	urinarySystem	False	0.410477644745323	5	343468	734
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.602828840473753	32	363803	2412
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.603698410819204	33	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.603698410819204	33	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.603698410819204	33	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.603698410819204	33	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.603698410819204	33	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.603698410819204	33	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.60185244135153	30	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.60185244135153	30	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	Chemotherapy-induced nausea and vomiting	otherPhenotypes	False	0.60185244135153	30	407539	2380
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	motion sickness	otherPhenotypes	False	0.58943430842421	23	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	motion sickness	otherPhenotypes	False	0.58943430842421	23	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	motion sickness	otherPhenotypes	False	0.58943430842421	23	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	motion sickness	otherPhenotypes	False	0.58943430842421	23	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	motion sickness	otherPhenotypes	False	0.58943430842421	23	359207	4555
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	targetBased	putamen volume	otherPhenotypes	False	0.249960935211347	5	314998	2199
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	cups of coffee per day measurement	otherPhenotypes	False	0.341212175166961	5	324747	7988
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	stricture	otherPhenotypes	False	0.317964370558289	6	195821	1625
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	parental longevity	otherPhenotypes	False	0.625504964820304	18	376029	3978
USP28 deubiquitinase inhibition: Primary qHTS	USP28	USP28	targetBased	parental longevity	otherPhenotypes	False	0.201672197282028	5	47480	1413
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	traffic air pollution measurement	otherPhenotypes	False	0.390029614219042	6	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	traffic air pollution measurement	otherPhenotypes	False	0.390029614219042	6	362577	2709
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ERAP1	targetBased	endoplasmic reticulum aminopeptidase 1 measurement	otherPhenotypes	False	0.455116827241385	8	335777	499
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	TNFSF10	targetBased	TNF-related apoptosis-inducing ligand measurement	otherPhenotypes	False	0.497981243826615	11	217035	883
uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1_inhibitors	ACP1	targetBased	low molecular weight phosphotyrosine protein phosphatase measurement	otherPhenotypes	False	0.301060005537995	8	363840	817
High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment	PTBP1	PTBP1	targetBased	refractive error measurement	otherPhenotypes	False	0.429084294927106	12	139718	4338
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	refractive error measurement	otherPhenotypes	False	0.265889158040303	12	217819	5697
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)	ASAP1_inhibitors	ASAP1	targetBased	refractive error measurement	otherPhenotypes	False	0.480471725300422	12	362577	680
Inhibitors of USP1/UAF1: Primary Screen	USP1	USP1	targetBased	refractive error measurement	otherPhenotypes	False	0.297584918951866	12	389569	904
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	hair shape measurement	otherPhenotypes	False	0.474449846044225	8	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	hair shape measurement	otherPhenotypes	False	0.474449846044225	8	64908	278
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	NRP1	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.469240692436416	5	363840	3086
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	pathwayBased	urinary albumin to creatinine ratio	urinarySystem	False	0.251083264537724	5	403345	4970
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	urinary albumin to creatinine ratio	urinarySystem	False	0.365276145786241	6	324747	7988
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	urinary albumin to creatinine ratio	urinarySystem	False	0.371898634498158	5	325630	216
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7)	SENP7	SENP7	targetBased	mosaic loss of chromosome Y measurement	otherPhenotypes	False	0.342873418690793	5	331670	4902
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	mosaic loss of chromosome Y measurement	otherPhenotypes	False	0.275508901419999	5	322361	619
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.225233983664371	11	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.225233983664371	11	296501	2737
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.457910839331591	5	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.457910839331591	5	316970	306
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	targetBased	mosquito bite reaction itch intensity measurement	otherPhenotypes	False	0.321797615180481	5	67275	2509
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	targetBased	mosquito bite reaction size measurement	otherPhenotypes	False	0.343173107060091	5	67275	2509
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	hair shape measurement	otherPhenotypes	False	0.239235651232535	12	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	hair shape measurement	otherPhenotypes	False	0.239235651232535	12	218234	1620
qHTS for Inhibitors of Glutaminase (GLS)	GLS	GLS	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.4847043892695	8	405291	844
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	NR5A2	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.473694041403612	5	363803	458
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.358010667832197	23	305610	2592
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	PLCG1	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.338265357396415	6	369953	3123
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.455373889917017	6	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.455373889917017	6	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.417802154131804	23	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.417802154131804	23	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.417802154131804	23	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.417802154131804	23	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.417802154131804	23	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.417802154131804	23	196177	519
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.377770709722656	5	59788	212
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).	PLCB3	PLCB3	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.340796551597279	6	369953	662
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	BCL2L11	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.457021767051037	12	325630	216
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	DAGLB	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.306923309120446	5	343468	202
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.28648755081342	11	88033	251
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.214816560508905	5	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.214816560508905	5	362577	2709
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.350899663461228	9	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.350899663461228	9	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	BMI-adjusted waist-hip ratio	otherPhenotypes	False	0.350899663461228	9	271402	1048
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.315879226588024	8	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.315879226588024	8	305610	1082
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.4820226637374	5	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.4820226637374	5	64908	278
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	NCOA1	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.389212447928239	5	359206	428
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.28356834798405	6	57013	201
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)	SENP6	SENP6	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.318551407464665	14	330392	5817
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.370545893832637	6	305610	2592
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	T wave morphology measurement	otherPhenotypes	False	0.47651560822262	5	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	T wave morphology measurement	otherPhenotypes	False	0.47651560822262	5	305610	1082
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.450394622930665	14	88033	251
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	ID4	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.48091126242743	5	31324	362
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.308741136870007	12	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.308741136870007	12	362577	2709
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.378335959534816	9	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.378335959534816	9	330107	7652
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.394882611626788	5	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.394882611626788	5	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	BMI-adjusted waist circumference	otherPhenotypes	False	0.394882611626788	5	271402	1048
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	GNAO1	targetBased	wellbeing measurement	otherPhenotypes	False	0.40400346925466	6	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	GNAO1	targetBased	wellbeing measurement	otherPhenotypes	False	0.40400346925466	6	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	GNAO1	targetBased	wellbeing measurement	otherPhenotypes	False	0.40400346925466	6	218528	750
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	wellbeing measurement	otherPhenotypes	False	0.492860376816887	14	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	wellbeing measurement	otherPhenotypes	False	0.492860376816887	14	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	wellbeing measurement	otherPhenotypes	False	0.492860376816887	14	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	wellbeing measurement	otherPhenotypes	False	0.492860376816887	14	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	wellbeing measurement	otherPhenotypes	False	0.492860376816887	14	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	wellbeing measurement	otherPhenotypes	False	0.492860376816887	14	336308	6862
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	wellbeing measurement	otherPhenotypes	False	0.332814750744406	6	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	wellbeing measurement	otherPhenotypes	False	0.332814750744406	6	362577	2709
Assay for HTS of Gi/Go-linked GPCRs using mGluR8: Primary Screening	GRM8	GRM8	targetBased	wellbeing measurement	otherPhenotypes	False	0.427290315897987	5	105151	2166
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	caffeine metabolite measurement	otherPhenotypes	False	0.366674007824534	6	324747	7988
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	TACC3	targetBased	BMI-adjusted hip circumference	otherPhenotypes	False	0.227049619717882	6	391179	2589
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)	SENP6	SENP6	targetBased	BMI-adjusted hip circumference	otherPhenotypes	False	0.270004942561114	6	330392	5817
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	BMI-adjusted hip circumference	otherPhenotypes	False	0.31795392957652	8	305610	2592
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	ID4	targetBased	BMI-adjusted hip circumference	otherPhenotypes	False	0.472970595657331	5	31324	362
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	BMI-adjusted hip circumference	otherPhenotypes	False	0.335218889498032	5	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	ATAD5	targetBased	BMI-adjusted hip circumference	otherPhenotypes	False	0.335218889498032	5	330107	7652
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	poisoning	otherPhenotypes	False	0.57993179479527	9	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	poisoning	otherPhenotypes	False	0.57993179479527	9	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	poisoning	otherPhenotypes	False	0.57993179479527	9	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	poisoning	otherPhenotypes	False	0.57993179479527	9	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	poisoning	otherPhenotypes	False	0.57993179479527	9	359207	4555
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	age at first birth measurement	otherPhenotypes	False	0.449361477344442	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	age at first birth measurement	otherPhenotypes	False	0.449361477344442	8	86095	1151
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	corneal disease	visualSystem	False	0.487165815279255	14	326271	221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	corneal disease	visualSystem	False	0.483844529757648	13	92518	501
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	response to ivacaftor - efficacy	otherPhenotypes	False	0.634832430281935	48	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	response to ivacaftor - efficacy	otherPhenotypes	False	0.634832430281935	48	296501	2737
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	renal tubule disease	urinarySystem	False	0.251099127799368	116	125268	2463
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	prophylactic surgery	otherPhenotypes	False	0.652727389691613	42	376029	3978
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	sprain	otherPhenotypes	False	0.577168330395272	6	316642	617
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	head injury	otherPhenotypes	False	0.577168330395272	6	324747	813
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	burn	otherPhenotypes	False	0.298242330135909	5	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	burn	otherPhenotypes	False	0.513776057609053	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	burn	otherPhenotypes	False	0.513776057609053	6	335239	695
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	complication	otherPhenotypes	False	0.435492976870646	6	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	complication	otherPhenotypes	False	0.435492976870646	6	127961	1153
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	high density lipoprotein particle size measurement	otherPhenotypes	False	0.524505965232	5	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	high density lipoprotein particle size measurement	otherPhenotypes	False	0.524505965232	5	316970	306
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	complication	otherPhenotypes	False	0.335603976573174	12	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	complication	otherPhenotypes	False	0.335603976573174	12	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	complication	otherPhenotypes	False	0.335603976573174	12	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	complication	otherPhenotypes	False	0.335603976573174	12	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	complication	otherPhenotypes	False	0.335603976573174	12	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	complication	otherPhenotypes	False	0.335603976573174	12	196177	519
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	follow-up	otherPhenotypes	False	0.62497799817203	20	376029	3978
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	parp inhibitor response	otherPhenotypes	False	0.519410926301161	6	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	parp inhibitor response	otherPhenotypes	False	0.519410926301161	6	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	parp inhibitor response	otherPhenotypes	False	0.519410926301161	6	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	parp inhibitor response	otherPhenotypes	False	0.519410926301161	6	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	parp inhibitor response	otherPhenotypes	False	0.519410926301161	6	124022	1156
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	adverse effect	otherPhenotypes	False	0.538287736419724	5	339772	8480
Thrombin 1536 HTS	F2_modulation	F2	targetBased	hematoma	otherPhenotypes	False	0.286243465856943	41	217233	557
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	bilateral oophorectomy	otherPhenotypes	False	0.622760631678199	15	376029	3978
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	Calcium channel blocker use measurement	otherPhenotypes	False	0.444450609025836	8	335531	328
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	Calcium channel blocker use measurement	otherPhenotypes	False	0.426078812904908	5	339674	2841
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	shortness of breath	otherPhenotypes	False	0.386146281732799	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	shortness of breath	otherPhenotypes	False	0.386146281732799	5	335239	695
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	sitting height measurement	otherPhenotypes	False	0.442176742965162	11	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	sitting height measurement	otherPhenotypes	False	0.442176742965162	11	86095	1151
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	serum urea measurement	otherPhenotypes	False	0.393442946561304	4	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	serum urea measurement	otherPhenotypes	False	0.393442946561304	4	64908	278
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	serum urea measurement	otherPhenotypes	False	0.362679187112094	7	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	serum urea measurement	otherPhenotypes	False	0.362679187112094	7	337446	1356
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	PAX8	targetBased	serum urea measurement	otherPhenotypes	False	0.434437345774364	6	353950	4145
uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1_inhibitors	ACP1	targetBased	serum urea measurement	otherPhenotypes	False	0.249537091328612	4	363840	817
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	serum urea measurement	otherPhenotypes	False	0.442402795953413	4	125268	2463
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	sitting height measurement	otherPhenotypes	False	0.327436201893939	6	343467	1710
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	serum urea measurement	otherPhenotypes	False	0.322811325024378	4	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	serum urea measurement	otherPhenotypes	False	0.322811325024378	4	127961	1153
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	FEN1	targetBased	lysophosphatidylcholine measurement	otherPhenotypes	False	0.201067962100013	15	386270	1331
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	FEN1	targetBased	lysophosphatidylethanolamine measurement	otherPhenotypes	False	0.295776526890475	13	386270	1331
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	FEN1	targetBased	phosphatidylcholine measurement	otherPhenotypes	False	0.224691587401133	188	386270	1331
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	toxicity	otherPhenotypes	False	0.552250941038769	6	339297	1446
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	urinary system disease	urinarySystem	True	0.27048913576062	294	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	urinary system disease	urinarySystem	True	0.27048913576062	294	86095	1151
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urinary system disease	urinarySystem	True	0.248626692124667	369	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urinary system disease	urinarySystem	True	0.248626692124667	369	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urinary system disease	urinarySystem	True	0.248626692124667	369	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urinary system disease	urinarySystem	True	0.248626692124667	369	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urinary system disease	urinarySystem	True	0.248626692124667	369	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	urinary system disease	urinarySystem	True	0.248626692124667	369	196177	519
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	urinary system disease	urinarySystem	True	0.325552885614388	2093	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	urinary system disease	urinarySystem	True	0.325552885614388	2093	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	urinary system disease	urinarySystem	True	0.325552885614388	2093	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	urinary system disease	urinarySystem	True	0.325552885614388	2093	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	urinary system disease	urinarySystem	True	0.325552885614388	2093	124022	1156
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	urinary system disease	urinarySystem	True	0.237242038071052	112	316642	617
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	autosomal recessive retinitis pigmentosa	visualSystem	False	0.458193712830096	8	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	autosomal recessive retinitis pigmentosa	visualSystem	False	0.458193712830096	8	314998	380
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	transient neonatal diabetes, dominant/recessive	pregnancyPerinatal	False	0.555971773589769	33	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	INS	targetBased	transient neonatal diabetes, dominant/recessive	pregnancyPerinatal	False	0.555971773589769	33	127961	1153
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	bronchoconstriction	otherPhenotypes	False	0.512930827305237	6	339297	1446
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	TACC3	targetBased	cortical surface area measurement	otherPhenotypes	False	0.237401211378774	5	391179	2589
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	NRP1	targetBased	cortical surface area measurement	otherPhenotypes	False	0.467572870033213	5	363840	3086
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	aortic measurement	otherPhenotypes	False	0.37001604833203	8	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	aortic measurement	otherPhenotypes	False	0.37001604833203	8	335180	1022
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	phospholipids:total lipids ratio	otherPhenotypes	False	0.597188853998803	12	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	phospholipids:total lipids ratio	otherPhenotypes	False	0.597188853998803	12	316970	306
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	triglycerides:total lipids ratio	otherPhenotypes	False	0.262257688042497	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	triglycerides:total lipids ratio	otherPhenotypes	False	0.262257688042497	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	triglycerides:total lipids ratio	otherPhenotypes	False	0.262257688042497	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	triglycerides:total lipids ratio	otherPhenotypes	False	0.262257688042497	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	triglycerides:total lipids ratio	otherPhenotypes	False	0.262257688042497	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	triglycerides:total lipids ratio	otherPhenotypes	False	0.262257688042497	6	196177	519
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	ABCB1	targetBased	response to tramadol	otherPhenotypes	False	0.599617629702221	902	396029	13426
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	ABCB1	targetBased	response to tramadol	otherPhenotypes	False	0.599617629702221	902	395981	5516
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	response to tramadol	otherPhenotypes	False	0.5994368905986	695	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	response to tramadol	otherPhenotypes	False	0.5994368905986	695	335239	695
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	cortical surface area measurement	otherPhenotypes	False	0.381959141656107	5	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	MSRA	targetBased	cortical surface area measurement	otherPhenotypes	False	0.381959141656107	5	362577	2709
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	xerostomia	otherPhenotypes	False	0.602266958722854	14	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	xerostomia	otherPhenotypes	False	0.602266958722854	14	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	xerostomia	otherPhenotypes	False	0.602266958722854	14	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	xerostomia	otherPhenotypes	False	0.602266958722854	14	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	xerostomia	otherPhenotypes	False	0.602266958722854	14	359207	4555
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	ST2 protein measurement	otherPhenotypes	False	0.491638173636288	11	75924	1804
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	TNFRSF10B	targetBased	TNF-related apoptosis-inducing ligand receptor 2 measurement	otherPhenotypes	False	0.31946859278494	5	363840	3764
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	phosphate measurement	otherPhenotypes	False	0.644251002036827	30	195560	517
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	cystitis	urinarySystem	False	0.429710165341523	7	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	cystitis	urinarySystem	False	0.429710165341523	7	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Atrophy	otherPhenotypes	False	0.65174071862781	45	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Atrophy	otherPhenotypes	False	0.65174071862781	45	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	Atrophy	otherPhenotypes	False	0.615694330133837	14	86095	1114
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	Conjunctival Disorder	visualSystem	False	0.209824222571834	45	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Conjunctival Disorder	visualSystem	False	0.209824222571834	45	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Conjunctival Disorder	visualSystem	False	0.209824222571834	45	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Conjunctival Disorder	visualSystem	False	0.209824222571834	45	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Conjunctival Disorder	visualSystem	False	0.209824222571834	45	124022	1156
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ERAP1	targetBased	anterior uveitis	visualSystem	False	0.328181053089274	7	335777	499
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	hidradenitis suppurativa	dermatology	False	0.317964370558289	6	217959	2390
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	hidradenitis suppurativa	dermatology	False	0.313571053965495	56	362051	17187
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	lichen disease	dermatology	False	0.20289283870718	5	217959	2390
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	lichen planus	dermatology	False	0.223028102833648	7	217959	2390
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	dry eye syndrome	visualSystem	False	0.648755531974305	36	326271	221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	dry eye syndrome	visualSystem	False	0.637763988057418	32	92518	501
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	dry eye syndrome	visualSystem	False	0.414509515503869	41	316642	617
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	dystocia	pregnancyPerinatal	False	0.478888500634794	12	324747	1043
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	overactive bladder	urinarySystem	False	0.516503334056033	9	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	overactive bladder	urinarySystem	False	0.516503334056033	9	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	overactive bladder	urinarySystem	False	0.518182524926282	6	86095	1114
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	inflammatory skin disease	dermatology	False	0.26562338010025	67	217959	2390
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	inflammatory skin disease	dermatology	False	0.238387288710991	102	324747	7988
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	inflammatory skin disease	dermatology	False	0.2292408897402	124	394050	3624
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	targetBased	ocular hypertension	visualSystem	False	0.407953223571259	6	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	targetBased	ocular hypertension	visualSystem	False	0.407953223571259	6	255537	2141
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	ocular hypertension	visualSystem	False	0.611084615406773	21	59788	212
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	ocular hypertension	visualSystem	False	0.66025094772883	116	339297	1446
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	mastodynia	otherPhenotypes	False	0.30513940941505	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	mastodynia	otherPhenotypes	False	0.30513940941505	8	86095	1151
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Multiple Organ Failure	otherPhenotypes	False	0.285721651902045	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Multiple Organ Failure	otherPhenotypes	False	0.285721651902045	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Multiple Organ Failure	otherPhenotypes	False	0.285721651902045	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Multiple Organ Failure	otherPhenotypes	False	0.285721651902045	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Multiple Organ Failure	otherPhenotypes	False	0.285721651902045	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Multiple Organ Failure	otherPhenotypes	False	0.285721651902045	5	196177	519
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	renal colic	urinarySystem	False	0.619673100980468	18	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	renal colic	urinarySystem	False	0.619673100980468	18	335239	695
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	renal colic	urinarySystem	False	0.546604802609276	8	316642	617
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	temporal arteritis	urinarySystem	False	0.30714232349166	12	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	targetBased	nephrogenic fibrosing dermopathy	dermatology	False	0.368678188787264	6	359207	1432
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Takayasu arteritis	urinarySystem	False	0.582949705673375	9	217959	2390
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	PTK2B	targetBased	Takayasu arteritis	urinarySystem	False	0.295650791854903	5	98749	818
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	uveitis	visualSystem	False	0.364757259322338	7	217959	2390
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	uveitis	visualSystem	False	0.416752007254864	20	362051	17187
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ERAP1	targetBased	uveitis	visualSystem	False	0.314925309604335	10	335777	499
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	diabetic foot	dermatology	False	0.361634602922128	6	339297	1446
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	cold urticaria	dermatology	False	0.216352661723063	7	362051	17187
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	cold urticaria	dermatology	False	0.267964562008773	17	330392	1295
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Cleft palate	otherPhenotypes	False	0.556037572799865	6	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Cleft palate	otherPhenotypes	False	0.556037572799865	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Cleft palate	otherPhenotypes	False	0.556037572799865	6	335239	695
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	GNAO1	targetBased	Microcephaly	otherPhenotypes	False	0.284707375537465	5	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	GNAO1	targetBased	Microcephaly	otherPhenotypes	False	0.284707375537465	5	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	GNAO1	targetBased	Microcephaly	otherPhenotypes	False	0.284707375537465	5	218528	750
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Microcephaly	otherPhenotypes	False	0.510065718520128	15	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Microcephaly	otherPhenotypes	False	0.510065718520128	15	131324	544
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	RBBP8	targetBased	Microcephaly	otherPhenotypes	False	0.228352777754121	12	335214	1652
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	kidney failure	urinarySystem	False	0.493746146299483	31	394050	3624
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	kidney failure	urinarySystem	False	0.411643326219711	6	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	kidney failure	urinarySystem	False	0.411643326219711	6	305610	3253
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	kidney failure	urinarySystem	False	0.515883498499901	5	324747	813
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	kidney failure	urinarySystem	False	0.583495942944549	11	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	kidney failure	urinarySystem	False	0.583495942944549	11	339674	2841
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	kidney failure	urinarySystem	False	0.479546108594059	5	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	kidney failure	urinarySystem	False	0.479546108594059	5	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	kidney failure	urinarySystem	False	0.479546108594059	5	355805	11440
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Microcephaly	otherPhenotypes	False	0.667110376709887	110	310014	1321
Fluorescence polarization assay for PLK1 inhibitors	PLK1	PLK1	targetBased	Microcephaly	otherPhenotypes	False	0.4069952958936	6	97099	518
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	PLK1	targetBased	Microcephaly	otherPhenotypes	False	0.4069952958936	6	364065	10181
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Microcephaly	otherPhenotypes	False	0.297884758049377	45	193542	587
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	Macrocephaly	otherPhenotypes	False	0.318769626798759	30	43989	342
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	glomerular disease	urinarySystem	False	0.304158932349898	303	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	glomerular disease	urinarySystem	False	0.304158932349898	303	305610	3253
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	glomerular disease	urinarySystem	False	0.214977181740286	65	343468	734
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Abnormality of the face	otherPhenotypes	False	0.492031919640425	6	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Abnormality of the face	otherPhenotypes	False	0.492031919640425	6	131324	544
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	nephritis	urinarySystem	False	0.210073842515543	88	343468	734
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	Tinnitus	otherPhenotypes	False	0.451078858361353	36	339772	8480
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	SIX1	targetBased	Hearing impairment	earDisease	False	0.230398511082925	5	364053	2026
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	Hearing impairment	earDisease	False	0.346702200888041	6	335531	328
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Hearing impairment	earDisease	False	0.436083201832298	7	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Hearing impairment	earDisease	False	0.436083201832298	7	331360	2760
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.	RGS16	RGS16	targetBased	circadian rhythm	otherPhenotypes	False	0.388200982800723	11	218528	826
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Abnormality of the eye	otherPhenotypes	False	0.398282137783638	48	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Abnormality of the eye	otherPhenotypes	False	0.398282137783638	48	314998	380
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	odontogenesis	otherPhenotypes	False	0.379348057659862	5	305610	2592
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	Eczematoid dermatitis	otherPhenotypes	False	0.404545167875709	5	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	Eczematoid dermatitis	otherPhenotypes	False	0.404545167875709	5	64908	278
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.560883027185879	20	217959	2390
qHTS for Inhibitors of Polymerase Iota	POLI	POLI	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.272352695183272	5	386063	3989
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	KLF5	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.371620403991022	8	290726	671
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	NFKB1	pathwayBased	Eczematoid dermatitis	otherPhenotypes	False	0.422588132823189	5	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	NFKB1	pathwayBased	Eczematoid dermatitis	otherPhenotypes	False	0.422588132823189	5	359244	3094
qHTS of IL-2 Activators	IL2	IL2	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.221004590902025	10	364617	238
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.477860463929269	12	75924	1804
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	Eczematoid dermatitis	otherPhenotypes	False	0.358575190084133	4	362051	17187
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	ALOX15	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.390629689362705	5	73174	1034
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	Eczematoid dermatitis	otherPhenotypes	False	0.476384591576234	5	88033	251
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Impotence	otherPhenotypes	False	0.507138182289749	5	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Impotence	otherPhenotypes	False	0.507138182289749	5	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Impotence	otherPhenotypes	False	0.507138182289749	5	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Impotence	otherPhenotypes	False	0.507138182289749	5	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Impotence	otherPhenotypes	False	0.507138182289749	5	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Impotence	otherPhenotypes	False	0.507138182289749	5	336308	6862
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619641488098591	45	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619641488098591	45	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619641488098591	45	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619641488098591	45	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619641488098591	45	359207	4555
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619329000739565	41	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619329000739565	41	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619329000739565	41	363803	502
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619329000739565	41	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619329000739565	41	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Hyperhidrosis	otherPhenotypes	False	0.619329000739565	41	363803	1081
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Pruritus	otherPhenotypes	False	0.569007324270006	86	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Pruritus	otherPhenotypes	False	0.426759366202705	57	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Pruritus	otherPhenotypes	False	0.426759366202705	57	335239	695
CYP2C19 Assay	CYP2C19_inhibitors	CYP2C19	targetBased	response to clopidogrel	otherPhenotypes	False	0.453192849865212	5	95857	20295
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Deeply set eye	visualSystem	False	0.559554695563483	14	310014	1321
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	Pyoderma	otherPhenotypes	False	0.394463347922351	8	362051	17187
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ERAP1	targetBased	Iridocyclitis	otherPhenotypes	False	0.336927185865904	6	335777	499
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Heterochromia iridis	otherPhenotypes	False	0.375434396349102	5	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Heterochromia iridis	otherPhenotypes	False	0.375434396349102	5	331360	2760
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Abnormality of refraction	otherPhenotypes	False	0.217156787015144	5	193542	587
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	targetBased	Myopia	visualSystem	False	0.415917536706065	5	276265	806
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Myopia	visualSystem	False	0.653717988912803	71	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Myopia	visualSystem	False	0.653717988912803	71	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Myopia	visualSystem	False	0.653717988912803	71	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Myopia	visualSystem	False	0.653717988912803	71	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Myopia	visualSystem	False	0.653717988912803	71	359207	4555
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	Myopia	visualSystem	False	0.288767205076378	17	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	Myopia	visualSystem	False	0.288767205076378	17	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	Myopia	visualSystem	False	0.288767205076378	17	355805	11440
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	targetBased	Retinal dystrophy	visualSystem	False	0.346702200888041	6	326888	645
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Retinal dystrophy	visualSystem	False	0.616194342273178	116	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Retinal dystrophy	visualSystem	False	0.616194342273178	116	314998	380
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	SMARCA2	targetBased	Blepharophimosis	otherPhenotypes	False	0.295548862901082	6	368927	3838
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	Abnormality of the ear	earDisease	False	0.384670659885501	5	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	Abnormality of the ear	earDisease	False	0.384670659885501	5	305610	1082
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Abnormality of the ear	earDisease	False	0.427164331666429	6	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Abnormality of the ear	earDisease	False	0.427164331666429	6	331360	2760
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Oculomotor apraxia	visualSystem	False	0.374008774569998	6	322361	619
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	Dystonia	otherPhenotypes	False	0.366110829913765	11	320682	7575
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Dystonia	otherPhenotypes	False	0.215873278873095	193	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Dystonia	otherPhenotypes	False	0.215873278873095	193	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Dystonia	otherPhenotypes	False	0.215873278873095	193	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Dystonia	otherPhenotypes	False	0.215873278873095	193	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Dystonia	otherPhenotypes	False	0.215873278873095	193	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Dystonia	otherPhenotypes	False	0.215873278873095	193	336308	6862
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	Tremor	otherPhenotypes	False	0.408561572907551	14	339297	1446
Glucocerebrosidase	GBA1	GBA1	targetBased	Tremor	otherPhenotypes	False	0.214328598105962	9	48118	549
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Splenomegaly	otherPhenotypes	False	0.65073716130998	289	217959	2390
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Spasticity	otherPhenotypes	False	0.577168330395272	6	363803	2412
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	VCP	targetBased	Spastic paraplegia	otherPhenotypes	False	0.37565697366244	8	217959	923
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	targetBased	Failure to thrive	otherPhenotypes	False	0.467699736313683	8	359207	1432
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	Failure to thrive	otherPhenotypes	False	0.373355129801714	5	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	Failure to thrive	otherPhenotypes	False	0.373355129801714	5	195980	695
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Fever	otherPhenotypes	False	0.337757292620543	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Fever	otherPhenotypes	False	0.337757292620543	6	335239	695
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	Fever	otherPhenotypes	False	0.303867288807819	138	362051	17187
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	Fever	otherPhenotypes	False	0.28835875990853	11	330392	1295
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Fever	otherPhenotypes	False	0.666308468235629	115	316642	617
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Growth delay	otherPhenotypes	False	0.480999904716623	4	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Growth delay	otherPhenotypes	False	0.480999904716623	4	131324	544
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Hallux valgus	otherPhenotypes	False	0.368678188787264	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Hallux valgus	otherPhenotypes	False	0.368678188787264	6	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	targetBased	Weight loss	otherPhenotypes	False	0.354842707858574	5	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	targetBased	Weight loss	otherPhenotypes	False	0.354842707858574	5	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	targetBased	Weight loss	otherPhenotypes	False	0.354842707858574	5	405130	6428
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	PABPC1	targetBased	Global developmental delay	otherPhenotypes	False	0.511899646334581	8	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	PABPC1	targetBased	Global developmental delay	otherPhenotypes	False	0.511899646334581	8	359244	1307
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Global developmental delay	otherPhenotypes	False	0.286883572500183	38	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Global developmental delay	otherPhenotypes	False	0.286883572500183	38	305600	1644
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Global developmental delay	otherPhenotypes	False	0.406065542559402	5	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Global developmental delay	otherPhenotypes	False	0.406065542559402	5	131324	544
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	NSD2	targetBased	Global developmental delay	otherPhenotypes	False	0.377202104775947	23	309684	1662
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	SMARCA4	targetBased	Global developmental delay	otherPhenotypes	False	0.385858790732128	15	344733	7043
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	targetBased	Global developmental delay	otherPhenotypes	False	0.507138182289749	5	292323	567
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Global developmental delay	otherPhenotypes	False	0.51395404279331	26	310014	1321
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	VCP	targetBased	Global developmental delay	otherPhenotypes	False	0.373676317317164	6	217959	923
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Global developmental delay	otherPhenotypes	False	0.367497926162359	20	193542	587
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	Pancytopenia	otherPhenotypes	False	0.374953526355154	11	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Pancytopenia	otherPhenotypes	False	0.374953526355154	11	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Pancytopenia	otherPhenotypes	False	0.374953526355154	11	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Pancytopenia	otherPhenotypes	False	0.374953526355154	11	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Pancytopenia	otherPhenotypes	False	0.374953526355154	11	124022	1156
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	Pancytopenia	otherPhenotypes	False	0.295608355955471	13	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	Pancytopenia	otherPhenotypes	False	0.295608355955471	13	218234	1620
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	GNAO1	targetBased	Choreoathetosis	otherPhenotypes	False	0.365970634380706	8	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	GNAO1	targetBased	Choreoathetosis	otherPhenotypes	False	0.365970634380706	8	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	GNAO1	targetBased	Choreoathetosis	otherPhenotypes	False	0.365970634380706	8	218528	750
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Abnormal facial shape	otherPhenotypes	False	0.563878136093242	11	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Abnormal facial shape	otherPhenotypes	False	0.563878136093242	11	131324	544
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Nausea and vomiting	otherPhenotypes	False	0.598733175441831	31	363803	2412
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Nausea and vomiting	otherPhenotypes	False	0.644439340477792	58	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Nausea and vomiting	otherPhenotypes	False	0.644439340477792	58	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Nausea and vomiting	otherPhenotypes	False	0.644439340477792	58	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Nausea and vomiting	otherPhenotypes	False	0.644439340477792	58	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Nausea and vomiting	otherPhenotypes	False	0.644439340477792	58	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Nausea and vomiting	otherPhenotypes	False	0.644439340477792	58	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	Nausea and vomiting	otherPhenotypes	False	0.597369836744691	29	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	Nausea and vomiting	otherPhenotypes	False	0.597369836744691	29	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	Nausea and vomiting	otherPhenotypes	False	0.597369836744691	29	407539	2380
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	targetBased	Nausea and vomiting	otherPhenotypes	False	0.458258398822735	6	335239	2035
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	targetBased	Nausea and vomiting	otherPhenotypes	False	0.458258398822735	6	335239	279
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.554173663816071	11	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.554173663816071	11	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.554173663816071	11	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.554173663816071	11	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.554173663816071	11	359207	4555
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	targetBased	Nausea and vomiting	otherPhenotypes	False	0.45786959288298	5	64908	446
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	targetBased	Nausea and vomiting	otherPhenotypes	False	0.45786959288298	5	64908	641
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	targetBased	Nausea and vomiting	otherPhenotypes	False	0.459536251174901	8	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	targetBased	Nausea and vomiting	otherPhenotypes	False	0.459536251174901	8	61606	416
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Nausea	otherPhenotypes	False	0.369083899333095	8	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Nausea	otherPhenotypes	False	0.540462795734878	9	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Nausea	otherPhenotypes	False	0.540462795734878	9	335239	695
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Nausea	otherPhenotypes	False	0.59173377598045	12	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Nausea	otherPhenotypes	False	0.59173377598045	12	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Nausea	otherPhenotypes	False	0.59173377598045	12	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Nausea	otherPhenotypes	False	0.59173377598045	12	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Nausea	otherPhenotypes	False	0.59173377598045	12	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Nausea	otherPhenotypes	False	0.59173377598045	12	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	Nausea	otherPhenotypes	False	0.368678188787264	6	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	Nausea	otherPhenotypes	False	0.368678188787264	6	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	Nausea	otherPhenotypes	False	0.368678188787264	6	407539	2380
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Constipation	otherPhenotypes	False	0.609204549926413	18	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Constipation	otherPhenotypes	False	0.662629221068349	183	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Constipation	otherPhenotypes	False	0.662629221068349	183	335239	695
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	Ascites	otherPhenotypes	False	0.285823079538503	5	339297	1446
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	Renal amyloidosis	urinarySystem	False	0.204773945705563	8	330392	1295
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Hypothermia	otherPhenotypes	False	0.577168330395272	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Hypothermia	otherPhenotypes	False	0.577168330395272	6	335239	695
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	targetBased	Hypothermia	otherPhenotypes	False	0.407553147894119	6	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	targetBased	Hypothermia	otherPhenotypes	False	0.407553147894119	6	61606	416
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	targetBased	Bilateral tonic-clonic seizure	otherPhenotypes	False	0.662025642890829	123	292323	567
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	Alopecia	dermatology	False	0.406683486984603	14	343467	1710
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	Acute kidney injury	dermatology	False	0.428466124826264	29	335239	801
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	Acute kidney injury	dermatology	False	0.428466124826264	29	335238	390
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Acute kidney injury	dermatology	False	0.551811421280784	5	324747	813
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	Acute kidney injury	dermatology	False	0.37267894555866	11	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	Acute kidney injury	dermatology	False	0.37267894555866	11	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	Acute kidney injury	dermatology	False	0.37267894555866	11	355805	11440
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	Cholestasis	otherPhenotypes	False	0.511236770729013	31	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	Cholestasis	otherPhenotypes	False	0.511236770729013	31	296501	2737
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Encephalopathy	otherPhenotypes	False	0.235586557295245	173	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Encephalopathy	otherPhenotypes	False	0.235586557295245	173	305600	1644
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	GNAO1	targetBased	Encephalopathy	otherPhenotypes	False	0.306047254909039	90	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	GNAO1	targetBased	Encephalopathy	otherPhenotypes	False	0.306047254909039	90	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	GNAO1	targetBased	Encephalopathy	otherPhenotypes	False	0.306047254909039	90	218528	750
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	pathwayBased	Encephalopathy	otherPhenotypes	False	0.500700306923787	18	403345	4970
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Cholestasis	otherPhenotypes	False	0.256713347875071	6	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Cholestasis	otherPhenotypes	False	0.256713347875071	6	337446	1356
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Hepatic steatosis	otherPhenotypes	False	0.380759481697189	603	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Hepatic steatosis	otherPhenotypes	False	0.380759481697189	603	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Hepatic steatosis	otherPhenotypes	False	0.380759481697189	603	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Hepatic steatosis	otherPhenotypes	False	0.380759481697189	603	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Hepatic steatosis	otherPhenotypes	False	0.380759481697189	603	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Hepatic steatosis	otherPhenotypes	False	0.380759481697189	603	196177	519
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	Hyperkalemia	urinarySystem	False	0.553098988776931	11	339297	1446
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Hypocalcemia	otherPhenotypes	False	0.373557985074629	5	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Hypocalcemia	otherPhenotypes	False	0.373557985074629	5	337446	1356
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	Hypocalcemia	otherPhenotypes	False	0.652037636559681	45	394050	3624
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	targetBased	Hypocalcemia	otherPhenotypes	False	0.425996073123389	5	405685	308
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Hyponatremia	urinarySystem	False	0.599026253305242	24	324747	813
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Hepatomegaly	otherPhenotypes	False	0.504139263648615	7	217959	2390
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Drooling	otherPhenotypes	False	0.51539889979238	8	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Drooling	otherPhenotypes	False	0.51539889979238	8	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Drooling	otherPhenotypes	False	0.51539889979238	8	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Drooling	otherPhenotypes	False	0.51539889979238	8	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Drooling	otherPhenotypes	False	0.51539889979238	8	359207	4555
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Headache	otherPhenotypes	False	0.513896061529299	13	363803	2412
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Headache	otherPhenotypes	False	0.60183546143348	19	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Headache	otherPhenotypes	False	0.60183546143348	19	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Headache	otherPhenotypes	False	0.60183546143348	19	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Headache	otherPhenotypes	False	0.60183546143348	19	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Headache	otherPhenotypes	False	0.60183546143348	19	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Headache	otherPhenotypes	False	0.60183546143348	19	336308	6862
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Headache	otherPhenotypes	False	0.546604802609276	8	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Headache	otherPhenotypes	False	0.546604802609276	8	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Headache	otherPhenotypes	False	0.546604802609276	8	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Headache	otherPhenotypes	False	0.546604802609276	8	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Headache	otherPhenotypes	False	0.546604802609276	8	359207	4555
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	MCOLN1	targetBased	Corneal opacity	otherPhenotypes	False	0.354996727602825	5	400814	482
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Headache	otherPhenotypes	False	0.666642011690004	210	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	Headache	otherPhenotypes	False	0.529395913623577	7	339772	8480
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	pathwayBased	Leukoencephalopathy	otherPhenotypes	False	0.40633883369097	8	193714	1590
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	pathwayBased	Leukoencephalopathy	otherPhenotypes	False	0.40633883369097	8	193400	1987
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	targetBased	Leukoencephalopathy	otherPhenotypes	False	0.40633883369097	8	404343	257
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	SLC12A5	targetBased	Febrile seizure (within the age range of 3 months to 6 years)	otherPhenotypes	False	0.406668473509458	6	189132	4127
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	Abnormal brain morphology	otherPhenotypes	False	0.447968830364562	7	195821	1625
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	targetBased	Abnormal brain morphology	otherPhenotypes	False	0.365175892500371	6	104728	4230
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Short stature	otherPhenotypes	False	0.530962407119983	6	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Short stature	otherPhenotypes	False	0.530962407119983	6	131324	544
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	HKDC1	targetBased	Short stature	otherPhenotypes	False	0.386146281732799	5	340696	540
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Myokymia	otherPhenotypes	False	0.597376524444087	35	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Myokymia	otherPhenotypes	False	0.597376524444087	35	305600	1644
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	MEN1	targetBased	Abnormal circulating calcium concentration	otherPhenotypes	False	0.374009488320032	4	263421	615
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	Varicose veins	otherPhenotypes	False	0.450377266868779	8	305610	2592
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Dyspareunia	otherPhenotypes	False	0.618373164314375	42	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Dyspareunia	otherPhenotypes	False	0.618373164314375	42	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	Dyspareunia	otherPhenotypes	False	0.507138182289749	5	86095	1114
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Tip-toe gait	otherPhenotypes	False	0.560405198256835	18	322361	619
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	Ascending aortic dissection	otherPhenotypes	False	0.534016505951106	8	75924	1804
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Miscarriage	otherPhenotypes	False	0.406085264599825	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Miscarriage	otherPhenotypes	False	0.406085264599825	8	86095	1151
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Abnormal central motor function	otherPhenotypes	False	0.585049361709701	59	322361	619
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Mydriasis	otherPhenotypes	False	0.628351401578255	15	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Mydriasis	otherPhenotypes	False	0.628351401578255	15	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Mydriasis	otherPhenotypes	False	0.628351401578255	15	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Mydriasis	otherPhenotypes	False	0.628351401578255	15	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Mydriasis	otherPhenotypes	False	0.628351401578255	15	359207	4555
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Abdominal distention	otherPhenotypes	False	0.60466648961276	9	324747	813
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	Low alkaline phosphatase	otherPhenotypes	False	0.51560110774517	24	195560	517
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Myalgia	otherPhenotypes	False	0.507746748108497	5	363803	2412
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Myalgia	otherPhenotypes	False	0.610462354553215	11	316642	617
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Hot flashes	otherPhenotypes	False	0.556904492876028	15	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Hot flashes	otherPhenotypes	False	0.556904492876028	15	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	Hot flashes	otherPhenotypes	False	0.36735962951331	8	86095	1114
Thrombin 1536 HTS	F2_modulation	F2	targetBased	Disseminated intravascular coagulation	otherPhenotypes	False	0.394707829939414	168	217233	557
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Feeding difficulties	otherPhenotypes	False	0.556048555043949	12	310014	1321
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Myelofibrosis	otherPhenotypes	False	0.636911227177659	1019	217959	2390
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	Shock	otherPhenotypes	False	0.306052838601385	21	335239	801
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	Shock	otherPhenotypes	False	0.306052838601385	21	335238	390
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Shock	otherPhenotypes	False	0.491202773628467	8	324747	813
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	Shock	otherPhenotypes	False	0.633272503785782	26	339297	1446
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	PADI4	targetBased	Abnormal pulmonary interstitial morphology	otherPhenotypes	False	0.519410926301161	6	326022	1334
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	Neonatal sepsis	pregnancyPerinatal	False	0.29859225203177	12	394050	3624
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	targetBased	Abnormality of movement	otherPhenotypes	False	0.513867929573946	8	292323	567
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	Fatigue	otherPhenotypes	False	0.595643737097559	23	108286	1415
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Tics	otherPhenotypes	False	0.507341037562665	5	363803	2412
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Tics	otherPhenotypes	False	0.508640410022131	20	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Tics	otherPhenotypes	False	0.508640410022131	20	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Tics	otherPhenotypes	False	0.508640410022131	20	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Tics	otherPhenotypes	False	0.508640410022131	20	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Tics	otherPhenotypes	False	0.508640410022131	20	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Tics	otherPhenotypes	False	0.508640410022131	20	336308	6862
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	Anal fissure	otherPhenotypes	False	0.372572946778723	12	335531	328
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	Tics	otherPhenotypes	False	0.406420539287005	5	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	Tics	otherPhenotypes	False	0.406420539287005	5	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	Tics	otherPhenotypes	False	0.406420539287005	5	355805	11440
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Metrorrhagia	otherPhenotypes	False	0.368678188787264	6	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Metrorrhagia	otherPhenotypes	False	0.368678188787264	6	86095	1151
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	tonsillitis	otherPhenotypes	False	0.426198928396305	5	316642	617
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	glomerulosclerosis	urinarySystem	False	0.312497999465374	243	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	glomerulosclerosis	urinarySystem	False	0.312497999465374	243	305610	3253
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	presbyopia	visualSystem	False	0.436850285231927	24	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	presbyopia	visualSystem	False	0.436850285231927	24	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	presbyopia	visualSystem	False	0.436850285231927	24	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	presbyopia	visualSystem	False	0.436850285231927	24	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	presbyopia	visualSystem	False	0.436850285231927	24	359207	4555
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	microphthalmia, isolated, with coloboma	visualSystem	False	0.50452073307516	9	362098	692
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	hepatorenal syndrome	otherPhenotypes	False	0.583744624649583	14	324747	813
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	nephrosis	urinarySystem	False	0.245967098584481	103	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	nephrosis	urinarySystem	False	0.245967098584481	103	305610	3253
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	dyschromatosis universalis hereditaria	dermatology	False	0.556368558535973	36	362098	692
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	coloboma	visualSystem	False	0.287331256244665	17	362098	692
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	coloboma	visualSystem	False	0.451305094416274	17	639428	9218
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	familial nephrotic syndrome	urinarySystem	False	0.236820611389682	79	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	familial nephrotic syndrome	urinarySystem	False	0.236820611389682	79	305610	3253
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	targetBased	glaucoma	visualSystem	False	0.375422807302491	13	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	targetBased	glaucoma	visualSystem	False	0.375422807302491	13	255537	2141
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	glaucoma	visualSystem	False	0.467225880506445	42	59788	212
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	dermatitis	dermatology	False	0.234529948793404	72	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	dermatitis	dermatology	False	0.234529948793404	72	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	dermatitis	dermatology	False	0.305089138975381	106	217959	2390
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	dermatitis	dermatology	False	0.25375414529724	215	324747	7988
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	dermatitis	dermatology	False	0.232795540972887	173	394050	3624
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	dermatitis	dermatology	False	0.229562102821983	805	362051	17187
Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression	VCAM1_expression	VCAM1	targetBased	glaucoma	visualSystem	False	0.318193363826114	11	94498	457
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	glaucoma	visualSystem	False	0.588251384537127	9	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	glaucoma	visualSystem	False	0.588251384537127	9	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	glaucoma	visualSystem	False	0.588251384537127	9	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	glaucoma	visualSystem	False	0.588251384537127	9	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	glaucoma	visualSystem	False	0.588251384537127	9	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	glaucoma	visualSystem	False	0.667126406812208	214	339297	1446
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	dermatitis	dermatology	False	0.282033062290176	228	330392	1295
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	dermatitis	dermatology	False	0.207533995450363	83	316642	617
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	cheilitis	dermatology	False	0.305088695596821	6	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	cheilitis	dermatology	False	0.305088695596821	6	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	cheilitis	dermatology	False	0.305088695596821	6	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	cheilitis	dermatology	False	0.305088695596821	6	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	cheilitis	dermatology	False	0.305088695596821	6	124022	1156
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	glomerulonephritis	urinarySystem	False	0.453732556434279	12	394050	3624
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	LDHA	targetBased	primary hyperoxaluria	urinarySystem	False	0.426970028765515	16	476056	732
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	HPGD	targetBased	nail disorder	dermatology	False	0.23781095651942	42	148480	6428
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	atypical chronic myeloid leukemia, BCR-ABL1 negative	urinarySystem	False	0.365240918885077	5	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	atypical chronic myeloid leukemia, BCR-ABL1 negative	urinarySystem	False	0.365240918885077	5	218234	1620
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	diabetes insipidus	urinarySystem	False	0.636202273524071	20	324747	813
uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1_inhibitors	ACP1	targetBased	refractive error	visualSystem	False	0.289330141019724	7	363840	817
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	targetBased	refractive error	visualSystem	False	0.370571771152022	5	276265	806
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	refractive error	visualSystem	False	0.234727747477472	8	193542	587
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	refractive error	visualSystem	False	0.284131803905047	7	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	refractive error	visualSystem	False	0.284131803905047	7	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	refractive error	visualSystem	False	0.284131803905047	7	355805	11440
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	alopecia	dermatology	False	0.406683486984603	14	343467	1710
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	Fuchs' endothelial dystrophy	visualSystem	False	0.317964370558289	6	59788	212
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	coloboma, ocular, autosomal dominant	visualSystem	False	0.507177626370594	5	639428	9218
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Tietz syndrome	visualSystem	False	0.865119071324702	993	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Tietz syndrome	visualSystem	False	0.865119071324702	993	331360	2760
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	multiple benign circumferential skin creases on limbs	dermatology	False	0.723505147515324	25	195821	1625
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	progressive osseous heteroplasia	dermatology	False	0.829331087202839	191	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	progressive osseous heteroplasia	dermatology	False	0.829331087202839	191	337446	1356
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Waardenburg syndrome type 1	visualSystem	False	0.297097401076229	17	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Waardenburg syndrome type 1	visualSystem	False	0.297097401076229	17	331360	2760
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	progressive supranuclear palsy-parkinsonism syndrome	visualSystem	False	0.713727143151145	27	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	progressive supranuclear palsy-parkinsonism syndrome	visualSystem	False	0.713727143151145	27	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	progressive supranuclear palsy-parkinsonism syndrome	visualSystem	False	0.713727143151145	27	271402	1048
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	MCOLN1	targetBased	Lisch epithelial corneal dystrophy	visualSystem	False	0.460633610973779	6	400814	482
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	supranuclear palsy, progressive, 1	visualSystem	False	0.803558269928458	35	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	supranuclear palsy, progressive, 1	visualSystem	False	0.803558269928458	35	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	supranuclear palsy, progressive, 1	visualSystem	False	0.803558269928458	35	271402	1048
qHTS for Inhibitors of WRN Helicase	WRN	WRN	targetBased	Werner syndrome	visualSystem	False	0.907108387719303	6225	364011	1678
qHTS Assay for Identification of Novel General Anesthetics	FTL	FTL	targetBased	hereditary hyperferritinemia with congenital cataracts	visualSystem	False	0.86894222650151	294	341499	255
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	familial gestational hyperthyroidism	pregnancyPerinatal	False	0.792500474621163	45	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	familial gestational hyperthyroidism	pregnancyPerinatal	False	0.792500474621163	45	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	targetBased	familial gestational hyperthyroidism	pregnancyPerinatal	False	0.792500474621163	45	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	targetBased	familial gestational hyperthyroidism	pregnancyPerinatal	False	0.792500474621163	45	72026	1794
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	age related macular degeneration 7	visualSystem	False	0.598242739303757	8	343467	1710
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	hereditary angioedema type 3	dermatology	False	0.848320324519467	99	217430	649
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	retinitis pigmentosa 37	visualSystem	False	0.832806550013503	123	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	retinitis pigmentosa 37	visualSystem	False	0.832806550013503	123	314998	380
uHTS identification of SUMO1-mediated protein-protein interactions	SUMO1	SUMO1	targetBased	orofacial cleft 10	urinarySystem	False	0.461068579727321	26	363840	1202
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome	visualSystem	False	0.769399353712043	54	280024	1717
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	reticulate acropigmentation of Kitamura	dermatology	False	0.725807307099538	20	369953	2294
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	keratoconus	visualSystem	False	0.323894027302343	8	88033	251
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	Bartter syndrome	urinarySystem	False	0.719032633702922	260	125268	2463
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	beta-thalassemia major	urinarySystem	False	0.434114341145484	5	217959	2390
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Waardenburg syndrome	visualSystem	False	0.710068003690276	557	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Waardenburg syndrome	visualSystem	False	0.710068003690276	557	331360	2760
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	familial idiopathic steroid-resistant nephrotic syndrome	urinarySystem	False	0.707847255095907	233	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	familial idiopathic steroid-resistant nephrotic syndrome	urinarySystem	False	0.707847255095907	233	305610	3253
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	skin pigmentation disorder	dermatology	False	0.29212597239064	852	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	skin pigmentation disorder	dermatology	False	0.29212597239064	852	331360	2760
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	idiopathic nephrotic syndrome	urinarySystem	False	0.236820611389682	79	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	idiopathic nephrotic syndrome	urinarySystem	False	0.236820611389682	79	305610	3253
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	idiopathic nephrotic syndrome	urinarySystem	False	0.287890460645187	5	316642	617
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	progressive supranuclear palsy	visualSystem	False	0.732176008180037	68	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	progressive supranuclear palsy	visualSystem	False	0.732176008180037	68	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	progressive supranuclear palsy	visualSystem	False	0.732176008180037	68	271402	1048
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	exudative vitreoretinopathy	visualSystem	False	0.408763145885811	13	193542	587
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Waardenburg syndrome type 2	visualSystem	False	0.701605857510609	495	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Waardenburg syndrome type 2	visualSystem	False	0.701605857510609	495	331360	2760
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Waardenburg-Shah syndrome	visualSystem	False	0.421752784512032	28	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Waardenburg-Shah syndrome	visualSystem	False	0.421752784512032	28	331360	2760
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Leber congenital amaurosis	visualSystem	False	0.373881501669139	9	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Leber congenital amaurosis	visualSystem	False	0.373881501669139	9	314998	380
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Turner syndrome	visualSystem	False	0.606613111606686	26	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Turner syndrome	visualSystem	False	0.606613111606686	26	86095	1151
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	hereditary angioedema	dermatology	False	0.586599784505418	14	218707	302
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	hereditary angioedema	dermatology	False	0.800372299981284	87	217430	649
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	chronic renal failure syndrome	urinarySystem	False	0.595650699705387	9	394050	3624
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	atypical progressive supranuclear palsy syndrome	visualSystem	False	0.262397135210795	11	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	atypical progressive supranuclear palsy syndrome	visualSystem	False	0.262397135210795	11	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	atypical progressive supranuclear palsy syndrome	visualSystem	False	0.262397135210795	11	271402	1048
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	urolithiasis	urinarySystem	False	0.474042854334973	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	urolithiasis	urinarySystem	False	0.474042854334973	5	335239	695
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	urolithiasis	urinarySystem	False	0.479789753665931	16	195560	517
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	hypertension, pregnancy-induced	pregnancyPerinatal	False	0.477185544651013	13	339297	1446
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	hypertension, pregnancy-induced	pregnancyPerinatal	False	0.445190716285571	6	316642	617
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	HKDC1	targetBased	retinitis pigmentosa 92	visualSystem	False	0.626498224873465	11	340696	540
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Ataxia-telangiectasia	visualSystem	False	0.965192627517889	20484	322361	619
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	steroid-resistant nephrotic syndrome	urinarySystem	False	0.242943000573078	82	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	steroid-resistant nephrotic syndrome	urinarySystem	False	0.242943000573078	82	305610	3253
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	SIX1	targetBased	BOR syndrome	urinarySystem	False	0.508497845130564	95	364053	2026
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	keratinization disease	dermatology	False	0.258960333711409	22	280024	1717
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Goldmann-Favre syndrome	visualSystem	False	0.671491858896114	78	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Goldmann-Favre syndrome	visualSystem	False	0.671491858896114	78	314998	380
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Cone rod dystrophy	visualSystem	False	0.470541175200366	9	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Cone rod dystrophy	visualSystem	False	0.470541175200366	9	314998	380
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Benign familial neonatal seizures	pregnancyPerinatal	False	0.933986431041984	515	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Benign familial neonatal seizures	pregnancyPerinatal	False	0.933986431041984	515	305600	1644
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	targetBased	Beta-thalassemia	urinarySystem	False	0.317964370558289	6	143816	859
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	pathwayBased	Beta-thalassemia	urinarySystem	False	0.520897841651956	12	403345	4970
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Posterior column ataxia - retinitis pigmentosa	visualSystem	False	0.457669512229267	53	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Posterior column ataxia - retinitis pigmentosa	visualSystem	False	0.457669512229267	53	314998	380
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Familial exudative vitreoretinopathy	visualSystem	False	0.780174169924281	54	193542	587
qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)	TDP1	TDP1	targetBased	Spinocerebellar ataxia type 1 with axonal neuropathy	visualSystem	False	0.507687855850537	23	344442	978
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT	TDP1	TDP1	targetBased	Spinocerebellar ataxia type 1 with axonal neuropathy	visualSystem	False	0.507687855850537	23	416824	63248
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT	TDP1	TDP1	targetBased	Spinocerebellar ataxia type 1 with axonal neuropathy	visualSystem	False	0.507687855850537	23	416856	49238
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	Corneal intraepithelial dyskeratosis with palmoplantar hyperkeratosis and laryngeal dyskeratosis	visualSystem	False	0.7275973224838	33	280024	1717
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Conjunctival telangiectasia	visualSystem	False	0.570511616340399	6831	322361	619
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	Fuchs endothelial corneal dystrophy	visualSystem	False	0.527795610915018	9	59788	212
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	targetBased	injury	otherPhenotypes	False	0.210637796927089	9	405685	308
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	injury	otherPhenotypes	False	0.207039818830432	6	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	injury	otherPhenotypes	False	0.205030048996913	5	339674	2841
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	temporal measurement	otherPhenotypes	False	0.221483745763702	13	376029	3978
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	phenotype	otherPhenotypes	True	0.274148596179842	502	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	phenotype	otherPhenotypes	True	0.274148596179842	502	296501	2737
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	phenotype	otherPhenotypes	True	0.282933484229465	1083	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	phenotype	otherPhenotypes	True	0.282933484229465	1083	305610	1082
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	targetBased	phenotype	otherPhenotypes	True	0.293999070189601	1660	305610	1552
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	targetBased	phenotype	otherPhenotypes	True	0.293999070189601	1660	343666	1267
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	targetBased	phenotype	otherPhenotypes	True	0.293999070189601	1660	342084	3260
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	phenotype	otherPhenotypes	True	0.233401115108272	132	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	phenotype	otherPhenotypes	True	0.233401115108272	132	64908	278
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	PABPC1	targetBased	phenotype	otherPhenotypes	True	0.215833426079512	21	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	PABPC1	targetBased	phenotype	otherPhenotypes	True	0.215833426079512	21	359244	1307
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	phenotype	otherPhenotypes	True	0.279024756582729	228	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	phenotype	otherPhenotypes	True	0.279024756582729	228	305600	1644
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	phenotype	otherPhenotypes	True	0.226912439019062	770	290355	265
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	GNAO1	targetBased	phenotype	otherPhenotypes	True	0.255441825504248	114	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	GNAO1	targetBased	phenotype	otherPhenotypes	True	0.255441825504248	114	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	GNAO1	targetBased	phenotype	otherPhenotypes	True	0.255441825504248	114	218528	750
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	phenotype	otherPhenotypes	True	0.213360683476414	144	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	phenotype	otherPhenotypes	True	0.213360683476414	144	337446	1356
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	phenotype	otherPhenotypes	True	0.234801149268041	101	218707	302
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	FUS	targetBased	phenotype	otherPhenotypes	True	0.265440757044351	452	385746	932
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	phenotype	otherPhenotypes	True	0.2477138718875	1661	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	phenotype	otherPhenotypes	True	0.2477138718875	1661	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	phenotype	otherPhenotypes	True	0.281853912575745	1142	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	targetBased	phenotype	otherPhenotypes	True	0.248770211345503	158	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	phenotype	otherPhenotypes	True	0.259270215951928	196	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	phenotype	otherPhenotypes	True	0.259270215951928	196	131324	544
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	phenotype	otherPhenotypes	True	0.227717794681408	345	363803	2412
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	pathwayBased	phenotype	otherPhenotypes	True	0.231496745825067	4173	403345	4970
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	targetBased	phenotype	otherPhenotypes	True	0.21688378017553	38	315412	318
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	phenotype	otherPhenotypes	True	0.234431769046404	930	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	phenotype	otherPhenotypes	True	0.25168062231905	2176	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	phenotype	otherPhenotypes	True	0.25168062231905	2176	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	targetBased	phenotype	otherPhenotypes	True	0.217289941225415	2292	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	targetBased	phenotype	otherPhenotypes	True	0.217289941225415	2292	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	targetBased	phenotype	otherPhenotypes	True	0.217289941225415	2292	405130	6428
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	phenotype	otherPhenotypes	True	0.2377004339069	386	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	phenotype	otherPhenotypes	True	0.2377004339069	386	195980	695
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	phenotype	otherPhenotypes	True	0.222455633937215	71	75924	1804
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	phenotype	otherPhenotypes	True	0.232058314359911	135	305610	2592
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	targetBased	phenotype	otherPhenotypes	True	0.201434847312008	5	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	targetBased	phenotype	otherPhenotypes	True	0.201434847312008	5	255537	2141
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	phenotype	otherPhenotypes	True	0.24960955397132	628	335239	801
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	phenotype	otherPhenotypes	True	0.24960955397132	628	335238	390
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	phenotype	otherPhenotypes	True	0.228624677519406	18	217430	649
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	phenotype	otherPhenotypes	True	0.207692672160012	66	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	phenotype	otherPhenotypes	True	0.207692672160012	66	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	phenotype	otherPhenotypes	True	0.240206610007938	3301	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	phenotype	otherPhenotypes	True	0.240206610007938	3301	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	phenotype	otherPhenotypes	True	0.240206610007938	3301	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	phenotype	otherPhenotypes	True	0.240206610007938	3301	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	phenotype	otherPhenotypes	True	0.240206610007938	3301	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	phenotype	otherPhenotypes	True	0.240206610007938	3301	196177	519
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	RAC1	targetBased	phenotype	otherPhenotypes	True	0.210058423390649	23	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	RAC1	targetBased	phenotype	otherPhenotypes	True	0.210058423390649	23	194628	521
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	phenotype	otherPhenotypes	True	0.233603961284032	332	86095	1114
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	phenotype	otherPhenotypes	True	0.223502686126302	139	320682	7575
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	phenotype	otherPhenotypes	True	0.230355339051983	1764	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	phenotype	otherPhenotypes	True	0.230355339051983	1764	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	phenotype	otherPhenotypes	True	0.230355339051983	1764	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	phenotype	otherPhenotypes	True	0.230355339051983	1764	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	phenotype	otherPhenotypes	True	0.230355339051983	1764	124022	1156
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	pathwayBased	phenotype	otherPhenotypes	True	0.242397155379951	1514	193714	1590
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	pathwayBased	phenotype	otherPhenotypes	True	0.242397155379951	1514	193400	1987
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	targetBased	phenotype	otherPhenotypes	True	0.242397155379951	1514	404343	257
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	phenotype	otherPhenotypes	True	0.265692956809599	551	108286	1415
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	targetBased	phenotype	otherPhenotypes	True	0.280933990781892	160	292323	567
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	phenotype	otherPhenotypes	True	0.244885621282117	631	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	phenotype	otherPhenotypes	True	0.244885621282117	631	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	phenotype	otherPhenotypes	True	0.244885621282117	631	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	phenotype	otherPhenotypes	True	0.244885621282117	631	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	phenotype	otherPhenotypes	True	0.244885621282117	631	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	phenotype	otherPhenotypes	True	0.244885621282117	631	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	phenotype	otherPhenotypes	True	0.224455547251817	773	322361	619
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	phenotype	otherPhenotypes	True	0.263975468887278	134	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	phenotype	otherPhenotypes	True	0.263975468887278	134	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	phenotype	otherPhenotypes	True	0.263975468887278	134	407539	2380
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	phenotype	otherPhenotypes	True	0.256452530114953	134	335531	328
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	phenotype	otherPhenotypes	True	0.239242259129088	196	310014	1321
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	phenotype	otherPhenotypes	True	0.257715109620676	201	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	phenotype	otherPhenotypes	True	0.257715109620676	201	218234	1620
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	phenotype	otherPhenotypes	True	0.234805503066106	87	195560	517
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	VCP	targetBased	phenotype	otherPhenotypes	True	0.212132305932713	190	217959	923
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	phenotype	otherPhenotypes	True	0.231340531180729	82	343467	1710
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	phenotype	otherPhenotypes	True	0.225490906603734	122	324747	813
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	phenotype	otherPhenotypes	True	0.278368371017333	949	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	phenotype	otherPhenotypes	True	0.278368371017333	949	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	phenotype	otherPhenotypes	True	0.21710149486562	347	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	phenotype	otherPhenotypes	True	0.244838466015635	194	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	phenotype	otherPhenotypes	True	0.24956271033612	126	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	phenotype	otherPhenotypes	True	0.24956271033612	126	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	phenotype	otherPhenotypes	True	0.24956271033612	126	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	phenotype	otherPhenotypes	True	0.24956271033612	126	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	phenotype	otherPhenotypes	True	0.24956271033612	126	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	phenotype	otherPhenotypes	True	0.232932126261099	441	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	phenotype	otherPhenotypes	True	0.219421723678963	35	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	YWHAG	targetBased	phenotype	otherPhenotypes	True	0.227484234385922	21	157962	312
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	GAA	targetBased	phenotype	otherPhenotypes	True	0.226772086059321	159	199169	715
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	GAA	targetBased	phenotype	otherPhenotypes	True	0.226772086059321	159	302297	1165
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	phenotype	otherPhenotypes	True	0.242213574412319	46	339674	2841
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	phenotype	otherPhenotypes	True	0.250200632097744	71	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	phenotype	otherPhenotypes	True	0.250200632097744	71	369953	498
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	phenotype	otherPhenotypes	True	0.241727313398729	114	194628	267
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	targetBased	phenotype	otherPhenotypes	True	0.227141151686048	506	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	targetBased	phenotype	otherPhenotypes	True	0.227141151686048	506	61606	416
Thrombin 1536 HTS	F2_modulation	F2	targetBased	phenotype	otherPhenotypes	True	0.269858141245707	1570	217233	557
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	targetBased	phenotype	otherPhenotypes	True	0.218143729079937	25	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	targetBased	phenotype	otherPhenotypes	True	0.218143729079937	25	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	targetBased	phenotype	otherPhenotypes	True	0.218143729079937	25	363803	502
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	phenotype	otherPhenotypes	True	0.244892545026701	300	324747	1043
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	phenotype	otherPhenotypes	True	0.248164335525304	161	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	phenotype	otherPhenotypes	True	0.248164335525304	161	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	phenotype	otherPhenotypes	True	0.248164335525304	161	355805	11440
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	phenotype	otherPhenotypes	True	0.216344243782476	23	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	phenotype	otherPhenotypes	True	0.216344243782476	23	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	phenotype	otherPhenotypes	True	0.216344243782476	23	363803	1081
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	phenotype	otherPhenotypes	True	0.229158262000016	137	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	phenotype	otherPhenotypes	True	0.229158262000016	137	331360	2760
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	phenotype	otherPhenotypes	True	0.239117269767702	32	195821	1625
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	targetBased	phenotype	otherPhenotypes	True	0.238800748100335	64	104728	4230
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	phenotype	otherPhenotypes	True	0.248665499405983	1069	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	BLM	targetBased	phenotype	otherPhenotypes	True	0.208509737527938	24	347933	673
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	phenotype	otherPhenotypes	True	0.225001928735883	150	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	phenotype	otherPhenotypes	True	0.211319618351075	2281	43989	342
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	phenotype	otherPhenotypes	True	0.208954471656546	50	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	phenotype	otherPhenotypes	True	0.208954471656546	50	314998	380
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	measurement	otherPhenotypes	True	0.229658981947438	99	376029	3978
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	measurement	otherPhenotypes	True	0.208971899764841	166	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	measurement	otherPhenotypes	True	0.208971899764841	166	305610	1082
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	measurement	otherPhenotypes	True	0.200888928650689	100	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	measurement	otherPhenotypes	True	0.200888928650689	100	64908	278
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	measurement	otherPhenotypes	True	0.269523218251014	139	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	measurement	otherPhenotypes	True	0.269523218251014	139	316970	306
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	measurement	otherPhenotypes	True	0.22303648873161	59	218707	302
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	measurement	otherPhenotypes	True	0.24202382912981	236	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	measurement	otherPhenotypes	True	0.24202382912981	236	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	measurement	otherPhenotypes	True	0.271136588663287	684	217959	2390
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	targetBased	measurement	otherPhenotypes	True	0.21809544812416	34	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	targetBased	measurement	otherPhenotypes	True	0.21809544812416	34	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	targetBased	measurement	otherPhenotypes	True	0.21809544812416	34	405130	6428
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	targetBased	measurement	otherPhenotypes	True	0.207133322425909	91	326888	645
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	measurement	otherPhenotypes	True	0.242634924515747	54	362098	692
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	measurement	otherPhenotypes	True	0.203060622176555	39	217819	5697
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	TNFSF10	targetBased	measurement	otherPhenotypes	True	0.206604252637049	89	217035	883
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	skin disease	dermatology	False	0.224544959790179	74	326271	221
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	measurement	otherPhenotypes	True	0.245453649513999	283	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	measurement	otherPhenotypes	True	0.245453649513999	283	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	measurement	otherPhenotypes	True	0.245453649513999	283	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	measurement	otherPhenotypes	True	0.245453649513999	283	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	measurement	otherPhenotypes	True	0.245453649513999	283	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	measurement	otherPhenotypes	True	0.245453649513999	283	196177	519
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	measurement	otherPhenotypes	True	0.20172767760219	56	639428	9218
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	targetBased	skin disease	dermatology	False	0.214015133144316	40	336894	489
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	measurement	otherPhenotypes	True	0.217205216045637	100	320682	7575
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	RORC	pathwayBased	measurement	otherPhenotypes	True	0.227146242786337	18	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	RORC	targetBased	measurement	otherPhenotypes	True	0.227146242786337	18	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	RORC	pathwayBased	measurement	otherPhenotypes	True	0.227146242786337	18	305439	16717
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	skin disease	dermatology	False	0.320182813484014	159	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	skin disease	dermatology	False	0.320182813484014	159	337446	1356
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	skin disease	dermatology	False	0.21518107966079	7	218707	302
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	skin disease	dermatology	False	0.278401379725361	222	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	skin disease	dermatology	False	0.278401379725361	222	86095	1151
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	measurement	otherPhenotypes	True	0.244824555397797	109	322361	619
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	SMARCA4	targetBased	skin disease	dermatology	False	0.220482443480522	21	344733	7043
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	measurement	otherPhenotypes	True	0.216391229982294	135	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	measurement	otherPhenotypes	True	0.216391229982294	135	218234	1620
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	ALOX15	targetBased	measurement	otherPhenotypes	True	0.24916547883391	33	73174	1034
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	measurement	otherPhenotypes	True	0.245739921296175	209	330392	1295
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	measurement	otherPhenotypes	True	0.226279803403565	89	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	measurement	otherPhenotypes	True	0.226279803403565	89	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	targetBased	measurement	otherPhenotypes	True	0.226279803403565	89	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	targetBased	measurement	otherPhenotypes	True	0.226279803403565	89	72026	1794
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	measurement	otherPhenotypes	True	0.2448652479932	48	343467	1710
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	measurement	otherPhenotypes	True	0.270885538045029	449	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	measurement	otherPhenotypes	True	0.270885538045029	449	356160	1703
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	skin disease	dermatology	False	0.297951958313085	58	217430	649
E3 Ligase HTS_1536	MDM2	MDM2	targetBased	skin disease	dermatology	False	0.218106796685164	70	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	RAC1	targetBased	skin disease	dermatology	False	0.271931652316108	17	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	RAC1	targetBased	skin disease	dermatology	False	0.271931652316108	17	194628	521
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	measurement	otherPhenotypes	True	0.222224535670317	36	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	measurement	otherPhenotypes	True	0.222224535670317	36	369953	498
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	phenotype	otherPhenotypes	True	0.213601173919794	26	217819	5697
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	skin disease	dermatology	False	0.201615645793362	106	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	skin disease	dermatology	False	0.201615645793362	106	218234	1620
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	measurement	otherPhenotypes	True	0.225701578100123	56	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	measurement	otherPhenotypes	True	0.225701578100123	56	331360	2760
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	skin disease	dermatology	False	0.200572349337349	60	71016	346
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	targetBased	skin disease	dermatology	False	0.217184683660643	4	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	targetBased	skin disease	dermatology	False	0.217184683660643	4	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	targetBased	skin disease	dermatology	False	0.217184683660643	4	363803	502
qHTS for Inhibitors of WRN Helicase	WRN	WRN	targetBased	skin disease	dermatology	False	0.204928920860157	72	364011	1678
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	skin disease	dermatology	False	0.311149172204962	170	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	skin disease	dermatology	False	0.224896834131575	6	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	skin disease	dermatology	False	0.224896834131575	6	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	skin disease	dermatology	False	0.224896834131575	6	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	skin disease	dermatology	False	0.224896834131575	6	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	skin disease	dermatology	False	0.224896834131575	6	359207	4555
qHTS for Inhibitors of Polymerase Eta	POLH	POLH	targetBased	skin disease	dermatology	False	0.287679982465798	172	388717	4730
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	skin disease	dermatology	False	0.217274841559717	4	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	skin disease	dermatology	False	0.217274841559717	4	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	skin disease	dermatology	False	0.217274841559717	4	363803	1081
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	BLM	targetBased	skin disease	dermatology	False	0.317478774154975	2030	347933	673
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	targetBased	measurement	otherPhenotypes	True	0.203477829856128	79	169141	462
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	measurement	otherPhenotypes	True	0.231206633320771	73	96879	447
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	targetBased	measurement	otherPhenotypes	True	0.231206633320771	73	96879	207
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	targetBased	measurement	otherPhenotypes	True	0.256605646252661	65	217959	771
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	targetBased	measurement	otherPhenotypes	True	0.256605646252661	65	217959	569
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	measurement	otherPhenotypes	True	0.266820347911369	76	195560	517
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	PLCG1	targetBased	skin disease	dermatology	False	0.258919779650107	36	369953	3123
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	skin disease	dermatology	False	0.280816297578975	38	195821	1625
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	kidney disease	urinarySystem	False	0.206253384946291	32	324747	2221
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	NCOA2	targetBased	kidney disease	urinarySystem	False	0.20491989460268	7	368927	620
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	kidney disease	urinarySystem	False	0.209855073244622	106	322361	619
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	kidney disease	urinarySystem	False	0.258997132450383	75	71016	346
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	kidney disease	urinarySystem	False	0.205300185463701	7	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	kidney disease	urinarySystem	False	0.205437300601875	7	339674	2841
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	medical procedure	pregnancyPerinatal	True	0.219261536681742	27	376029	3978
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	sign or symptom	otherPhenotypes	False	0.223702952910628	596	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	sign or symptom	otherPhenotypes	False	0.21380820454211	19	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	sign or symptom	otherPhenotypes	False	0.224960643293984	1851	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	sign or symptom	otherPhenotypes	False	0.224960643293984	1851	335239	695
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	sign or symptom	otherPhenotypes	False	0.200661504082457	12	108286	1415
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	sign or symptom	otherPhenotypes	False	0.217097730602049	21	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	sign or symptom	otherPhenotypes	False	0.217097730602049	21	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	sign or symptom	otherPhenotypes	False	0.217097730602049	21	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	sign or symptom	otherPhenotypes	False	0.217097730602049	21	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	sign or symptom	otherPhenotypes	False	0.217097730602049	21	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	sign or symptom	otherPhenotypes	False	0.217097730602049	21	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	sign or symptom	otherPhenotypes	False	0.212493281266987	16	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	sign or symptom	otherPhenotypes	False	0.212493281266987	16	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	sign or symptom	otherPhenotypes	False	0.212493281266987	16	407539	2380
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	sign or symptom	otherPhenotypes	False	0.215524826594564	20	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	sign or symptom	otherPhenotypes	False	0.215524826594564	20	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	sign or symptom	otherPhenotypes	False	0.215524826594564	20	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	sign or symptom	otherPhenotypes	False	0.215524826594564	20	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	sign or symptom	otherPhenotypes	False	0.215524826594564	20	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	sign or symptom	otherPhenotypes	False	0.219827490199956	42	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	sign or symptom	otherPhenotypes	False	0.209923546669298	8	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	sign or symptom	otherPhenotypes	False	0.209923546669298	8	339674	2841
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	sign or symptom	otherPhenotypes	False	0.227185402580422	517	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	sign or symptom	otherPhenotypes	False	0.220862379013076	85	339772	8480
qHTS Assay for Identification of Novel General Anesthetics	FTL	FTL	targetBased	eye disease	visualSystem	False	0.28977995594375	104	341499	255
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	eye disease	visualSystem	False	0.291722767344867	84	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	eye disease	visualSystem	False	0.291722767344867	84	337446	1356
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	MCOLN1	targetBased	eye disease	visualSystem	False	0.308753278727696	525	400814	482
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	eye disease	visualSystem	False	0.281061627575314	51	280024	1717
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	eye disease	visualSystem	False	0.236807189521913	68	217959	2390
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	eye disease	visualSystem	False	0.279020461944072	30	362098	692
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	eye disease	visualSystem	False	0.28345872421107	451	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	eye disease	visualSystem	False	0.28345872421107	451	306502	1509
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	GFER	targetBased	eye disease	visualSystem	False	0.273714146187464	14	288728	10857
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	GFER	targetBased	eye disease	visualSystem	False	0.273714146187464	14	288728	10857
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	eye disease	visualSystem	False	0.204271906795391	74	639428	9218
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	eye disease	visualSystem	False	0.243288896985541	298	324747	2221
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	eye disease	visualSystem	False	0.323339127989229	6917	322361	619
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	HKDC1	targetBased	eye disease	visualSystem	False	0.21237459436633	11	340696	540
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	eye disease	visualSystem	False	0.287305442430176	29	71016	346
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	eye disease	visualSystem	False	0.270259826449272	66	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	eye disease	visualSystem	False	0.220871695391398	23	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	eye disease	visualSystem	False	0.220871695391398	23	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	eye disease	visualSystem	False	0.220871695391398	23	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	eye disease	visualSystem	False	0.220871695391398	23	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	eye disease	visualSystem	False	0.220871695391398	23	359207	4555
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	eye disease	visualSystem	False	0.268092728333054	36	194628	267
Glucocerebrosidase	GBA1	GBA1	targetBased	eye disease	visualSystem	False	0.322305630477413	1353	48118	549
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	eye disease	visualSystem	False	0.274336577807696	529	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	eye disease	visualSystem	False	0.274336577807696	529	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	eye disease	visualSystem	False	0.274336577807696	529	271402	1048
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	eye disease	visualSystem	False	0.294018014960615	933	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	eye disease	visualSystem	False	0.294018014960615	933	331360	2760
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	eye disease	visualSystem	False	0.235454814898518	302	343467	1710
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	longevity	otherPhenotypes	False	0.20823118124288	6	376029	3978
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	anthropometric measurement	otherPhenotypes	False	0.206330618411454	55	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	anthropometric measurement	otherPhenotypes	False	0.206330618411454	55	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	anthropometric measurement	otherPhenotypes	False	0.206330618411454	55	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	anthropometric measurement	otherPhenotypes	False	0.206330618411454	55	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	anthropometric measurement	otherPhenotypes	False	0.206330618411454	55	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	anthropometric measurement	otherPhenotypes	False	0.206330618411454	55	196177	519
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	anthropometric measurement	otherPhenotypes	False	0.216808094698051	20	343467	1710
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	genomic measurement	otherPhenotypes	False	0.220522686645284	13	322361	619
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	RORC	pathwayBased	liver enzyme measurement	otherPhenotypes	False	0.209825197007052	4	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	RORC	targetBased	liver enzyme measurement	otherPhenotypes	False	0.209825197007052	4	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	RORC	pathwayBased	liver enzyme measurement	otherPhenotypes	False	0.209825197007052	4	305439	16717
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	vitreous body disease	visualSystem	False	0.300203406903863	183	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	vitreous body disease	visualSystem	False	0.300203406903863	183	314998	380
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	keratitis	visualSystem	False	0.215981370294214	12	326271	221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	keratitis	visualSystem	False	0.212478116079643	11	92518	501
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	conjunctivitis	visualSystem	False	0.216465590684974	13	326271	221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	conjunctivitis	visualSystem	False	0.212392445783752	11	92518	501
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	renal tubule disease	urinarySystem	False	0.322919165184644	449	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	renal tubule disease	urinarySystem	False	0.322919165184644	449	337446	1356
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	renal tubule disease	urinarySystem	False	0.203385357827335	32	324747	2221
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	lacrimal apparatus disease	visualSystem	False	0.216058340696137	14	326271	221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	lacrimal apparatus disease	visualSystem	False	0.215033896341473	11	92518	501
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	corneal disease	visualSystem	False	0.280575679861364	31	280024	1717
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	eye adnexa disease	visualSystem	False	0.216526463387769	15	326271	221
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	eye adnexa disease	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	eye adnexa disease	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	eye adnexa disease	visualSystem	False	0.242166353923502	297	324747	2221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	eye adnexa disease	visualSystem	False	0.215272756916457	13	92518	501
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	eye adnexa disease	visualSystem	False	0.267934147735005	20	194628	267
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	eyelid disease	visualSystem	False	0.216066114727944	14	326271	221
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	eyelid disease	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	eyelid disease	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	eyelid disease	visualSystem	False	0.242166353923502	297	324747	2221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	eyelid disease	visualSystem	False	0.215197833454623	12	92518	501
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	eyelid disease	visualSystem	False	0.267684723371809	19	194628	267
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	pregnancy disorder	pregnancyPerinatal	False	0.238639999906322	10	335531	328
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	pregnancy disorder	pregnancyPerinatal	False	0.263920022224899	18	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	pregnancy disorder	pregnancyPerinatal	False	0.263920022224899	18	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	targetBased	pregnancy disorder	pregnancyPerinatal	False	0.263920022224899	18	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	targetBased	pregnancy disorder	pregnancyPerinatal	False	0.263920022224899	18	72026	1794
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	pregnancy disorder	pregnancyPerinatal	False	0.207151207169385	13	339297	1446
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	puerperal disorder	pregnancyPerinatal	False	0.2234939334885	36	324747	1043
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	urinary system disease	urinarySystem	True	0.253062605621121	61	376029	3978
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	urinary system disease	urinarySystem	True	0.330058650266577	556	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	urinary system disease	urinarySystem	True	0.330058650266577	556	337446	1356
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	urinary system disease	urinarySystem	True	0.272885783802447	176	217959	2390
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	urinary system disease	urinarySystem	True	0.212796570868195	61	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	urinary system disease	urinarySystem	True	0.212796570868195	61	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	DICER1	targetBased	urinary system disease	urinarySystem	True	0.243512961322434	96	46715	2829
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	urinary system disease	urinarySystem	True	0.233153560162444	385	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	urinary system disease	urinarySystem	True	0.221343708770663	20	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	urinary system disease	urinarySystem	True	0.221343708770663	20	335239	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	targetBased	urinary system disease	urinarySystem	True	0.250398735099291	440	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	urinary system disease	urinarySystem	True	0.256937163214503	230	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	urinary system disease	urinarySystem	True	0.256937163214503	230	403871	1243
qHTS for Inhibitors of Polymerase Kappa	POLK	POLK	targetBased	urinary system disease	urinarySystem	True	0.207337116169609	11	395295	2034
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	SIX1	targetBased	urinary system disease	urinarySystem	True	0.236936460500531	48	364053	2026
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	urinary system disease	urinarySystem	True	0.29806660386618	429	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	urinary system disease	urinarySystem	True	0.29806660386618	429	305610	3253
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	urinary system disease	urinarySystem	True	0.247694604438599	40	324747	2221
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	urinary system disease	urinarySystem	True	0.216102383776006	82	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	NCOA2	targetBased	urinary system disease	urinarySystem	True	0.214331966927032	10	368927	620
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	urinary system disease	urinarySystem	True	0.286459320563299	174	322361	619
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	urinary system disease	urinarySystem	True	0.252301220512274	139	125268	2463
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	urinary system disease	urinarySystem	True	0.260696168490879	82	71016	346
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	PSIP1	targetBased	urinary system disease	urinarySystem	True	0.211014322964064	23	369953	2353
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	urinary system disease	urinarySystem	True	0.218420417823048	13	324747	813
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	urinary system disease	urinarySystem	True	0.219306968167222	428	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	urinary system disease	urinarySystem	True	0.277768187042269	159	193542	587
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	urinary system disease	urinarySystem	True	0.205308637766739	8	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	urinary system disease	urinarySystem	True	0.205493649288796	7	339674	2841
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	urinary system disease	urinarySystem	True	0.294899242780575	164	194628	267
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	urinary system disease	urinarySystem	True	0.206097760545633	153	195821	1625
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	urinary system disease	urinarySystem	True	0.279549165177453	1600	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	targetBased	urinary system disease	urinarySystem	True	0.218914475035945	166	343468	734
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	puerperal disorder	pregnancyPerinatal	False	0.200845273087741	4	339772	8480
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	urinary system disease	urinarySystem	True	0.259241048271146	16	335531	328
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	urinary system disease	urinarySystem	True	0.202884478229809	32	195560	517
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	urinary system disease	urinarySystem	True	0.207875883131892	144	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	urinary system disease	urinarySystem	True	0.207875883131892	144	331360	2760
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	perinatal disease	pregnancyPerinatal	False	0.311058927279803	174	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	perinatal disease	pregnancyPerinatal	False	0.311058927279803	174	305600	1644
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	phosphate measurement	otherPhenotypes	False	0.206489694908761	6	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	SCARB1	targetBased	phosphate measurement	otherPhenotypes	False	0.206489694908761	6	316970	306
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	bladder disease	urinarySystem	False	0.241156857151733	27	376029	3978
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	bladder disease	urinarySystem	False	0.231414536320551	58	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	bladder disease	urinarySystem	False	0.231414536320551	58	86095	1151
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	bladder disease	urinarySystem	False	0.212849613938898	27	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	bladder disease	urinarySystem	False	0.212849613938898	27	403871	1243
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	bladder disease	urinarySystem	False	0.289162207329892	853	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	bladder disease	urinarySystem	False	0.289162207329892	853	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	bladder disease	urinarySystem	False	0.289162207329892	853	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	bladder disease	urinarySystem	False	0.289162207329892	853	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	bladder disease	urinarySystem	False	0.289162207329892	853	124022	1156
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	bladder disease	urinarySystem	False	0.267949103146554	56	322361	619
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	bladder disease	urinarySystem	False	0.227392711997064	37	193542	587
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	bladder disease	urinarySystem	False	0.280169716004274	123	194628	267
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	integumentary system disease	dermatology	True	0.241618992377113	81	326271	221
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	BRCA1	pathwayBased	integumentary system disease	dermatology	True	0.338275470558646	10246	376029	3978
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	integumentary system disease	dermatology	True	0.321725988748087	177	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	integumentary system disease	dermatology	True	0.321725988748087	177	337446	1356
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	integumentary system disease	dermatology	True	0.218239473823266	8	218707	302
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	FUS	targetBased	integumentary system disease	dermatology	True	0.207770349394696	21	385746	932
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	integumentary system disease	dermatology	True	0.258280684229034	114	280024	1717
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	integumentary system disease	dermatology	True	0.320294779178675	6985	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	integumentary system disease	dermatology	True	0.320294779178675	6985	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	integumentary system disease	dermatology	True	0.282291162301668	331	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	targetBased	integumentary system disease	dermatology	True	0.231551164738435	296	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	integumentary system disease	dermatology	True	0.250964511037462	124	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	integumentary system disease	dermatology	True	0.250964511037462	124	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	DICER1	targetBased	integumentary system disease	dermatology	True	0.227649483329488	76	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	EZH2	targetBased	integumentary system disease	dermatology	True	0.219690689643801	340	57013	201
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	integumentary system disease	dermatology	True	0.249517728181391	333	324747	7988
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	PRKAR1A	targetBased	integumentary system disease	dermatology	True	0.214104561438318	32	343468	285
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	NSD2	targetBased	integumentary system disease	dermatology	True	0.202698183089435	23	309684	1662
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	integumentary system disease	dermatology	True	0.226866990310819	37	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	integumentary system disease	dermatology	True	0.226866990310819	37	335239	695
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	integumentary system disease	dermatology	True	0.302981769888463	524	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	integumentary system disease	dermatology	True	0.302981769888463	524	195980	695
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	integumentary system disease	dermatology	True	0.281276995229199	51	362098	692
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	targetBased	integumentary system disease	dermatology	True	0.219242727343915	66	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	targetBased	integumentary system disease	dermatology	True	0.219949152924035	146	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	pathwayBased	integumentary system disease	dermatology	True	0.219949152924035	146	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	PLCG1	targetBased	integumentary system disease	dermatology	True	0.265538854023612	66	369953	3123
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	pathwayBased	integumentary system disease	dermatology	True	0.210426820010327	1435	362051	17187
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	SMARCA4	targetBased	integumentary system disease	dermatology	True	0.240585125404373	61	344733	7043
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	integumentary system disease	dermatology	True	0.238927781287978	467	86095	1114
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	integumentary system disease	dermatology	True	0.26829646163786	300	369953	3080
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	integumentary system disease	dermatology	True	0.211868070367457	80	71016	346
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	NCOA2	targetBased	integumentary system disease	dermatology	True	0.226013855884408	19	368927	620
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	integumentary system disease	dermatology	True	0.334727150574033	9183	322361	619
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ERAP1	targetBased	integumentary system disease	dermatology	True	0.210763552404453	85	335777	499
qHTS for Inhibitors of WRN Helicase	WRN	WRN	targetBased	integumentary system disease	dermatology	True	0.235164338695319	92	364011	1678
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	integumentary system disease	dermatology	True	0.253657003198063	180	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	NOD2	targetBased	integumentary system disease	dermatology	True	0.219160319060528	89	292323	1836
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	integumentary system disease	dermatology	True	0.26050221008225	20	335531	328
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	integumentary system disease	dermatology	True	0.313361782505648	292	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	integumentary system disease	dermatology	True	0.233083601317823	9	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	integumentary system disease	dermatology	True	0.233083601317823	9	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	integumentary system disease	dermatology	True	0.233083601317823	9	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	integumentary system disease	dermatology	True	0.233083601317823	9	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	integumentary system disease	dermatology	True	0.233083601317823	9	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	integumentary system disease	dermatology	True	0.234214026096396	42	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	integumentary system disease	dermatology	True	0.211077296512427	13	305610	3794
qHTS for Inhibitors of Polymerase Eta	POLH	POLH	targetBased	integumentary system disease	dermatology	True	0.290001196342719	175	388717	4730
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	integumentary system disease	dermatology	True	0.296573564076537	512	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	integumentary system disease	dermatology	True	0.296573564076537	512	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	integumentary system disease	dermatology	True	0.296573564076537	512	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	integumentary system disease	dermatology	True	0.296573564076537	512	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	integumentary system disease	dermatology	True	0.296573564076537	512	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	integumentary system disease	dermatology	True	0.296573564076537	512	196177	519
E3 Ligase HTS_1536	MDM2	MDM2	targetBased	integumentary system disease	dermatology	True	0.248132302982701	201	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	RAC1	targetBased	integumentary system disease	dermatology	True	0.276360418913388	26	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	RAC1	targetBased	integumentary system disease	dermatology	True	0.276360418913388	26	194628	521
USP8 deubiquitinase inhibition: Primary qHTS	USP8	USP8	targetBased	integumentary system disease	dermatology	True	0.230988642834145	22	47480	2010
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	Conjunctival Disorder	visualSystem	False	0.212392445783752	11	92518	501
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	Conjunctival Disorder	visualSystem	False	0.216465590684974	13	326271	221
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	integumentary system disease	dermatology	True	0.208638751954248	9	339674	2841
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	integumentary system disease	dermatology	True	0.318572746917791	417	194628	267
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	targetBased	integumentary system disease	dermatology	True	0.217184683660643	4	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	targetBased	integumentary system disease	dermatology	True	0.217184683660643	4	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	targetBased	integumentary system disease	dermatology	True	0.217184683660643	4	363803	502
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	integumentary system disease	dermatology	True	0.203068573354383	128	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	BLM	targetBased	integumentary system disease	dermatology	True	0.319022293003942	2074	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	MDM4	targetBased	integumentary system disease	dermatology	True	0.253011513845307	58	331671	10022
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	integumentary system disease	dermatology	True	0.224633684922851	6	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	integumentary system disease	dermatology	True	0.224633684922851	6	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	integumentary system disease	dermatology	True	0.224633684922851	6	363803	1081
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	integumentary system disease	dermatology	True	0.305701219195517	1397	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	integumentary system disease	dermatology	True	0.305701219195517	1397	331360	2760
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	integumentary system disease	dermatology	True	0.312803637004698	1187	195821	1625
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	targetBased	integumentary system disease	dermatology	True	0.223719116409706	65	336894	489
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	integumentary system disease	dermatology	True	0.246337867169019	56	369953	2294
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	integumentary system disease	dermatology	True	0.20462501936725	17	290355	265
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	integumentary system disease	dermatology	True	0.246792913857849	423	394050	3624
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	integumentary system disease	dermatology	True	0.298134545120243	59	217430	649
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	integumentary system disease	dermatology	True	0.32268748240652	4236	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	integumentary system disease	dermatology	True	0.32268748240652	4236	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	integumentary system disease	dermatology	True	0.32268748240652	4236	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	integumentary system disease	dermatology	True	0.32268748240652	4236	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	integumentary system disease	dermatology	True	0.32268748240652	4236	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	targetBased	integumentary system disease	dermatology	True	0.322665894064112	2421	356517	1139
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	integumentary system disease	dermatology	True	0.222102404791046	168	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	integumentary system disease	dermatology	True	0.222102404791046	168	218234	1620
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	targetBased	integumentary system disease	dermatology	True	0.269533734198049	394	330392	1295
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	HPGD	targetBased	integumentary system disease	dermatology	True	0.248030262803952	59	148480	6428
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	STAT3	pathwayBased	integumentary system disease	dermatology	True	0.247939909811404	1148	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	STAT3	pathwayBased	integumentary system disease	dermatology	True	0.247939909811404	1148	194666	1722
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	targetBased	integumentary system disease	dermatology	True	0.221682559714614	86	318291	483
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	integumentary system disease	dermatology	True	0.272194444747796	1140	43989	342
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	epidermolysis bullosa	dermatology	False	0.288620795955208	63	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	epidermolysis bullosa	dermatology	False	0.288620795955208	63	337446	1356
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	epidermolysis bullosa	dermatology	False	0.321548624338087	6829	322361	619
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	keratosis	dermatology	False	0.256254840008914	20	280024	1717
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	inflammatory skin disease	dermatology	False	0.215546322496399	48	326271	221
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	inflammatory skin disease	dermatology	False	0.223020615678467	34	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	inflammatory skin disease	dermatology	False	0.223020615678467	34	86095	1151
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	palmoplantar keratosis	dermatology	False	0.256254680470245	20	280024	1717
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	renal tubular transport disease	urinarySystem	False	0.24888482952799	106	125268	2463
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	sebaceous gland disease	dermatology	False	0.219486556030722	24	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	sebaceous gland disease	dermatology	False	0.219486556030722	24	86095	1151
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	vesiculobullous skin disease	dermatology	False	0.28862087547986	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	vesiculobullous skin disease	dermatology	False	0.28862087547986	64	337446	1356
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	vesiculobullous skin disease	dermatology	False	0.321669431855278	6836	322361	619
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	biological_process	otherPhenotypes	True	0.221704326191863	521	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	biological_process	otherPhenotypes	True	0.221704326191863	521	296501	2737
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	ABCB1	targetBased	biological_process	otherPhenotypes	True	0.219324273207192	364	396029	13426
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	ABCB1	targetBased	biological_process	otherPhenotypes	True	0.219324273207192	364	395981	5516
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	biological_process	otherPhenotypes	True	0.227445157492578	510	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	biological_process	otherPhenotypes	True	0.227445157492578	510	86095	1151
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	biological_process	otherPhenotypes	True	0.219960026386201	32	363803	2412
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	biological_process	otherPhenotypes	True	0.213277145081845	181	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	biological_process	otherPhenotypes	True	0.267591240947233	278	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	biological_process	otherPhenotypes	True	0.267591240947233	278	335239	695
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	biological_process	otherPhenotypes	True	0.218659863761334	22	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	TRPC6	targetBased	biological_process	otherPhenotypes	True	0.218659863761334	22	305610	3253
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	biological_process	otherPhenotypes	True	0.248483278326225	61	86095	1114
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	biological_process	otherPhenotypes	True	0.220015374779802	87	108286	1415
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	biological_process	otherPhenotypes	True	0.25993515763855	51	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	biological_process	otherPhenotypes	True	0.25993515763855	51	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	biological_process	otherPhenotypes	True	0.25993515763855	51	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	biological_process	otherPhenotypes	True	0.25993515763855	51	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	biological_process	otherPhenotypes	True	0.25993515763855	51	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	biological_process	otherPhenotypes	True	0.25993515763855	51	336308	6862
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Abnormality of head or neck	otherPhenotypes	False	0.236077311849956	12	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Abnormality of head or neck	otherPhenotypes	False	0.236077311849956	12	131324	544
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	biological_process	otherPhenotypes	True	0.213738473055367	42	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	biological_process	otherPhenotypes	True	0.213844789760025	5	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	biological_process	otherPhenotypes	True	0.234467814965784	8	339674	2841
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.222099699568389	38	310014	1321
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.206158034285837	4	324747	813
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.206059540806662	7	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.206059540806662	7	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.206059540806662	7	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.206059540806662	7	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of head or neck	otherPhenotypes	False	0.206059540806662	7	359207	4555
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	biological_process	otherPhenotypes	True	0.208768714704729	16	324747	1043
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	biological_process	otherPhenotypes	True	0.204014019976004	63	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	biological_process	otherPhenotypes	True	0.247044351836674	42	339772	8480
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of the mouth	otherPhenotypes	False	0.206059540806662	7	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of the mouth	otherPhenotypes	False	0.206059540806662	7	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of the mouth	otherPhenotypes	False	0.206059540806662	7	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of the mouth	otherPhenotypes	False	0.206059540806662	7	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of the mouth	otherPhenotypes	False	0.206059540806662	7	359207	4555
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	response to xenobiotic stimulus	otherPhenotypes	False	0.211340336396757	16	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	response to xenobiotic stimulus	otherPhenotypes	False	0.211340336396757	16	296501	2737
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Abnormality of the head	otherPhenotypes	False	0.227625008811793	11	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Abnormality of the head	otherPhenotypes	False	0.227625008811793	11	131324	544
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	multicellular organismal process	otherPhenotypes	False	0.218859720751752	22	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	multicellular organismal process	otherPhenotypes	False	0.202880715093684	10	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	multicellular organismal process	otherPhenotypes	False	0.202880715093684	10	335239	695
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	multicellular organismal process	otherPhenotypes	False	0.215015618477571	18	108286	1415
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	multicellular organismal process	otherPhenotypes	False	0.251145307044483	27	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	multicellular organismal process	otherPhenotypes	False	0.251145307044483	27	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	multicellular organismal process	otherPhenotypes	False	0.251145307044483	27	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	multicellular organismal process	otherPhenotypes	False	0.251145307044483	27	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	multicellular organismal process	otherPhenotypes	False	0.251145307044483	27	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	multicellular organismal process	otherPhenotypes	False	0.251145307044483	27	336308	6862
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	multicellular organismal process	otherPhenotypes	False	0.207389202423301	14	339772	8480
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Abnormality of the head	otherPhenotypes	False	0.222099699568389	38	310014	1321
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Abnormality of the head	otherPhenotypes	False	0.206158034285837	4	324747	813
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of the head	otherPhenotypes	False	0.206059540806662	7	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of the head	otherPhenotypes	False	0.206059540806662	7	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of the head	otherPhenotypes	False	0.206059540806662	7	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of the head	otherPhenotypes	False	0.206059540806662	7	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of the head	otherPhenotypes	False	0.206059540806662	7	359207	4555
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Abnormality of the vertebral column	otherPhenotypes	False	0.210000345549412	18	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Abnormality of the vertebral column	otherPhenotypes	False	0.220240219675583	61	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Abnormality of the vertebral column	otherPhenotypes	False	0.220240219675583	61	335239	695
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Abnormality of the vertebral column	otherPhenotypes	False	0.224407686531836	34	316642	617
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Abnormal skull morphology	otherPhenotypes	False	0.222099667016421	37	310014	1321
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Abnormality of the face	otherPhenotypes	False	0.206158034285837	4	324747	813
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	Abnormality of the ear	earDisease	False	0.214282786623495	4	335531	328
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of the face	otherPhenotypes	False	0.206059540806662	7	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of the face	otherPhenotypes	False	0.206059540806662	7	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of the face	otherPhenotypes	False	0.206059540806662	7	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of the face	otherPhenotypes	False	0.206059540806662	7	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of the face	otherPhenotypes	False	0.206059540806662	7	359207	4555
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Abnormality of the nose	otherPhenotypes	False	0.206158034285837	4	324747	813
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.274148592438218	497	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.274148592438218	497	296501	2737
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.282933483861209	1083	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.282933483861209	1083	305610	1082
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.293716140947477	1655	305610	1552
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.293716140947477	1655	343666	1267
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.293716140947477	1655	342084	3260
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.227908898420073	124	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	RORA	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.227908898420073	124	64908	278
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.279024465728859	224	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.279024465728859	224	305600	1644
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.225142340730059	206	290355	265
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	GNAO1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.255441825504248	114	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	GNAO1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.255441825504248	114	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	GNAO1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.255441825504248	114	218528	750
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.21336066648229	142	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.21336066648229	142	337446	1356
Factor XIa 1536 HTS	F11_modulation	F11	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.234801127844918	100	218707	302
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	FUS	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.265440757044351	452	385746	932
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.247669786416519	1609	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.247669786416519	1609	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.281853817991274	1127	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.248770201494916	153	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.259254518934055	179	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.259254518934055	179	131324	544
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.227680140191224	332	363803	2412
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.231496549675002	3955	403345	4970
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.21687480378248	32	315412	318
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.234372857018332	883	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.251461216927757	563	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.251461216927757	563	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.217289893812431	2272	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.217289893812431	2272	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.217289893812431	2272	405130	6428
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of the eye	otherPhenotypes	False	0.221105846322644	31	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of the eye	otherPhenotypes	False	0.221105846322644	31	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of the eye	otherPhenotypes	False	0.221105846322644	31	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of the eye	otherPhenotypes	False	0.221105846322644	31	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of the eye	otherPhenotypes	False	0.221105846322644	31	359207	4555
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.23769941523092	382	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.23769941523092	382	195980	695
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.221599661213477	68	75924	1804
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.232057584353328	132	305610	2592
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249609519864019	598	335239	801
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249609519864019	598	335238	390
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.228624677519406	18	217430	649
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.20769230437738	64	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.20769230437738	64	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240206446344234	3243	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240206446344234	3243	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240206446344234	3243	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240206446344234	3243	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240206446344234	3243	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240206446344234	3243	196177	519
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Abnormal retinal morphology	visualSystem	False	0.205193660841397	42	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Abnormal retinal morphology	visualSystem	False	0.205193660841397	42	314998	380
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	RAC1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.209950559774517	21	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	RAC1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.209950559774517	21	194628	521
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.232593283769271	312	86095	1114
qHTS Assay for NPC1 Promoter Activators	NPC1	NPC1	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.202023865375822	138	320682	7575
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.226129078134989	1710	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.226129078134989	1710	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.226129078134989	1710	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.226129078134989	1710	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.226129078134989	1710	124022	1156
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.242397154537007	1513	193714	1590
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.242397154537007	1513	193400	1987
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.242397154537007	1513	404343	257
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.265401626271701	549	108286	1415
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.280921624273777	156	292323	567
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244855073617114	622	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244855073617114	622	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244855073617114	622	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244855073617114	622	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244855073617114	622	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244855073617114	622	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.263880761840598	127	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.263880761840598	127	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.263880761840598	127	407539	2380
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.256319847104748	121	335531	328
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.239241631876263	192	310014	1321
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.257299727549416	197	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	RUNX1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.257299727549416	197	218234	1620
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	ALPL	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.234805460738875	86	195560	517
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	VCP	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.211997979433031	186	217959	923
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.225438988255363	117	324747	813
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.27836837098729	948	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.27836837098729	948	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	SMAD3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.215654434912818	330	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244838406350132	187	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249403112446386	112	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249403112446386	112	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249403112446386	112	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249403112446386	112	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.249403112446386	112	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.232704381916126	385	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.21780685091152	28	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	YWHAG	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.227484234385922	21	157962	312
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	GAA	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.226755385845552	155	199169	715
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	GAA	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.226755385845552	155	302297	1165
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.240552996868809	38	339674	2841
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.250200632097744	71	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.250200632097744	71	369953	498
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.227000927873932	495	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.227000927873932	495	61606	416
Thrombin 1536 HTS	F2_modulation	F2	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.269671121305418	1563	217233	557
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.218143729079937	25	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.218143729079937	25	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.218143729079937	25	363803	502
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.244408556150635	286	324747	1043
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.248164325106968	159	361330	3713
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.248164325106968	159	57705	3413
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.248164325106968	159	355805	11440
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.216344243782476	23	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.216344243782476	23	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.216344243782476	23	363803	1081
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.237613917173819	27	195821	1625
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.237643221357431	44	104728	4230
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.248267205682317	573	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	BLM	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.208509737527938	24	347933	673
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.223905567002108	73	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	pathwayBased	Phenotypic abnormality	otherPhenotypes	False	0.211319274097515	2122	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of refraction	otherPhenotypes	False	0.217840835724177	25	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of refraction	otherPhenotypes	False	0.217840835724177	25	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of refraction	otherPhenotypes	False	0.217840835724177	25	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of refraction	otherPhenotypes	False	0.217840835724177	25	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of refraction	otherPhenotypes	False	0.217840835724177	25	359207	4555
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.208954471656546	50	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.208954471656546	50	314998	380
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	PABPC1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.215829291563171	17	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	PABPC1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.215829291563171	17	359244	1307
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	KDM5B	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.213601173919794	26	217819	5697
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.224455541953319	770	322361	619
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.231340531180729	82	343467	1710
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	Phenotypic abnormality	otherPhenotypes	False	0.241710242540475	107	194628	267
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	pathwayBased	Growth abnormality	otherPhenotypes	False	0.212742047920975	16	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	pathwayBased	Growth abnormality	otherPhenotypes	False	0.212742047920975	16	131324	544
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	targetBased	Abnormality of the endocrine system	otherPhenotypes	False	0.202227924201512	5	324747	813
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Abnormality of the abdominal organs	otherPhenotypes	False	0.226294077825643	128	217959	2390
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.205421150623913	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Nausea and vomiting	otherPhenotypes	False	0.205421150623913	6	335239	695
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormality of the integument	dermatology	False	0.206276689002309	15	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormality of the integument	dermatology	False	0.206276689002309	15	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormality of the integument	dermatology	False	0.206276689002309	15	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormality of the integument	dermatology	False	0.206276689002309	15	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormality of the integument	dermatology	False	0.206276689002309	15	359207	4555
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	targetBased	Abnormality of the integument	dermatology	False	0.2061725265493	14	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	targetBased	Abnormality of the integument	dermatology	False	0.2061725265493	14	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	targetBased	Abnormality of the integument	dermatology	False	0.2061725265493	14	363803	502
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Abnormality of the integument	dermatology	False	0.2061725265493	14	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Abnormality of the integument	dermatology	False	0.2061725265493	14	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	targetBased	Abnormality of the integument	dermatology	False	0.2061725265493	14	363803	1081
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abnormal pupillary function	visualSystem	False	0.210297653401403	6	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abnormal pupillary function	visualSystem	False	0.210297653401403	6	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abnormal pupillary function	visualSystem	False	0.210297653401403	6	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abnormal pupillary function	visualSystem	False	0.210297653401403	6	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abnormal pupillary function	visualSystem	False	0.210297653401403	6	359207	4555
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	Abnormal posterior eye segment morphology	visualSystem	False	0.205193660841397	42	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	Abnormal posterior eye segment morphology	visualSystem	False	0.205193660841397	42	314998	380
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	Abnormal circulating calcium concentration	otherPhenotypes	False	0.217086703759336	18	394050	3624
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	Abnormal EKG	otherPhenotypes	False	0.244432841642989	690	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	targetBased	Abnormal EKG	otherPhenotypes	False	0.244432841642989	690	305610	1082
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	targetBased	Abnormal EKG	otherPhenotypes	False	0.244410116295124	1167	305610	1552
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	targetBased	Abnormal EKG	otherPhenotypes	False	0.244410116295124	1167	343666	1267
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	targetBased	Abnormal EKG	otherPhenotypes	False	0.244410116295124	1167	342084	3260
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Abnormality of temperature regulation	otherPhenotypes	False	0.220374455963716	4	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Abnormality of temperature regulation	otherPhenotypes	False	0.220374455963716	4	335239	695
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	targetBased	Abdominal symptom	otherPhenotypes	False	0.205511433186452	32	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	targetBased	Abdominal symptom	otherPhenotypes	False	0.205511433186452	32	296501	2737
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Abdominal symptom	otherPhenotypes	False	0.204821664526379	8	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	targetBased	Abdominal symptom	otherPhenotypes	False	0.217235739478052	33	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.222328758405658	114	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.222328758405658	114	335239	695
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	targetBased	Abdominal symptom	otherPhenotypes	False	0.220164458221006	49	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	targetBased	Abdominal symptom	otherPhenotypes	False	0.220164458221006	49	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	targetBased	Abdominal symptom	otherPhenotypes	False	0.220164458221006	49	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	targetBased	Abdominal symptom	otherPhenotypes	False	0.220164458221006	49	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	targetBased	Abdominal symptom	otherPhenotypes	False	0.220164458221006	49	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	targetBased	Abdominal symptom	otherPhenotypes	False	0.220164458221006	49	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	targetBased	Abdominal symptom	otherPhenotypes	False	0.215321018787221	24	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	targetBased	Abdominal symptom	otherPhenotypes	False	0.215321018787221	24	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	targetBased	Abdominal symptom	otherPhenotypes	False	0.215321018787221	24	407539	2380
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.212047879755137	8	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.212047879755137	8	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.212047879755137	8	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.212047879755137	8	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	Abdominal symptom	otherPhenotypes	False	0.212047879755137	8	359207	4555
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	Constitutional symptom	otherPhenotypes	False	0.218313695640581	38	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Constitutional symptom	otherPhenotypes	False	0.222215670472661	242	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	Constitutional symptom	otherPhenotypes	False	0.222215670472661	242	335239	695
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	targetBased	Constitutional symptom	otherPhenotypes	False	0.200068706560494	11	108286	1415
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Abnormality of temperature regulation	otherPhenotypes	False	0.221852021187306	40	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	Constitutional symptom	otherPhenotypes	False	0.208105949660196	7	339772	8480
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	Constitutional symptom	otherPhenotypes	False	0.225235004600427	61	316642	617
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A	targetBased	Abnormal brain morphology	otherPhenotypes	False	0.222100627332917	41	310014	1321
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	Abnormality of the lymphatic system	otherPhenotypes	False	0.216641914539825	97	217959	2390
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	isolated microphthalmia	visualSystem	False	0.23404703585396	8	362098	692
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	reticulate pigment disorder	dermatology	False	0.241727955075814	8	369953	2294
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	eye accommodation disease	visualSystem	False	0.213955490451401	14	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	eye accommodation disease	visualSystem	False	0.213955490451401	14	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	eye accommodation disease	visualSystem	False	0.213955490451401	14	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	eye accommodation disease	visualSystem	False	0.213955490451401	14	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	eye accommodation disease	visualSystem	False	0.213955490451401	14	359207	4555
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	dermatitis	dermatology	False	0.215573123057295	51	326271	221
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	dermatitis	dermatology	False	0.202626550145767	8	339297	1446
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	dermatitis	dermatology	False	0.297165163219304	57	217430	649
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	uveal disorder	visualSystem	False	0.287175065092813	24	71016	346
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	disorder of pilosebaceous unit	dermatology	False	0.219512677701291	28	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	disorder of pilosebaceous unit	dermatology	False	0.219512677701291	28	86095	1151
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	disorder of pilosebaceous unit	dermatology	False	0.297915975847967	53	193542	587
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	keratoconjunctivitis	visualSystem	False	0.215981370294214	12	326271	221
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	keratoconjunctivitis	visualSystem	False	0.212317522321918	11	92518	501
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	vitreous disorder	visualSystem	False	0.300203406903863	183	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	vitreous disorder	visualSystem	False	0.300203406903863	183	314998	380
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	isolated anophthalmia-microphthalmia syndrome	visualSystem	False	0.23404703585396	8	362098	692
qHTS for Inhibitors of Polymerase Eta	POLH	POLH	targetBased	hereditary photodermatosis	dermatology	False	0.287005147233176	165	388717	4730
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	BLM	targetBased	hereditary photodermatosis	dermatology	False	0.31212671437521	2004	347933	673
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	inherited renal tubular disease	urinarySystem	False	0.322919165133619	449	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	inherited renal tubular disease	urinarySystem	False	0.322919165133619	449	337446	1356
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	inherited renal tubular disease	urinarySystem	False	0.203385357827335	32	324747	2221
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	KCNJ1	targetBased	inherited renal tubular disease	urinarySystem	False	0.249203007199883	112	125268	2463
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	diffuse palmoplantar keratoderma	dermatology	False	0.256195977540126	18	280024	1717
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	corneal dystrophy	visualSystem	False	0.256196290588387	19	280024	1717
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	hereditary palmoplantar keratoderma	dermatology	False	0.256254680470245	20	280024	1717
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	inherited epidermolysis bullosa	dermatology	False	0.288620795955208	63	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	inherited epidermolysis bullosa	dermatology	False	0.288620795955208	63	337446	1356
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	inherited epidermolysis bullosa	dermatology	False	0.321548624338087	6829	322361	619
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	HPGD	targetBased	inherited isolated nail anomaly	dermatology	False	0.236431540663592	39	148480	6428
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	skin pigmentation disorder	dermatology	False	0.28121347468596	19	362098	692
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	skin pigmentation disorder	dermatology	False	0.241727955075814	8	369953	2294
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	hyperpigmentation of the skin	dermatology	False	0.28121347468596	19	362098	692
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	hyperpigmentation of the skin	dermatology	False	0.241727955075814	8	369953	2294
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	skin vascular disease	dermatology	False	0.296996435539609	56	217430	649
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	hypopigmentation of the skin	dermatology	False	0.288169762350656	784	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	hypopigmentation of the skin	dermatology	False	0.288169762350656	784	331360	2760
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	epidermal disease	dermatology	False	0.288688867396843	67	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	epidermal disease	dermatology	False	0.288688867396843	67	337446	1356
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	epidermal disease	dermatology	False	0.256255127166806	21	280024	1717
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	epidermal disease	dermatology	False	0.321909627319327	6863	322361	619
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	epidermal disease	dermatology	False	0.261745728168516	234	369953	3080
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	superficial corneal dystrophy	visualSystem	False	0.256196290588387	19	280024	1717
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	vitreoretinal degeneration	visualSystem	False	0.300203406903863	183	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	vitreoretinal degeneration	visualSystem	False	0.300203406903863	183	314998	380
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	dermis disorder	dermatology	False	0.276173222037058	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	dermis disorder	dermatology	False	0.276173222037058	64	337446	1356
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	disorder of visual system	visualSystem	True	0.221701506471116	33	326271	221
qHTS Assay for Identification of Novel General Anesthetics	FTL	FTL	targetBased	disorder of visual system	visualSystem	True	0.28978101796452	105	341499	255
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	disorder of visual system	visualSystem	True	0.293659325627087	89	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	disorder of visual system	visualSystem	True	0.293659325627087	89	337446	1356
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	MCOLN1	targetBased	disorder of visual system	visualSystem	True	0.308753278727696	525	400814	482
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	disorder of visual system	visualSystem	True	0.281085244250405	55	280024	1717
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	disorder of visual system	visualSystem	True	0.236807727352505	73	217959	2390
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	disorder of visual system	visualSystem	True	0.279022374592434	31	362098	692
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	disorder of visual system	visualSystem	True	0.283476587843887	454	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	disorder of visual system	visualSystem	True	0.283476587843887	454	306502	1509
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	GFER	targetBased	disorder of visual system	visualSystem	True	0.273714146187464	14	288728	10857
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	GFER	targetBased	disorder of visual system	visualSystem	True	0.273714146187464	14	288728	10857
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	targetBased	disorder of visual system	visualSystem	True	0.222862505194961	67	59788	212
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	YAP1	targetBased	disorder of visual system	visualSystem	True	0.204688554652709	85	639428	9218
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	disorder of visual system	visualSystem	True	0.243288896985541	298	324747	2221
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	disorder of visual system	visualSystem	True	0.323339146766986	6920	322361	619
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	HKDC1	targetBased	disorder of visual system	visualSystem	True	0.21237459436633	11	340696	540
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	targetBased	disorder of visual system	visualSystem	True	0.248532452657967	54	92518	501
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	BAP1	targetBased	disorder of visual system	visualSystem	True	0.287305442430176	29	71016	346
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	HTRA1	targetBased	disorder of visual system	visualSystem	True	0.235454819554259	303	343467	1710
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	disorder of visual system	visualSystem	True	0.27026191982487	86	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	disorder of visual system	visualSystem	True	0.221452348587319	27	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	disorder of visual system	visualSystem	True	0.221452348587319	27	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	disorder of visual system	visualSystem	True	0.221452348587319	27	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	disorder of visual system	visualSystem	True	0.221452348587319	27	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	disorder of visual system	visualSystem	True	0.221452348587319	27	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	disorder of visual system	visualSystem	True	0.229534895205258	175	339297	1446
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	disorder of visual system	visualSystem	True	0.2680927432524	36	194628	267
Glucocerebrosidase	GBA1	GBA1	targetBased	disorder of visual system	visualSystem	True	0.322305630477413	1353	48118	549
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	disorder of visual system	visualSystem	True	0.302178509416749	589	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	disorder of visual system	visualSystem	True	0.302178509416749	589	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	disorder of visual system	visualSystem	True	0.302178509416749	589	271402	1048
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	disorder of visual system	visualSystem	True	0.294018067583688	1006	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	disorder of visual system	visualSystem	True	0.294018067583688	1006	331360	2760
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	NR2E3	targetBased	disorder of visual system	visualSystem	True	0.311024837839567	373	362026	1281
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	NR2E3	targetBased	disorder of visual system	visualSystem	True	0.311024837839567	373	314998	380
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	hypertension, pregnancy-induced	pregnancyPerinatal	False	0.212400150087939	8	335531	328
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	skin appendage disorder	dermatology	False	0.205390607784912	17	217959	2390
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	skin appendage disorder	dermatology	False	0.300463100533616	54	193542	587
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	toxemia of pregnancy	pregnancyPerinatal	False	0.212400150087939	8	335531	328
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	toxemia of pregnancy	pregnancyPerinatal	False	0.203609138464774	7	339297	1446
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	obstetric disorder	pregnancyPerinatal	False	0.238639999906322	10	335531	328
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	obstetric disorder	pregnancyPerinatal	False	0.263920022224899	18	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	obstetric disorder	pregnancyPerinatal	False	0.263920022224899	18	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	targetBased	obstetric disorder	pregnancyPerinatal	False	0.263920022224899	18	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	targetBased	obstetric disorder	pregnancyPerinatal	False	0.263920022224899	18	72026	1794
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	obstetric disorder	pregnancyPerinatal	False	0.207151207169385	13	339297	1446
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	obstetric disorder	pregnancyPerinatal	False	0.223920529276082	46	324747	1043
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	obstetric disorder	pregnancyPerinatal	False	0.200845273087741	4	339772	8480
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.311058927279803	174	305609	3405
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.311058927279803	174	305600	1644
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.238639999906322	10	335531	328
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.263937233490496	18	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	TSHR	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.263937233490496	18	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	TSHR	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.263937233490496	18	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	TSHR	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.263937233490496	18	72026	1794
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.207151207169385	13	339297	1446
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.22403071172027	48	324747	1043
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	pregnancy or perinatal disease	pregnancyPerinatal	True	0.200845273087741	4	339772	8480
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	targetBased	hereditary skin disorder	dermatology	False	0.221056991643452	56	326271	221
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	hereditary skin disorder	dermatology	False	0.311328319262541	142	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	hereditary skin disorder	dermatology	False	0.311328319262541	142	337446	1356
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	hereditary skin disorder	dermatology	False	0.25712943381446	36	280024	1717
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	hereditary skin disorder	dermatology	False	0.229346865781216	87	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	hereditary skin disorder	dermatology	False	0.229346865781216	87	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	hereditary skin disorder	dermatology	False	0.240394634788731	100	217959	2390
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	targetBased	hereditary skin disorder	dermatology	False	0.23308453999305	119	324747	7988
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	hereditary skin disorder	dermatology	False	0.229930588953071	148	394050	3624
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	STAT1	pathwayBased	hereditary skin disorder	dermatology	False	0.2998820169248	341	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	STAT1	targetBased	hereditary skin disorder	dermatology	False	0.2998820169248	341	195980	695
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	ABCB6	targetBased	hereditary skin disorder	dermatology	False	0.281262832698174	37	362098	692
Factor XIIa 1536 HTS	F12_modulation	F12	targetBased	hereditary skin disorder	dermatology	False	0.296191779790716	52	217430	649
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hereditary skin disorder	dermatology	False	0.292739201701327	217	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hereditary skin disorder	dermatology	False	0.292739201701327	217	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hereditary skin disorder	dermatology	False	0.292739201701327	217	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hereditary skin disorder	dermatology	False	0.292739201701327	217	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hereditary skin disorder	dermatology	False	0.292739201701327	217	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	targetBased	hereditary skin disorder	dermatology	False	0.292739201701327	217	196177	519
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	ADAM10	targetBased	hereditary skin disorder	dermatology	False	0.242092336166551	18	369953	2294
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	targetBased	hereditary skin disorder	dermatology	False	0.271509006887075	557	356517	1139
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	hereditary skin disorder	dermatology	False	0.322034848925037	6893	322361	619
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	ADAM17	targetBased	hereditary skin disorder	dermatology	False	0.262481931694042	249	369953	3080
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	HRAS	targetBased	hereditary skin disorder	dermatology	False	0.295408563193018	106	194628	267
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	hereditary skin disorder	dermatology	False	0.288326625767503	889	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	hereditary skin disorder	dermatology	False	0.288326625767503	889	331360	2760
HCS assay for microtubule stabilizers	TUBB	TUBB	targetBased	hereditary skin disorder	dermatology	False	0.262244406995486	11	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	BLM	targetBased	hereditary skin disorder	dermatology	False	0.312233117189633	2012	347933	673
qHTS for Inhibitors of Polymerase Eta	POLH	POLH	targetBased	hereditary skin disorder	dermatology	False	0.287642106454097	168	388717	4730
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.206610763261833	15	290355	265
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.210721928566546	39	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.210721928566546	39	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.20856576817664	98	217959	2390
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.212314616693139	26	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.221170766705419	53	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.221170766705419	53	335239	695
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.210637796927089	9	405685	308
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.209189692508195	9	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.209189692508195	9	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.209189692508195	9	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.209189692508195	9	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.209189692508195	9	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.214867634915667	32	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.208145087889447	7	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.206135318055928	5	339674	2841
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.219504008290006	65	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	injury, poisoning or other complication	otherPhenotypes	True	0.217688559948727	25	339772	8480
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Rare genetic eye disease	visualSystem	False	0.289266011311957	70	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Rare genetic eye disease	visualSystem	False	0.289266011311957	70	337446	1356
Colorimetric Assay for Inhibitors for NALP1	NLRP1	NLRP1	targetBased	Rare genetic eye disease	visualSystem	False	0.242921321380059	19	280024	1717
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Rare genetic eye disease	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Rare genetic eye disease	visualSystem	False	0.283323839826436	429	306502	1509
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	GFER	targetBased	Rare genetic eye disease	visualSystem	False	0.273691231054783	13	288728	10857
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	GFER	targetBased	Rare genetic eye disease	visualSystem	False	0.273691231054783	13	288728	10857
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Rare genetic eye disease	visualSystem	False	0.242166353923502	297	324747	2221
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Rare genetic eye disease	visualSystem	False	0.321769407374809	6893	322361	619
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Rare genetic eye disease	visualSystem	False	0.260540871426773	28	193542	587
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	Rare genetic eye disease	visualSystem	False	0.274281094403899	405	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	Rare genetic eye disease	visualSystem	False	0.274281094403899	405	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	Rare genetic eye disease	visualSystem	False	0.274281094403899	405	271402	1048
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Rare genetic eye disease	visualSystem	False	0.218962075333794	165	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Rare genetic eye disease	visualSystem	False	0.218962075333794	165	331360	2760
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.242166353923502	297	324747	2221
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.321405339285814	6830	322361	619
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	pathwayBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.273581815537388	58	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	MAPT	targetBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.273581815537388	58	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	pathwayBased	Genetic neuro-ophthalmological disease	visualSystem	False	0.273581815537388	58	271402	1048
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A	targetBased	pathological process	otherPhenotypes	False	0.219906370702315	28	339772	8480
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Genetic renal tubular disease	urinarySystem	False	0.28913810312953	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Genetic renal tubular disease	urinarySystem	False	0.28913810312953	64	337446	1356
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Rare genetic palpebral, lacrimal system and conjunctival disease	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Rare genetic palpebral, lacrimal system and conjunctival disease	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Rare genetic palpebral, lacrimal system and conjunctival disease	visualSystem	False	0.242166353923502	297	324747	2221
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Rare genetic palpebral, lacrimal system and conjunctival disease	visualSystem	False	0.32140534142591	6830	322361	619
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Genetic lens and zonula anomaly	visualSystem	False	0.288620872587898	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Genetic lens and zonula anomaly	visualSystem	False	0.288620872587898	64	337446	1356
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	GFER	targetBased	Genetic lens and zonula anomaly	visualSystem	False	0.273637136315339	12	288728	10857
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	GFER	targetBased	Genetic lens and zonula anomaly	visualSystem	False	0.273637136315339	12	288728	10857
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Genetic skin vascular disorder	dermatology	False	0.321405339040011	6828	322361	619
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Rare palpebral disease	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Rare palpebral disease	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Rare palpebral disease	visualSystem	False	0.242166353923502	297	324747	2221
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Kinetic eyelid anomaly	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Kinetic eyelid anomaly	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Kinetic eyelid anomaly	visualSystem	False	0.242166353923502	297	324747	2221
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Rare conjunctival disease	visualSystem	False	0.321405341199674	6829	322361	619
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Conjunctival vascular anomaly	visualSystem	False	0.321405341199674	6829	322361	619
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Rare cataract	visualSystem	False	0.288620872587898	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Rare cataract	visualSystem	False	0.288620872587898	64	337446	1356
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	GFER	targetBased	Rare cataract	visualSystem	False	0.273637136315339	12	288728	10857
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	GFER	targetBased	Rare cataract	visualSystem	False	0.273637136315339	12	288728	10857
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Systemic disease with cataract	visualSystem	False	0.288620872587898	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Systemic disease with cataract	visualSystem	False	0.288620872587898	64	337446	1356
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Musculoskeletal disease with cataract	visualSystem	False	0.288620872587898	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Musculoskeletal disease with cataract	visualSystem	False	0.288620872587898	64	337446	1356
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	CTNNB1	targetBased	Genetic vitreous-retinal disease	visualSystem	False	0.259791560364447	21	193542	587
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Oculomotor apraxia or related oculomotor disease	visualSystem	False	0.321405339059619	6829	322361	619
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Myopathy with eye involvement	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Myopathy with eye involvement	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Myopathy with eye involvement	visualSystem	False	0.242166353923502	297	324747	2221
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Myasthenic syndrome with eye involvement	visualSystem	False	0.283323839826436	429	306502	2634
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	SLC5A7	targetBased	Myasthenic syndrome with eye involvement	visualSystem	False	0.283323839826436	429	306502	1509
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	PREPL	targetBased	Myasthenic syndrome with eye involvement	visualSystem	False	0.242166353923502	297	324747	2221
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	TDP2	targetBased	Spinocerebellar ataxia with oculomotor anomaly	visualSystem	False	0.238653819111612	5	369953	1241
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Spinocerebellar ataxia with oculomotor anomaly	visualSystem	False	0.321405339134326	6829	322361	619
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Genodermatosis with ocular features	visualSystem	False	0.218756106297772	111	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Genodermatosis with ocular features	visualSystem	False	0.218756106297772	111	331360	2760
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	MITF	targetBased	Pigmentation disorder with eye involvement	visualSystem	False	0.218756106297772	111	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	MITF	targetBased	Pigmentation disorder with eye involvement	visualSystem	False	0.218756106297772	111	331360	2760
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Rare genetic renal disease	urinarySystem	False	0.28913810312953	64	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	GNAS	targetBased	Rare genetic renal disease	urinarySystem	False	0.28913810312953	64	337446	1356
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ATM	targetBased	Autosomal recessive cerebellar ataxia due to a DNA repair defect	visualSystem	False	0.321405339059619	6829	322361	619

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Keloid	VERAPAMIL	targetBased	4	Terminated	01/10/2012	https://clinicaltrials.gov/study/NCT01720056	1	LoF	protect	Objective of study achieved after interim analysis.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	nephrolithiasis	VERAPAMIL	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01675362	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Tinnitus	VERAPAMIL	targetBased	4	Recruiting	26/09/2019	https://clinicaltrials.gov/study/NCT04404439	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Anal fissure	DILTIAZEM	targetBased	2	Recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT04153032	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Anal fissure	DILTIAZEM	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01217515	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	ischemia reperfusion injury	DILTIAZEM	targetBased	3	Unknown status	01/06/2002	https://clinicaltrials.gov/study/NCT01771978	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	post operative nausea and vomiting	DILTIAZEM	targetBased	2	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529004	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Syncope	PROPRANOLOL	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093860	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Syncope	PROPRANOLOL	targetBased	4	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00060866	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pregnancy	PROPRANOLOL	targetBased	3	Terminated	14/07/2020	https://clinicaltrials.gov/study/NCT04299438	0.35	LoF	protect	Stopped at interim analysis
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Tremor	PROPRANOLOL	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02111369	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	essential tremor	PROPRANOLOL	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02111369	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	burn	PROPRANOLOL	targetBased	2	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01957449	0.2	LoF	protect	At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	burn	PROPRANOLOL	targetBased	2	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01902810	0.2	LoF	protect	At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	burn	PROPRANOLOL	targetBased	2	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00673309	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	burn	PROPRANOLOL	targetBased	2	Terminated	01/11/2015	https://clinicaltrials.gov/study/NCT02452255	0.2	LoF	protect	Shriner's Burn Hospital closed the study and access to study-related data is unavailable. We are unable to submit the additional information or results-data
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	burn	PROPRANOLOL	targetBased	2	Terminated	01/01/2004	https://clinicaltrials.gov/study/NCT00675714	0.2	LoF	protect	At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ascites	PROPRANOLOL	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02649335	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	dystocia	PROPRANOLOL	targetBased	2	Withdrawn	01/01/2004	https://clinicaltrials.gov/study/NCT00315913	0.2	LoF	protect	Lack of feasibility
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Graves ophthalmopathy	PROPRANOLOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01458600	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Headache	PROPRANOLOL	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00236561	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Headache	PROPRANOLOL	targetBased	4	Terminated	01/06/2008	https://clinicaltrials.gov/study/NCT00862095	1	LoF	protect	inadequate enrollment, insufficient funds to continue enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	PROPRANOLOL	targetBased	2	Withdrawn	01/10/2009	https://clinicaltrials.gov/study/NCT01007084	0.2	LoF	protect	Lack of eligible patient recruits/feasibility considerations.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	PROPRANOLOL	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02957331	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	PROPRANOLOL	targetBased	2	Terminated	15/02/2006	https://clinicaltrials.gov/study/NCT00356187	0.2	LoF	protect	Slow enrollment, end of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	PROPRANOLOL	targetBased	2	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00069355	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	age-related macular degeneration	PROPRANOLOL	targetBased	2	Unknown status	01/09/2018	https://clinicaltrials.gov/study/NCT03609307	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	severe pre-eclampsia	LABETALOL	targetBased	2	Unknown status	23/02/2017	https://clinicaltrials.gov/study/NCT03325348	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension, pregnancy-induced	LABETALOL	targetBased	4	Terminated	01/05/2020	https://clinicaltrials.gov/study/NCT04343235	1	LoF	protect	Challenges with enrollment; primary investigator left the institution
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	4	Completed	11/09/2017	https://clinicaltrials.gov/study/NCT03506724	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	2	Withdrawn	01/06/2015	https://clinicaltrials.gov/study/NCT00293735	0.2	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	4	Recruiting	20/06/2022	https://clinicaltrials.gov/study/NCT05309460	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02531490	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT01912677	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	3	Recruiting	17/07/2020	https://clinicaltrials.gov/study/NCT04298034	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02050529	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	nephrolithiasis	ISOPROTERENOL	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00323843	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Hypothermia	BUSPIRONE	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00334360	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Hypothermia	BUSPIRONE	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00334360	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	BUSPIRONE	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00895830	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	BUSPIRONE	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00895830	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Impotence	APOMORPHINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05246631	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	HALOPERIDOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT02143531	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea	HALOPERIDOL	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tics	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post-operative sign or symptom	HALOPERIDOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01862302	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	autoimmune thrombocytopenic purpura	THALIDOMIDE	targetBased	2	Withdrawn	01/10/2013	https://clinicaltrials.gov/study/NCT01976195	0.2	LoF	protect	No eligible patient was enrolled.
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Hypoalbuminemia	THALIDOMIDE	targetBased	3	Terminated	01/09/2007	https://clinicaltrials.gov/study/NCT00529633	0.7	LoF	protect	Low enrollment -- We could not recruit patients willing to be enrolled
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	oral mucositis	THALIDOMIDE	targetBased	3	Not yet recruiting	15/09/2023	https://clinicaltrials.gov/study/NCT06031012	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	uveitis	THALIDOMIDE	targetBased	4	Terminated	01/01/2004	https://clinicaltrials.gov/study/NCT00314665	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Beta-thalassemia	THALIDOMIDE	targetBased	3	Completed	25/01/2022	https://clinicaltrials.gov/study/NCT06146478	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Beta-thalassemia	THALIDOMIDE	targetBased	2	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT05132270	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Beta-thalassemia	THALIDOMIDE	targetBased	2	Completed	01/09/2021	https://clinicaltrials.gov/study/NCT06239389	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Beta-thalassemia	THALIDOMIDE	targetBased	2	Completed	07/07/2020	https://clinicaltrials.gov/study/NCT06153784	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT02277678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT02277678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE	targetBased	2	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03483870	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE	targetBased	2	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03483870	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01071057	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01071057	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Headache	MORPHINE	targetBased	4	Suspended	01/09/2015	https://clinicaltrials.gov/study/NCT02473276	1	GoF	protect	Temporary pause due to enrollment challenges
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Headache	MORPHINE	targetBased	4	Suspended	01/09/2015	https://clinicaltrials.gov/study/NCT02473276	1	GoF	protect	Temporary pause due to enrollment challenges
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Completed	14/06/2018	https://clinicaltrials.gov/study/NCT03580187	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Completed	14/06/2018	https://clinicaltrials.gov/study/NCT03580187	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01123551	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01123551	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00755989	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00755989	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Not yet recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT03511833	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Not yet recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT03511833	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Completed	08/02/2018	https://clinicaltrials.gov/study/NCT03585374	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	3	Completed	08/02/2018	https://clinicaltrials.gov/study/NCT03585374	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01689597	1	GoF	protect	Withdrawn - no participants enrolled
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	MORPHINE	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01689597	1	GoF	protect	Withdrawn - no participants enrolled
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Otitis media	MORPHINE	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT01244126	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Otitis media	MORPHINE	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT01244126	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	MORPHINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00784472	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	MORPHINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00784472	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	urolithiasis	MORPHINE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01318187	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	urolithiasis	MORPHINE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01318187	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	MORPHINE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00388011	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	MORPHINE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00388011	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	MORPHINE	targetBased	2	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02848599	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	MORPHINE	targetBased	2	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02848599	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	shortness of breath	MORPHINE	targetBased	3	Recruiting	23/10/2020	https://clinicaltrials.gov/study/NCT04188418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	shortness of breath	MORPHINE	targetBased	3	Recruiting	23/10/2020	https://clinicaltrials.gov/study/NCT04188418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	limb injury	MORPHINE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06464146	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	limb injury	MORPHINE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06464146	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01546701	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01546701	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Withdrawn	01/06/2018	https://clinicaltrials.gov/study/NCT03529097	1	GoF	protect	No participants enrolles
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Withdrawn	01/06/2018	https://clinicaltrials.gov/study/NCT03529097	1	GoF	protect	No participants enrolles
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01906762	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01906762	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Completed	17/10/2015	https://clinicaltrials.gov/study/NCT03865004	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Completed	17/10/2015	https://clinicaltrials.gov/study/NCT03865004	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02782273	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02782273	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Unknown status	01/12/2012	https://clinicaltrials.gov/study/NCT01543165	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	4	Unknown status	01/12/2012	https://clinicaltrials.gov/study/NCT01543165	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02781415	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	MORPHINE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02781415	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	MORPHINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	MORPHINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	MORPHINE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06411665	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	MORPHINE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06411665	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02868944	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02868944	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03036384	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03036384	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT03607916	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT03607916	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	3	Completed	15/03/2014	https://clinicaltrials.gov/study/NCT03263689	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	MORPHINE	targetBased	3	Completed	15/03/2014	https://clinicaltrials.gov/study/NCT03263689	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	tonsillitis	MORPHINE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01691690	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	tonsillitis	MORPHINE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01691690	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	burn	MORPHINE	targetBased	4	Recruiting	11/05/2021	https://clinicaltrials.gov/study/NCT05217160	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	burn	MORPHINE	targetBased	4	Recruiting	11/05/2021	https://clinicaltrials.gov/study/NCT05217160	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature birth	MORPHINE	targetBased	2	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00494429	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature birth	MORPHINE	targetBased	2	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00494429	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	CODEINE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00386269	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	CODEINE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00386269	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	CODEINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01189773	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	CODEINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01189773	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Myopia	CODEINE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02625753	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Myopia	CODEINE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02625753	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	CODEINE	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	CODEINE	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	injury	CODEINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01189773	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Myopia	CODEINE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02625753	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Cleft palate	CODEINE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00386269	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	CODEINE	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	mastodynia	AFIMOXIFENE	targetBased	2	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00272714	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	mastodynia	AFIMOXIFENE	targetBased	2	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00272714	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	mastodynia	AFIMOXIFENE	targetBased	2	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00272714	0.2		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	NALOXONE	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01071057	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	NALOXONE	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01071057	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus	NALOXONE	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01071057	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	2	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02137213	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	2	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02137213	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	3	Unknown status	31/07/2017	https://clinicaltrials.gov/study/NCT03687268	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	3	Unknown status	31/07/2017	https://clinicaltrials.gov/study/NCT03687268	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00992576	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00992576	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02573922	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02573922	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02573922	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH04	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE	targetBased	2	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02137213	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00992576	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE	targetBased	3	Unknown status	31/07/2017	https://clinicaltrials.gov/study/NCT03687268	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	TAMOXIFEN	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06440967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	TAMOXIFEN	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06440967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Gynecomastia	TAMOXIFEN	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00637871	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Gynecomastia	TAMOXIFEN	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00637871	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	20/10/2021	https://clinicaltrials.gov/study/NCT05033041	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	20/10/2021	https://clinicaltrials.gov/study/NCT05033041	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	20/10/2021	https://clinicaltrials.gov/study/NCT05033041	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	20/10/2021	https://clinicaltrials.gov/study/NCT05033041	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	20/10/2021	https://clinicaltrials.gov/study/NCT05033041	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	20/10/2021	https://clinicaltrials.gov/study/NCT05033041	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01781377	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01781377	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01781377	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01781377	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01781377	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pregnancy	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT01781377	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	injury	METOCLOPRAMIDE	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	injury	METOCLOPRAMIDE	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	injury	METOCLOPRAMIDE	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	injury	METOCLOPRAMIDE	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	injury	METOCLOPRAMIDE	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	injury	METOCLOPRAMIDE	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02979548	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02979548	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02979548	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02979548	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02979548	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02979548	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vertigo	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vertigo	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vertigo	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vertigo	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vertigo	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vertigo	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hyperemesis gravidarum	METOCLOPRAMIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02163434	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hyperemesis gravidarum	METOCLOPRAMIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02163434	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hyperemesis gravidarum	METOCLOPRAMIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02163434	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hyperemesis gravidarum	METOCLOPRAMIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02163434	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hyperemesis gravidarum	METOCLOPRAMIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02163434	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hyperemesis gravidarum	METOCLOPRAMIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02163434	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011673	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011673	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011673	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011673	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011673	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011673	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00632606	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00632606	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00632606	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00632606	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00632606	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	METOCLOPRAMIDE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00632606	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	15/09/2022	https://clinicaltrials.gov/study/NCT05533281	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	15/09/2022	https://clinicaltrials.gov/study/NCT05533281	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	15/09/2022	https://clinicaltrials.gov/study/NCT05533281	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	15/09/2022	https://clinicaltrials.gov/study/NCT05533281	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	15/09/2022	https://clinicaltrials.gov/study/NCT05533281	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE	targetBased	4	Completed	15/09/2022	https://clinicaltrials.gov/study/NCT05533281	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	premature birth	METOCLOPRAMIDE	targetBased	4	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00242450	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	premature birth	METOCLOPRAMIDE	targetBased	4	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00242450	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	premature birth	METOCLOPRAMIDE	targetBased	4	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00242450	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	premature birth	METOCLOPRAMIDE	targetBased	4	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00242450	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	premature birth	METOCLOPRAMIDE	targetBased	4	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00242450	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	premature birth	METOCLOPRAMIDE	targetBased	4	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00242450	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	iris melanoma	PACLITAXEL	targetBased	2	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00288041	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	iris melanoma	PACLITAXEL	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT00329641	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stricture	PACLITAXEL	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02753998	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stricture	PACLITAXEL	targetBased	2	Terminated	01/05/2013	https://clinicaltrials.gov/study/NCT01868984	0.2	LoF	protect	catheters no longer available - difficult to recruit subjects
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stricture	PACLITAXEL	targetBased	2	Withdrawn	01/03/2014	https://clinicaltrials.gov/study/NCT02040454	0.2	LoF	protect	required catheters not available
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	renovascular hypertension	PACLITAXEL	targetBased	3	Recruiting	01/10/2019	https://clinicaltrials.gov/study/NCT04366596	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Urethral stricture	PACLITAXEL	targetBased	3	Completed	01/05/2023	https://clinicaltrials.gov/study/NCT06123520	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	toxicity	PACLITAXEL	targetBased	2	Terminated	01/07/2001	https://clinicaltrials.gov/study/NCT00025298	0.2	LoF	protect	low accrual
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Acute kidney injury	ALPROSTADIL	targetBased	2	Recruiting	20/10/2022	https://clinicaltrials.gov/study/NCT05475717	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Acute kidney injury	ALPROSTADIL	targetBased	2	Recruiting	20/10/2022	https://clinicaltrials.gov/study/NCT05475717	0.2	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pregnancy	ALPROSTADIL	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02620215	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pregnancy	ALPROSTADIL	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02620215	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	acute kidney failure	ALPROSTADIL	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03892447	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	acute kidney failure	ALPROSTADIL	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03892447	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	chronic renal failure syndrome	ALPROSTADIL	targetBased	4	Unknown status	01/02/2018	https://clinicaltrials.gov/study/NCT03682952	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	chronic renal failure syndrome	ALPROSTADIL	targetBased	4	Unknown status	01/02/2018	https://clinicaltrials.gov/study/NCT03682952	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	exfoliation syndrome	TIMOLOL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00331240	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e3bbcd-01d4-4dba-be22-308dffecf236	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01292460	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d03de7-06b7-4cfc-9d1b-616969df209c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT01655758	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00332072	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00159653	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72b0d0ec-832a-4c25-b845-2537ab506354	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01652664	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	2	Completed	01/07/1999	https://clinicaltrials.gov/study/NCT00332345	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e7427c3-0195-4212-9839-ab5629906ffc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa1986-1c24-4733-96b3-e6d8e1d44558	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00333125	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f39126-3e3b-4633-a4e0-c1f09a794eec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01749904	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c062ca-add7-4ddf-ba7c-7b5dd531e9ec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6ab3f6-3644-434c-b6cf-e4f111d18962	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00061542	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0972bed1-fb7f-583c-dfab-5db701c7c4a6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00219596	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a236f05-1ee1-4180-9d80-31518d2204c7	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/12/1999	https://clinicaltrials.gov/study/NCT00332436	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3206f5f4-103f-4f04-9c95-35cf17e7a3eb	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=258bbc8d-00ee-45b0-ac35-6f16c4e8d45f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550f843b-4069-42c1-ae5c-09bac19d95ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0c28b92-898a-4755-9eaf-58f790a189ab	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00108017	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ae5ed44-8e5a-41ed-a223-988b4c1436ac	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c20b537-88c6-4ec7-a359-e0ba67afe431	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00293800	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00314171	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00293787	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00332059	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00332384	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01217606	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00314158	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00150267	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/08/2001	https://clinicaltrials.gov/study/NCT00332540	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46726565-6d61-736f-6e73-344576657221	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45ac65b3-19f7-4f33-aebf-cadd3daa4bf1	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917383	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00230763	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02565173	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00311389	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f62dd1-dad2-4892-8a5d-21e5e54509ce	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/01/1993	https://clinicaltrials.gov/study/NCT00751127	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00277498	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167c5ae9-c354-4658-98ca-8b5b0939c841	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00051155	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00869141	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	2	Terminated	01/12/2003	https://clinicaltrials.gov/study/NCT00579969	0.2	LoF	protect	Study stopped and data not analyzed
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01426113	0.7	LoF	protect	Study terminated due to corporate decision.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00219596	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT02154217	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01151904	1	LoF	protect	Difficulty with patient recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01514734	1	LoF	protect	Low recruitment rate
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00763061	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00348023	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01484951	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Unknown status	01/09/2007	https://clinicaltrials.gov/study/NCT00980473	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED51	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e3bbcd-01d4-4dba-be22-308dffecf236	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01677507	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01336569	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01779284	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00108017	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00972257	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00757835	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00444184	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00333125	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c641b6c-3335-4ec3-89b9-2d97a8901062	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00519753	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00981786	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d03de7-06b7-4cfc-9d1b-616969df209c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Terminated	01/06/2012	https://clinicaltrials.gov/study/NCT01514721	1	LoF	protect	low enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	2	Completed	24/04/2009	https://clinicaltrials.gov/study/NCT00832377	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01448837	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	04/08/2009	https://clinicaltrials.gov/study/NCT00906087	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT01004900	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Recruiting	06/11/2017	https://clinicaltrials.gov/study/NCT03193333	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Active, not recruiting	01/09/2015	https://clinicaltrials.gov/study/NCT02390284	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	2	Completed	01/12/1998	https://clinicaltrials.gov/study/NCT00317577	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00972426	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46726565-6d61-736f-6e73-344576657221	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	2	Completed	13/03/2006	https://clinicaltrials.gov/study/NCT00572936	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00061542	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01471158	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c20b537-88c6-4ec7-a359-e0ba67afe431	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01652664	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00486486	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED01	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45ac65b3-19f7-4f33-aebf-cadd3daa4bf1	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811850	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01518244	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02802137	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00800540	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00716859	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	3	Completed	12/03/2007	https://clinicaltrials.gov/study/NCT00449956	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01230736	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9726422-f794-4d39-a437-17dcb8c0f3b5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00230763	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c20b537-88c6-4ec7-a359-e0ba67afe431	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2832de-114f-49e1-8851-99d01c4361ff	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98d81fc6-4482-45e5-8106-4dfd56f3433b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00331240	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4386a2d5-f577-4768-9efe-7d11a8938644	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75b3b776-5eb8-4381-ade1-5cf0e942d5ed	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ae5ed44-8e5a-41ed-a223-988b4c1436ac	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00293787	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32e96044-2713-40f2-b6f7-c342a31382d8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00273455	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ed21930-1e05-46de-8acd-cb6f4798a7fa	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0c28b92-898a-4755-9eaf-58f790a189ab	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02053298	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00314171	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23b61c26-75fb-4d2a-9282-b7af27cbc6cb	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917383	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00913029	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02565173	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550f843b-4069-42c1-ae5c-09bac19d95ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/01/1993	https://clinicaltrials.gov/study/NCT00751127	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03612817	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15732de7-64b9-4c42-897d-89ae1b330192	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT03966560	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00311389	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f39126-3e3b-4633-a4e0-c1f09a794eec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00051155	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f949fa34-6a9a-40d5-91ab-ff1cbb79b9ea	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85724f95-6fc9-4f0c-b69d-05a23b093e2b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e3bbcd-01d4-4dba-be22-308dffecf236	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01292460	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Recruiting	02/01/2019	https://clinicaltrials.gov/study/NCT04098861	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3206f5f4-103f-4f04-9c95-35cf17e7a3eb	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01217606	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=258bbc8d-00ee-45b0-ac35-6f16c4e8d45f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6ab3f6-3644-434c-b6cf-e4f111d18962	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46726565-6d61-736f-6e73-344576657221	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Withdrawn	01/09/2019	https://clinicaltrials.gov/study/NCT03648229	1	LoF	protect	Funding unavailable
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00314158	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f62dd1-dad2-4892-8a5d-21e5e54509ce	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00277498	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d83efec-cd72-4093-a8d4-4dd5021e151e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e7427c3-0195-4212-9839-ab5629906ffc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c062ca-add7-4ddf-ba7c-7b5dd531e9ec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00397241	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c33fd-aa86-49ad-a767-c79ade4a62c7	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00293800	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbba38a-dbd6-4d3b-8788-cadb7d5246ee	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11268176-a549-43d4-a683-beab6dec0d0a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63f36fa6-bd5a-49b2-b7bf-28ce0db3c6dc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72b0d0ec-832a-4c25-b845-2537ab506354	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00159653	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fa20dc-b181-48be-83ce-d66a83753878	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a236f05-1ee1-4180-9d80-31518d2204c7	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	2	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00991822	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00150267	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	2	Completed	29/03/2016	https://clinicaltrials.gov/study/NCT02754596	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d58ead9-dec9-448b-9f46-07b48c1f636c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa1986-1c24-4733-96b3-e6d8e1d44558	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01749904	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0972bed1-fb7f-583c-dfab-5db701c7c4a6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01243567	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167c5ae9-c354-4658-98ca-8b5b0939c841	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c57114-5f79-4d70-9423-7b87fb554971	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	corneal edema	TIMOLOL	targetBased	3	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00800423	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	wet macular degeneration	TIMOLOL	targetBased	2	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02571972	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	wet macular degeneration	TIMOLOL	targetBased	2	Completed	08/02/2017	https://clinicaltrials.gov/study/NCT03034772	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	varicose ulcer	TIMOLOL	targetBased	2	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02422017	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	TIMOLOL	targetBased	2	Recruiting	07/04/2021	https://clinicaltrials.gov/study/NCT05114239	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	TIMOLOL	targetBased	2	Completed	20/08/2018	https://clinicaltrials.gov/study/NCT03452072	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	TIMOLOL	targetBased	2	Terminated	02/01/2019	https://clinicaltrials.gov/study/NCT03579160	0.2	LoF	protect	Due to the insufficient accrual rate and strategic reasons to focus our efforts on higher impact research projects.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	eye disease	TIMOLOL	targetBased	4	Completed	04/05/2009	https://clinicaltrials.gov/study/NCT00957190	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	age-related macular degeneration	TIMOLOL	targetBased	2	Completed	08/02/2017	https://clinicaltrials.gov/study/NCT03034772	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	paronychia	TIMOLOL	targetBased	3	Recruiting	01/04/2023	https://clinicaltrials.gov/study/NCT06140186	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Fatigue	DOCETAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00040885	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	iris melanoma	VORINOSTAT	targetBased	2	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00121225	0.2	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Premature rupture of membranes	DINOPROSTONE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355966	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Premature rupture of membranes	DINOPROSTONE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355966	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Premature rupture of membranes	DINOPROSTONE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355303	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Premature rupture of membranes	DINOPROSTONE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355303	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pregnancy	DINOPROSTONE	targetBased	3	Terminated	01/12/2016	https://clinicaltrials.gov/study/NCT02888041	0.7	GoF	protect	Not enough patients
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pregnancy	DINOPROSTONE	targetBased	3	Terminated	01/12/2016	https://clinicaltrials.gov/study/NCT02888041	0.7	GoF	protect	Not enough patients
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pregnancy	DINOPROSTONE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00602095	0.7	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pregnancy	DINOPROSTONE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00602095	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	29/04/2016	https://clinicaltrials.gov/study/NCT02595528	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	29/04/2016	https://clinicaltrials.gov/study/NCT02595528	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	29/04/2016	https://clinicaltrials.gov/study/NCT02595528	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	29/04/2016	https://clinicaltrials.gov/study/NCT02595528	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	29/04/2016	https://clinicaltrials.gov/study/NCT02595528	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	01/03/2019	https://clinicaltrials.gov/study/NCT03857542	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	01/03/2019	https://clinicaltrials.gov/study/NCT03857542	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	01/03/2019	https://clinicaltrials.gov/study/NCT03857542	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	01/03/2019	https://clinicaltrials.gov/study/NCT03857542	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	01/03/2019	https://clinicaltrials.gov/study/NCT03857542	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05124275	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05124275	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05124275	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05124275	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05124275	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05578001	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05578001	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05578001	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05578001	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Active, not recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT05578001	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03804268	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03804268	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03804268	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03804268	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03804268	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04657172	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04657172	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04657172	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04657172	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04657172	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06451666	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06451666	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06451666	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06451666	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06451666	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	15/02/2021	https://clinicaltrials.gov/study/NCT04675151	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	15/02/2021	https://clinicaltrials.gov/study/NCT04675151	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	15/02/2021	https://clinicaltrials.gov/study/NCT04675151	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	15/02/2021	https://clinicaltrials.gov/study/NCT04675151	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	2	Completed	15/02/2021	https://clinicaltrials.gov/study/NCT04675151	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	22/12/2022	https://clinicaltrials.gov/study/NCT05646719	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	22/12/2022	https://clinicaltrials.gov/study/NCT05646719	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	22/12/2022	https://clinicaltrials.gov/study/NCT05646719	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	22/12/2022	https://clinicaltrials.gov/study/NCT05646719	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	22/12/2022	https://clinicaltrials.gov/study/NCT05646719	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Sjogren syndrome	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Sjogren syndrome	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Sjogren syndrome	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Sjogren syndrome	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Sjogren syndrome	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	dry eye syndrome	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05119920	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	dry eye syndrome	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05119920	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	dry eye syndrome	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05119920	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	dry eye syndrome	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05119920	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	dry eye syndrome	PILOCARPINE	targetBased	2	Completed	03/01/2022	https://clinicaltrials.gov/study/NCT05119920	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4	Completed	01/08/1978	https://clinicaltrials.gov/study/NCT00803803	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4	Completed	01/08/1978	https://clinicaltrials.gov/study/NCT00803803	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4	Completed	01/08/1978	https://clinicaltrials.gov/study/NCT00803803	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4	Completed	01/08/1978	https://clinicaltrials.gov/study/NCT00803803	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4	Completed	01/08/1978	https://clinicaltrials.gov/study/NCT00803803	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	open-angle glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	ocular hypertension	PILOCARPINE	targetBased	3	Withdrawn	05/06/2019	https://clinicaltrials.gov/study/NCT04005079	0.7	GoF	protect	not performing Trabectomes
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00762645	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00762645	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00762645	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00762645	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	angle-closure glaucoma	PILOCARPINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00762645	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05506137	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05506137	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05506137	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05506137	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05506137	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02982577	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02982577	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02982577	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02982577	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02982577	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Miosis	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Miosis	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Miosis	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Miosis	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Miosis	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84428e9a-f486-44d9-ad93-4ea9069a6787	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	3	Recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03933631	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	3	Recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03933631	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	3	Recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03933631	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	3	Recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03933631	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	3	Recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03933631	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ded29a-448d-4c4a-9307-403836a67da4	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB51	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB51	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB51	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB51	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB51	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB01	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB01	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB01	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB01	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	glaucoma	PILOCARPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EB01	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	proliferative vitreoretinopathy	COLCHICINE	targetBased	3	Unknown status	01/09/2006	https://clinicaltrials.gov/study/NCT00370760	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ischemia reperfusion injury	COLCHICINE	targetBased	3	Enrolling by invitation	04/12/2022	https://clinicaltrials.gov/study/NCT05734612	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	chronic kidney disease	COLCHICINE	targetBased	2	Recruiting	01/11/2022	https://clinicaltrials.gov/study/NCT05677555	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	chronic kidney disease	COLCHICINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01173107	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	chronic kidney disease	COLCHICINE	targetBased	2	Recruiting	01/11/2021	https://clinicaltrials.gov/study/NCT04500665	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Behcet's syndrome	COLCHICINE	targetBased	2	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00700297	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Behcet's syndrome	COLCHICINE	targetBased	2	Completed	25/03/2019	https://clinicaltrials.gov/study/NCT03888846	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	mastodynia	ACETAMINOPHEN	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00382083	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	fasting	ACETAMINOPHEN	targetBased	4	Recruiting	06/10/2020	https://clinicaltrials.gov/study/NCT04625608	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	renal colic	ACETAMINOPHEN	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02304783	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	renal colic	ACETAMINOPHEN	targetBased	4	Withdrawn	01/09/2016	https://clinicaltrials.gov/study/NCT01685658	1		protect	same study already published
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	renal colic	ACETAMINOPHEN	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01906762	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	renal colic	ACETAMINOPHEN	targetBased	2	Recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05722782	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	renal colic	ACETAMINOPHEN	targetBased	4	Completed	17/10/2015	https://clinicaltrials.gov/study/NCT03865004	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hypertension, pregnancy-induced	ACETAMINOPHEN	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02891174	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	nephrolithiasis	ACETAMINOPHEN	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02095665	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	nephrolithiasis	ACETAMINOPHEN	targetBased	3	Completed	27/07/2018	https://clinicaltrials.gov/study/NCT03584373	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Nausea	ACETAMINOPHEN	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	urolithiasis	ACETAMINOPHEN	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01318187	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	idiopathic nephrotic syndrome	ACETAMINOPHEN	targetBased	3	Recruiting	29/03/2023	https://clinicaltrials.gov/study/NCT05627557	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49a93a8-158a-4184-b4bc-cac3031ad8b6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b253c9c-007e-4109-9d8d-2f318d522420	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11c28c6c-d2f0-4092-8ef1-4262b17be50e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Completed	06/12/2016	https://clinicaltrials.gov/study/NCT02761980	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb3b29d2-d705-48b9-8893-8a8ce4694bfb	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55768b45-fd98-4779-85b6-6a50c628677e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00267293	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=523561fb-f6a7-4cde-9be2-bba02e60e208	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Terminated	01/03/2010	https://clinicaltrials.gov/study/NCT01019980	1		protect	Placebo - Active Drug Not Available. No patients received drug. There are no study results to disclose.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00eb3e4b-1507-4c9a-83a5-ef50cb312753	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00325819	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=182a105b-bd49-42b5-b4e0-46e5ec0197e3	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d7cbf19-6533-4788-8dc8-e8bb9d116447	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02BE71	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce11862b-24c6-4d51-87a9-930858a47de5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Suspended	01/08/2010	https://clinicaltrials.gov/study/NCT01182974	0.7		protect	Difficulty in patient enrollment
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a38f63a-8852-6dab-e053-2a95a90a90d6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fd31f1c-0fab-4fd2-a0f1-56ade1f013f0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT01359020	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02280239	1		protect	Only enrolled 10 participants over 9 months which is less then anticipated (75).
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008c5055-4ae3-498f-a7bf-5bd00f738c6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01946594	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2354204f-0d47-4232-8ca6-f74913847ac7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e119fafe-9d50-4555-9bd9-389e4a1e2718	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f172d58-4050-424b-9743-130d8e618fe8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d08eca3-d469-4e0a-a137-e0242870a166	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad165e36-2704-3527-e053-2995a90a6d2a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	2	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01958866	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=842706f9-eedf-1783-49ed-e6b7ae7d650e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d384e88-5c11-4600-ac6c-a38371570138	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55fffc1d-8449-4c28-a391-c6f60dd85622	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02283203	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9eee551c-0bf8-4351-a0f2-68af9fc51eb7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=478e8edb-ca2c-5f76-e054-00144ff8d46c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c98b5bd-be18-4334-b6c7-bf51cd8ccb00	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b705a2-2312-46f8-871b-09df2bbff1e6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=889c5b6a-879e-425c-a25a-435766e9d601	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d3a6994-86f4-3a9a-e053-2991aa0a8a6c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Terminated	01/10/2012	https://clinicaltrials.gov/study/NCT01530880	1		protect	PI no longer at institution
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Unknown status	01/12/2014	https://clinicaltrials.gov/study/NCT02294071	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d21e453-db6d-4c8a-b6f4-8ede319d0c95	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0b36e4d-3667-58f6-e053-2a95a90afad7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8c6d31-0dec-4353-8094-f4abf92f644d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56728a9d-ada8-4784-898a-21d639606358	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=135b2e99-92d1-4312-8ff9-ca44368f6874	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491ad8a0-1d6b-457a-982a-e68b1def7b55	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f466c660-69eb-4581-81ff-1499fa421d8b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9181e35a-c8d9-4109-b03d-114cd7d42bae	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2307f52c-8ea3-43b4-9b9f-bd60ac939f24	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02BE01	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=028062ea-5072-45c1-80f0-e291d94b4dbe	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4722601-10c3-21a7-e053-2995a90a161a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd759f58-5912-40d5-a5de-632df3e61a79	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88edcc93-eb8f-4949-89b3-f398dbee0f10	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02BE51	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01002573	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de2b2e34-62a5-451f-ab68-531d1c9d4d82	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bdc48d22-c606-665e-e053-2995a90a9dbe	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01869699	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe37f2e-cf13-451d-8988-e96a5712e359	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00434681	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02212990	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00493311	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77a5f0d0-18cf-4618-85b7-90c86a1f2e23	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15361568-74a9-4dc2-a27a-4e1298c86b51	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00564629	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fever	ACETAMINOPHEN	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03918135	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Febrile seizure (within the age range of 3 months to 6 years)	ACETAMINOPHEN	targetBased	4	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00568217	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hypertrophy	ACETAMINOPHEN	targetBased	2	Completed	02/08/2019	https://clinicaltrials.gov/study/NCT03714919	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Cleft palate	ACETAMINOPHEN	targetBased	2	Withdrawn	01/12/2015	https://clinicaltrials.gov/study/NCT01760330	0.2		protect	Unable to obtain funding
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Cleft palate	ACETAMINOPHEN	targetBased	2	Completed	14/01/2018	https://clinicaltrials.gov/study/NCT03412474	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	2	Unknown status	15/01/2019	https://clinicaltrials.gov/study/NCT03865147	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02667730	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	3	Completed	08/02/2018	https://clinicaltrials.gov/study/NCT03585374	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02432456	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	4	Completed	16/10/2022	https://clinicaltrials.gov/study/NCT04199572	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	2	Completed	10/01/2020	https://clinicaltrials.gov/study/NCT05764707	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	injury	ACETAMINOPHEN	targetBased	2	Completed	20/04/2019	https://clinicaltrials.gov/study/NCT03767933	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	tonsillitis	ACETAMINOPHEN	targetBased	4	Recruiting	01/03/2018	https://clinicaltrials.gov/study/NCT03323047	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	tonsillitis	ACETAMINOPHEN	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01691690	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myopia	ACETAMINOPHEN	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02625753	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	nail disorder	ACETAMINOPHEN	targetBased	4	Completed	10/11/2022	https://clinicaltrials.gov/study/NCT05544734	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Tension-type headache	ACETAMINOPHEN	targetBased	2	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01755702	0.2		protect	Study was terminated due to unforeseen difficulties with subject recruitment. No safety issues were identified in the study with this new formulation.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	preeclampsia	ACETAMINOPHEN	targetBased	2	Recruiting	10/06/2019	https://clinicaltrials.gov/study/NCT03978767	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	preeclampsia	ACETAMINOPHEN	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02891174	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9c3c12b-4efa-4ec4-a156-c403aff81753	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f3b1404-9252-470a-aa8c-b360c85731f3	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7cf7c5d-5c9a-4201-9e30-1cd616071855	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1f8cf03-d4fc-42b3-aada-efc3ffd8e1ba	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b995a0b2-898d-4a8f-b44f-097ae54e0ba5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45276fb7-80c0-4949-b59c-0970e156c13d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4cde7fc-d86a-1418-e053-2a95a90aed25	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f0f6488-0366-4bdf-ad49-cdbdced9d0c9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6124c8d9-15bc-4a84-a545-6db9d185ff82	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4	Withdrawn	05/09/2017	https://clinicaltrials.gov/study/NCT03472872	1		protect	no longer recruiting or studying
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2321b5fb-9b3a-4435-8deb-e8cfd2208b43	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4ba51b8-e86f-4227-e053-2995a90a853e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44a25c50-b16b-407c-99ea-668afca25924	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7897198-c917-4937-9f56-e63eab73c9d6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33f2319-2181-46db-a094-3e874b324c0a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f466c660-69eb-4581-81ff-1499fa421d8b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008c5055-4ae3-498f-a7bf-5bd00f738c6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=653ed8ac-102b-40e7-8fa7-af3b66bf1b26	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55fffc1d-8449-4c28-a391-c6f60dd85622	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0b36e4d-3667-58f6-e053-2a95a90afad7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de2b2e34-62a5-451f-ab68-531d1c9d4d82	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d08eca3-d469-4e0a-a137-e0242870a166	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c2d9335-34ac-460f-89c7-3a90cfc1301c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05d80f93-020c-48a5-b72f-4a91908949b8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11c28c6c-d2f0-4092-8ef1-4262b17be50e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=248e8c14-4f50-46a4-8da4-d8edc47e5aac	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=763a5334-a741-4678-9947-603776622450	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e902e339-b5bc-4c5d-9861-662f739ccb12	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd759f58-5912-40d5-a5de-632df3e61a79	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9181e35a-c8d9-4109-b03d-114cd7d42bae	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be15ca57-575b-4c2a-833b-d300c2cefe5e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30e483da-eaf1-4c73-9fed-333337f9ba86	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4722601-10c3-21a7-e053-2995a90a161a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e243dbe-138f-4346-ba22-ceea01e97052	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=413d82d3-a896-4f15-9fca-c1b7b9a1ee63	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd101c27-6ba9-4cd3-baec-a354504c37a0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a0fb67e-a46a-4137-ac73-c7b12bc1977d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fd761e6-64fe-44cc-8b74-10ce31ccfd66	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51dd467b-aae8-41fa-e054-00144ff8d46c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a563c0ea-28b8-1093-e053-2a95a90aedc8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92c12df0-f9e5-08f2-e053-2a95a90a9207	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7486dadf-cd61-478c-8c0e-ad14f7e7ac6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3430c7e4-e142-407e-bed5-358dd6bd10f7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=842706f9-eedf-1783-49ed-e6b7ae7d650e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8c6d31-0dec-4353-8094-f4abf92f644d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad788820-1320-4e21-9b9f-82dc0e454335	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba3e9c30-28b9-4604-8af8-00d1f2eed873	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a8f798e-cd54-4b39-b8d4-28227ebbaeb5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ddb86a8-e34c-4a03-a60a-d3fedaf90608	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84e7be8f-2785-45ef-9c44-de05394fcd99	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4	Completed	20/04/2019	https://clinicaltrials.gov/study/NCT03910088	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82719258-a8a7-1885-e053-2991aa0a843c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d21e453-db6d-4c8a-b6f4-8ede319d0c95	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=182a105b-bd49-42b5-b4e0-46e5ec0197e3	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bd940ca-bcc6-48e8-a98a-ddcea09a0e04	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c4cc3d-9a68-42a1-801d-5d4ec107ffad	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba17b25c-fc4d-4673-82a3-49ab07cab1d9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f172d58-4050-424b-9743-130d8e618fe8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=028062ea-5072-45c1-80f0-e291d94b4dbe	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2307f52c-8ea3-43b4-9b9f-bd60ac939f24	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe37f2e-cf13-451d-8988-e96a5712e359	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad6408ff-079b-4757-e053-2995a90a53eb	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94fdab-27ea-4c0f-a91c-735ce697304b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49a93a8-158a-4184-b4bc-cac3031ad8b6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294a5ed5-8ae9-48cb-a6ec-094729ba40b2	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=424961db-c6dd-49d2-8d60-413f39f8db7d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5ea858e-76d9-4777-b3dc-5d614f66d485	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c98b5bd-be18-4334-b6c7-bf51cd8ccb00	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47c61858-72ce-409b-a3af-a63620cf7d13	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55768b45-fd98-4779-85b6-6a50c628677e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd167c7c-2e4a-49b9-9fec-d16c15ec77bf	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b705a2-2312-46f8-871b-09df2bbff1e6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=478e8edb-ca2c-5f76-e054-00144ff8d46c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87a8176e-9d32-4a8e-84ab-c81b2f74d46f	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853012b8-d3b7-78d3-e053-2a91aa0ab0f2	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=328fd31e-e715-4aa5-a0a0-ebe64f21d8d6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4325b17-23bc-44ac-868d-bb0886853a73	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=babdbe4e-a14c-4ddd-a93b-7ac4f54a10b7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6197eff5-0351-42ef-bb3f-cbc26e6d0d14	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1241e896-be03-48f5-b825-b520189e2b3b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb3b29d2-d705-48b9-8893-8a8ce4694bfb	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bfacd95-3300-46a3-8699-1dcca035b6df	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e5db7f-fc7a-45cd-8407-b9e8a47be8cb	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5278a128-41ec-4494-e054-00144ff8d46c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28f41696-7d67-436e-aa33-86d8ba82efd7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a3f498d-445f-410b-818f-9f119bd6c492	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b253c9c-007e-4109-9d8d-2f318d522420	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3d9120c-f7ef-4d08-99ab-33a967a46f6c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=889c5b6a-879e-425c-a25a-435766e9d601	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=399e0e51-c2a7-451c-b74d-d3db140cef69	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56728a9d-ada8-4784-898a-21d639606358	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf30c75-e867-4a2f-a481-702d7aa96c23	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9eee551c-0bf8-4351-a0f2-68af9fc51eb7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2354204f-0d47-4232-8ca6-f74913847ac7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bdc48d22-c606-665e-e053-2995a90a9dbe	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd3f2ccc-ae74-4000-888c-7f25e41dbc3d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491ad8a0-1d6b-457a-982a-e68b1def7b55	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77a5f0d0-18cf-4618-85b7-90c86a1f2e23	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=251f2782-e7ae-11e1-aff1-0800200c9a66	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d3a6994-86f4-3a9a-e053-2991aa0a8a6c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d7cbf19-6533-4788-8dc8-e8bb9d116447	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce11862b-24c6-4d51-87a9-930858a47de5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f631f45-06e4-4860-abb7-1e1b1e146035	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9881226c-b7cc-4b6d-9c6b-acd4cf76024a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24a562b5-501e-49ef-8c9d-27d07e86ea97	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a280262a-bd29-4d9c-b4a0-4512dfff6d73	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e32881f5-2bb5-4756-aa86-a09473ab590b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=135b2e99-92d1-4312-8ff9-ca44368f6874	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60183922-bfd3-4377-884a-51b2f0a4c93a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02fa9c00-214a-4289-8ab5-d470ce04a70f	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=523561fb-f6a7-4cde-9be2-bba02e60e208	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d384e88-5c11-4600-ac6c-a38371570138	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fd31f1c-0fab-4fd2-a0f1-56ade1f013f0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b8f83ed-1ca9-49ac-9b2a-2609b68200f9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15361568-74a9-4dc2-a27a-4e1298c86b51	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6dddc7c-370f-447b-b24e-8cc68b352c4c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27312ee4-d1f4-4a95-9c45-91fa5a01f5ba	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	3	Terminated	12/03/2012	https://clinicaltrials.gov/study/NCT01552798	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e944d5-3473-4d8c-8df4-2ffc7474e9fa	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36a4ec1f-50c3-4d61-ada9-987ccad3563c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Headache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b37b786e-0cce-419d-94ed-3b64a1eb1201	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	post operative nausea and vomiting	ACETAMINOPHEN	targetBased	3	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT02102555	0.7		protect	study closed due to difficulty enrolling subjects - no results
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	post operative nausea and vomiting	ACETAMINOPHEN	targetBased	4	Completed	20/07/2018	https://clinicaltrials.gov/study/NCT03588338	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	perineal laceration during delivery	ACETAMINOPHEN	targetBased	2	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT03041779	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	drug-induced hepatitis	ACETAMINOPHEN	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00616018	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	kidney disease	ACETAMINOPHEN	targetBased	3	Active, not recruiting	25/06/2021	https://clinicaltrials.gov/study/NCT04629248	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	chronic renal failure syndrome	FENOLDOPAM	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00122018	0.2	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	chronic renal failure syndrome	FENOLDOPAM	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00122018	0.2	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	chronic renal failure syndrome	FENOLDOPAM	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00122018	0.2	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00286403	0.2	GoF	protect	The study was terminated due to logistics at a local hospital.
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Acute kidney injury	FENOLDOPAM	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00286403	0.2	GoF	protect	The study was terminated due to logistics at a local hospital.
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00286403	0.2	GoF	protect	The study was terminated due to logistics at a local hospital.
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00621790	0.7	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Acute kidney injury	FENOLDOPAM	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00621790	0.7	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00621790	0.7	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00557219	0.7	GoF	protect	Main cooperator finished cooperation
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Acute kidney injury	FENOLDOPAM	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00557219	0.7	GoF	protect	Main cooperator finished cooperation
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00557219	0.7	GoF	protect	Main cooperator finished cooperation
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	kidney failure	FENOLDOPAM	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00982527	0.7	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	kidney failure	FENOLDOPAM	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00982527	0.7	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	kidney failure	FENOLDOPAM	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00982527	0.7	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	kidney failure	FENOLDOPAM	targetBased	4	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01073189	1	GoF	protect	withdrew due to funding
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	kidney failure	FENOLDOPAM	targetBased	4	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01073189	1	GoF	protect	withdrew due to funding
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	kidney failure	FENOLDOPAM	targetBased	4	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01073189	1	GoF	protect	withdrew due to funding
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00368017	0.2	GoF	protect	unable to replace Fellow conducting the study who left institution in 2007
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00368017	0.2	GoF	protect	unable to replace Fellow conducting the study who left institution in 2007
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00368017	0.2	GoF	protect	unable to replace Fellow conducting the study who left institution in 2007
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00368017	0.2	GoF	protect	unable to replace Fellow conducting the study who left institution in 2007
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00368017	0.2	GoF	protect	unable to replace Fellow conducting the study who left institution in 2007
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00368017	0.2	GoF	protect	unable to replace Fellow conducting the study who left institution in 2007
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00745225	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00745225	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00745225	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00745225	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00745225	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00745225	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Recruiting	01/04/2018	https://clinicaltrials.gov/study/NCT03471117	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Recruiting	01/04/2018	https://clinicaltrials.gov/study/NCT03471117	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Recruiting	01/04/2018	https://clinicaltrials.gov/study/NCT03471117	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Recruiting	01/04/2018	https://clinicaltrials.gov/study/NCT03471117	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Recruiting	01/04/2018	https://clinicaltrials.gov/study/NCT03471117	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Recruiting	01/04/2018	https://clinicaltrials.gov/study/NCT03471117	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT01253928	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT01253928	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT01253928	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT01253928	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT01253928	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	4	Unknown status	01/03/2007	https://clinicaltrials.gov/study/NCT01253928	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ischemia reperfusion injury	PIOGLITAZONE	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05775380	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ischemia reperfusion injury	PIOGLITAZONE	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05775380	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ischemia reperfusion injury	PIOGLITAZONE	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05775380	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ischemia reperfusion injury	PIOGLITAZONE	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05775380	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ischemia reperfusion injury	PIOGLITAZONE	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05775380	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ischemia reperfusion injury	PIOGLITAZONE	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05775380	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01068444	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01068444	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01068444	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01068444	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01068444	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01068444	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00062764	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00062764	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00062764	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00062764	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00062764	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatitis	PIOGLITAZONE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00062764	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	nephrolithiasis	PIOGLITAZONE	targetBased	4	Recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT04370093	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	nephrolithiasis	PIOGLITAZONE	targetBased	4	Recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT04370093	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	nephrolithiasis	PIOGLITAZONE	targetBased	4	Recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT04370093	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	nephrolithiasis	PIOGLITAZONE	targetBased	4	Recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT04370093	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	nephrolithiasis	PIOGLITAZONE	targetBased	4	Recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT04370093	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	nephrolithiasis	PIOGLITAZONE	targetBased	4	Recruiting	17/10/2019	https://clinicaltrials.gov/study/NCT04370093	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Ataxia-telangiectasia	PIOGLITAZONE	targetBased	4	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02733679	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Ataxia-telangiectasia	PIOGLITAZONE	targetBased	4	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02733679	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Ataxia-telangiectasia	PIOGLITAZONE	targetBased	4	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02733679	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Ataxia-telangiectasia	PIOGLITAZONE	targetBased	4	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02733679	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Ataxia-telangiectasia	PIOGLITAZONE	targetBased	4	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02733679	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Ataxia-telangiectasia	PIOGLITAZONE	targetBased	4	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02733679	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	2	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00013598	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	2	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00013598	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	2	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00013598	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	2	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00013598	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	2	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00013598	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	2	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00013598	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	PIOGLITAZONE	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Polycystic Kidney Disease	PIOGLITAZONE	targetBased	2	Completed	26/01/2016	https://clinicaltrials.gov/study/NCT02697617	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Polycystic Kidney Disease	PIOGLITAZONE	targetBased	2	Completed	26/01/2016	https://clinicaltrials.gov/study/NCT02697617	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Polycystic Kidney Disease	PIOGLITAZONE	targetBased	2	Completed	26/01/2016	https://clinicaltrials.gov/study/NCT02697617	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Polycystic Kidney Disease	PIOGLITAZONE	targetBased	2	Completed	26/01/2016	https://clinicaltrials.gov/study/NCT02697617	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Polycystic Kidney Disease	PIOGLITAZONE	targetBased	2	Completed	26/01/2016	https://clinicaltrials.gov/study/NCT02697617	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Polycystic Kidney Disease	PIOGLITAZONE	targetBased	2	Completed	26/01/2016	https://clinicaltrials.gov/study/NCT02697617	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Headache	FENTANYL	targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02638506	1	GoF	protect	Covid restrictions
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Headache	FENTANYL	targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02638506	1	GoF	protect	Covid restrictions
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL	targetBased	4	Terminated	04/09/2018	https://clinicaltrials.gov/study/NCT03528512	1	GoF	protect	Staffing for study was eliminated
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL	targetBased	4	Terminated	04/09/2018	https://clinicaltrials.gov/study/NCT03528512	1	GoF	protect	Staffing for study was eliminated
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00724035	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00724035	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT05437575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT05437575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Multiple Organ Failure	FENTANYL	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02587273	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Multiple Organ Failure	FENTANYL	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02587273	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	newborn respiratory distress syndrome	FENTANYL	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	newborn respiratory distress syndrome	FENTANYL	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic kidney disease	FENTANYL	targetBased	3	Recruiting	17/05/2021	https://clinicaltrials.gov/study/NCT04908345	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic kidney disease	FENTANYL	targetBased	3	Recruiting	17/05/2021	https://clinicaltrials.gov/study/NCT04908345	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Otitis media	FENTANYL	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT01244126	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Otitis media	FENTANYL	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT01244126	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cannabis use	FENTANYL	targetBased	4	Recruiting	14/03/2023	https://clinicaltrials.gov/study/NCT05873465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cannabis use	FENTANYL	targetBased	4	Recruiting	14/03/2023	https://clinicaltrials.gov/study/NCT05873465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Myoclonus	FENTANYL	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02518789	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Myoclonus	FENTANYL	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02518789	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Achalasia	FENTANYL	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04177342	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Achalasia	FENTANYL	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04177342	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	oxidative stress	FENTANYL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02202239	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	oxidative stress	FENTANYL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02202239	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	FENTANYL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00667043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	FENTANYL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00667043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	FENTANYL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02224443	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	FENTANYL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02224443	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	FENTANYL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01627873	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	FENTANYL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01627873	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	shortness of breath	FENTANYL	targetBased	3	Recruiting	23/10/2020	https://clinicaltrials.gov/study/NCT04188418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	shortness of breath	FENTANYL	targetBased	3	Recruiting	23/10/2020	https://clinicaltrials.gov/study/NCT04188418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	FENTANYL	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	FENTANYL	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leg injury	FENTANYL	targetBased	4	Recruiting	10/01/2020	https://clinicaltrials.gov/study/NCT04199013	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leg injury	FENTANYL	targetBased	4	Recruiting	10/01/2020	https://clinicaltrials.gov/study/NCT04199013	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	FENTANYL	targetBased	4	Unknown status	01/12/2012	https://clinicaltrials.gov/study/NCT02116842	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	FENTANYL	targetBased	4	Unknown status	01/12/2012	https://clinicaltrials.gov/study/NCT02116842	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	FENTANYL	targetBased	2	Completed	28/09/2022	https://clinicaltrials.gov/study/NCT05487196	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	FENTANYL	targetBased	2	Completed	28/09/2022	https://clinicaltrials.gov/study/NCT05487196	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	FENTANYL	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01621230	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	FENTANYL	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01621230	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	tonsillitis	FENTANYL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00654511	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	tonsillitis	FENTANYL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00654511	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic otitis media	FENTANYL	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01188551	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic otitis media	FENTANYL	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01188551	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Multiple Organ Failure	ROSIGLITAZONE	targetBased	3	Unknown status	01/04/2006	https://clinicaltrials.gov/study/NCT00409097	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Multiple Organ Failure	ROSIGLITAZONE	targetBased	3	Unknown status	01/04/2006	https://clinicaltrials.gov/study/NCT00409097	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Multiple Organ Failure	ROSIGLITAZONE	targetBased	3	Unknown status	01/04/2006	https://clinicaltrials.gov/study/NCT00409097	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Multiple Organ Failure	ROSIGLITAZONE	targetBased	3	Unknown status	01/04/2006	https://clinicaltrials.gov/study/NCT00409097	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Multiple Organ Failure	ROSIGLITAZONE	targetBased	3	Unknown status	01/04/2006	https://clinicaltrials.gov/study/NCT00409097	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Multiple Organ Failure	ROSIGLITAZONE	targetBased	3	Unknown status	01/04/2006	https://clinicaltrials.gov/study/NCT00409097	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	dry eye syndrome	NALTREXONE	targetBased	2	Completed	31/07/2018	https://clinicaltrials.gov/study/NCT03660475	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	dry eye syndrome	NALTREXONE	targetBased	2	Completed	31/07/2018	https://clinicaltrials.gov/study/NCT03660475	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	dry eye syndrome	NALTREXONE	targetBased	2	Completed	31/07/2018	https://clinicaltrials.gov/study/NCT03660475	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Fatigue	NALTREXONE	targetBased	2	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT05430152	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Fatigue	NALTREXONE	targetBased	2	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT05430152	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Fatigue	NALTREXONE	targetBased	2	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT05430152	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	frontal fibrosing alopecia	NALTREXONE	targetBased	2	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT04409041	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	frontal fibrosing alopecia	NALTREXONE	targetBased	2	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT04409041	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	frontal fibrosing alopecia	NALTREXONE	targetBased	2	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT04409041	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	post-operative atrial fibrillation	AMIODARONE	targetBased	4	Completed	20/01/2023	https://clinicaltrials.gov/study/NCT05681182	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	post-operative atrial fibrillation	AMIODARONE	targetBased	4	Completed	20/01/2023	https://clinicaltrials.gov/study/NCT05681182	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	post-operative atrial fibrillation	AMIODARONE	targetBased	4	Completed	20/01/2023	https://clinicaltrials.gov/study/NCT05681182	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypoxemia	ALFENTANIL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01470170	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypoxemia	ALFENTANIL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01470170	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	adverse effect	NEBIVOLOL	targetBased	4	Withdrawn	01/01/2030	https://clinicaltrials.gov/study/NCT04432610	1	LoF	protect	COVID pandemic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic kidney disease	METHADONE	targetBased	3	Recruiting	17/05/2021	https://clinicaltrials.gov/study/NCT04908345	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic kidney disease	METHADONE	targetBased	3	Recruiting	17/05/2021	https://clinicaltrials.gov/study/NCT04908345	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Headache	MIRTAZAPINE	targetBased	4	Completed	15/11/2021	https://clinicaltrials.gov/study/NCT05108688	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	MIRTAZAPINE	targetBased	4	Completed	15/07/2019	https://clinicaltrials.gov/study/NCT04013386	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Weight loss	MIRTAZAPINE	targetBased	2	Terminated	01/11/2008	https://clinicaltrials.gov/study/NCT00832520	0.2	LoF	protect	Low accrual rate.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	MIRTAZAPINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02336750	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	OXYCODONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT02277678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	OXYCODONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT02277678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic kidney disease	OXYCODONE	targetBased	4	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02452437	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic kidney disease	OXYCODONE	targetBased	4	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02452437	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Achalasia	OXYCODONE	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04177342	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Achalasia	OXYCODONE	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04177342	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	OXYCODONE	targetBased	4	Recruiting	19/05/2023	https://clinicaltrials.gov/study/NCT05924165	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	OXYCODONE	targetBased	4	Recruiting	19/05/2023	https://clinicaltrials.gov/study/NCT05924165	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	OXYCODONE	targetBased	3	Completed	27/07/2018	https://clinicaltrials.gov/study/NCT03584373	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	OXYCODONE	targetBased	3	Completed	27/07/2018	https://clinicaltrials.gov/study/NCT03584373	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	OXYCODONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00784472	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	OXYCODONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00784472	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	OXYCODONE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02573922	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	OXYCODONE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02573922	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nausea	OXYCODONE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT02295124	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nausea	OXYCODONE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT02295124	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	preeclampsia	OXYCODONE	targetBased	2	Recruiting	10/06/2019	https://clinicaltrials.gov/study/NCT03978767	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	preeclampsia	OXYCODONE	targetBased	2	Recruiting	10/06/2019	https://clinicaltrials.gov/study/NCT03978767	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	burn	OXYCODONE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT06142591	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	burn	OXYCODONE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT06142591	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	skin atrophy	ESTRADIOL	targetBased	2	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT01553773	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	skin atrophy	ESTRADIOL	targetBased	2	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT01553773	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00391417	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00391417	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00185237	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00185237	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00206622	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00206622	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT01389102	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTRADIOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT01389102	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	dry eye syndrome	ESTRADIOL	targetBased	2	Completed	18/01/2019	https://clinicaltrials.gov/study/NCT03821415	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	dry eye syndrome	ESTRADIOL	targetBased	2	Completed	18/01/2019	https://clinicaltrials.gov/study/NCT03821415	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee7025c5-4cff-4da9-9ff0-100af626612d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee7025c5-4cff-4da9-9ff0-100af626612d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa530dfd-3a48-46b9-9678-a7bc48316e41	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa530dfd-3a48-46b9-9678-a7bc48316e41	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0178a92c-62b1-d5cf-cf54-2c85af88a74a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0178a92c-62b1-d5cf-cf54-2c85af88a74a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a8bfdf-0fac-4e86-a299-daf64a2e885e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a8bfdf-0fac-4e86-a299-daf64a2e885e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70d00600-b8d3-4820-8db6-40d4536a6f9e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70d00600-b8d3-4820-8db6-40d4536a6f9e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02770365	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02770365	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	injury	ESTRADIOL	targetBased	4	Recruiting	29/09/2021	https://clinicaltrials.gov/study/NCT04899778	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	injury	ESTRADIOL	targetBased	4	Recruiting	29/09/2021	https://clinicaltrials.gov/study/NCT04899778	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00140998	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00140998	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134745	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134745	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00837616	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00837616	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	3	Completed	23/07/1998	https://clinicaltrials.gov/study/NCT01710696	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTRADIOL	targetBased	3	Completed	23/07/1998	https://clinicaltrials.gov/study/NCT01710696	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cystitis	ESTRADIOL	targetBased	4	Enrolling by invitation	31/01/2023	https://clinicaltrials.gov/study/NCT05551949	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cystitis	ESTRADIOL	targetBased	4	Enrolling by invitation	31/01/2023	https://clinicaltrials.gov/study/NCT05551949	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4	Completed	20/06/2017	https://clinicaltrials.gov/study/NCT03240081	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4	Completed	20/06/2017	https://clinicaltrials.gov/study/NCT03240081	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6183e05-b9b6-460e-b7bd-e6885bd0b696	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6183e05-b9b6-460e-b7bd-e6885bd0b696	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	3	Completed	15/11/2022	https://clinicaltrials.gov/study/NCT05617820	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	3	Completed	15/11/2022	https://clinicaltrials.gov/study/NCT05617820	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50ee3815-7675-4bc0-a88a-ab3886aea795	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50ee3815-7675-4bc0-a88a-ab3886aea795	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02516202	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTRADIOL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02516202	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ESTRADIOL	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01943812	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ESTRADIOL	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01943812	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	SUFENTANIL	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02232347	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	SUFENTANIL	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02232347	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	SUFENTANIL	targetBased	3	Completed	05/08/2022	https://clinicaltrials.gov/study/NCT05288348	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	SUFENTANIL	targetBased	3	Completed	05/08/2022	https://clinicaltrials.gov/study/NCT05288348	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	SUFENTANIL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02134093	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	SUFENTANIL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02134093	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	4	Terminated	01/10/2015	https://clinicaltrials.gov/study/NCT02573597	1	GoF	protect	Difficulty in recruitment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	4	Terminated	01/10/2015	https://clinicaltrials.gov/study/NCT02573597	1	GoF	protect	Difficulty in recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02264834	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02264834	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00437996	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00437996	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02868944	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02868944	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03036384	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03036384	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	4	Completed	16/03/2023	https://clinicaltrials.gov/study/NCT05698407	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pregnancy	SUFENTANIL	targetBased	4	Completed	16/03/2023	https://clinicaltrials.gov/study/NCT05698407	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Reduced consciousness	AMANTADINE	targetBased	2	Recruiting	01/03/2023	https://clinicaltrials.gov/study/NCT05479032	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		post-operative sign or symptom	AMANTADINE	targetBased	4	Active, not recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03988010	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Myalgia	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Spasticity	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Spasticity	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cleft lip/palate	EPINEPHRINE	targetBased	3	Recruiting	24/04/2024	https://clinicaltrials.gov/study/NCT06284434	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	EPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EA01	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	EPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EA51	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pregnancy	EPINEPHRINE	targetBased	4	Withdrawn	01/10/2019	https://clinicaltrials.gov/study/NCT03335293	1	GoF	protect	Due to FDA constraints on the off label use of the medications we will not be able to conduct this evaluation.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	EPINEPHRINE	targetBased	4	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02118467	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	EPINEPHRINE	targetBased	4	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT06265259	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	EPINEPHRINE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01367743	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	EPINEPHRINE	targetBased	2	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02591771	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cataract	EPINEPHRINE	targetBased	4	Terminated	01/09/2016	https://clinicaltrials.gov/study/NCT02895035	1	GoF	protect	Data analysis was never performed by sub-investigator
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Mydriasis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b5282a9-b149-4f0a-978e-5adbf48ec8aa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	epistaxis	EPINEPHRINE	targetBased	3	Completed	01/09/2021	https://clinicaltrials.gov/study/NCT05738564	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Hip dysplasia	EPINEPHRINE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02365961	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	urticaria	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad07e9bf-cc81-4736-86c7-2b2de9386eb2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	urticaria	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76462d55-5448-0fd0-e053-2991aa0aa49f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	urticaria	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7664bb0d-dc1a-ca8b-e053-2991aa0ad627	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	urticaria	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59dc8445-6cec-40f0-8bde-c23510293509	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	urticaria	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	EPINEPHRINE	targetBased	2	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01202487	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	EPINEPHRINE	targetBased	2	Unknown status	15/01/2019	https://clinicaltrials.gov/study/NCT03865147	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	injury	EPINEPHRINE	targetBased	4	Completed	19/06/2019	https://clinicaltrials.gov/study/NCT04536493	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	toxicity	EPINEPHRINE	targetBased	4	Recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT04799184	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angioedema	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Varicose veins	EPINEPHRINE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02627846	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL CITRATE	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT05437575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL CITRATE	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT05437575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL CITRATE	targetBased	4	Terminated	04/09/2018	https://clinicaltrials.gov/study/NCT03528512	1	GoF	protect	Staffing for study was eliminated
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	FENTANYL CITRATE	targetBased	4	Terminated	04/09/2018	https://clinicaltrials.gov/study/NCT03528512	1	GoF	protect	Staffing for study was eliminated
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cannabis use	FENTANYL CITRATE	targetBased	4	Recruiting	14/03/2023	https://clinicaltrials.gov/study/NCT05873465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cannabis use	FENTANYL CITRATE	targetBased	4	Recruiting	14/03/2023	https://clinicaltrials.gov/study/NCT05873465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	FENTANYL CITRATE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00667043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	FENTANYL CITRATE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00667043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	shortness of breath	FENTANYL CITRATE	targetBased	3	Recruiting	23/10/2020	https://clinicaltrials.gov/study/NCT04188418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	shortness of breath	FENTANYL CITRATE	targetBased	3	Recruiting	23/10/2020	https://clinicaltrials.gov/study/NCT04188418	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leg injury	FENTANYL CITRATE	targetBased	4	Recruiting	10/01/2020	https://clinicaltrials.gov/study/NCT04199013	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	leg injury	FENTANYL CITRATE	targetBased	4	Recruiting	10/01/2020	https://clinicaltrials.gov/study/NCT04199013	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01765e76-e656-4539-8112-8b7709597c79	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01765e76-e656-4539-8112-8b7709597c79	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00651469	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00651469	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8132454a-6135-4bac-b206-83a55eb8dbc6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8132454a-6135-4bac-b206-83a55eb8dbc6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=077bf6ff-afb8-4cb7-9faa-fbb6fd9f037f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=077bf6ff-afb8-4cb7-9faa-fbb6fd9f037f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd15dbd7-75b7-416e-af55-1e90c2bab051	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd15dbd7-75b7-416e-af55-1e90c2bab051	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=723d0427-cf3f-4ad7-8b93-cb1250f345f6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=723d0427-cf3f-4ad7-8b93-cb1250f345f6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065f33e4-b587-4e66-b896-ca9ab7b7c876	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065f33e4-b587-4e66-b896-ca9ab7b7c876	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f2664f-3de8-4e58-a860-1b5abd6eb7d7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f2664f-3de8-4e58-a860-1b5abd6eb7d7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=384e7a40-dcbd-4908-bf5e-65abc9932973	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=384e7a40-dcbd-4908-bf5e-65abc9932973	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbcb4427-7a99-467c-915f-a8b4c90e2832	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbcb4427-7a99-467c-915f-a8b4c90e2832	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00752635	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00752635	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e762db5b-f7e5-4b62-bee9-30f0322a4bac	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e762db5b-f7e5-4b62-bee9-30f0322a4bac	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63b8c65b-c6fd-44eb-99e5-d6858c871f28	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63b8c65b-c6fd-44eb-99e5-d6858c871f28	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd69aa29-1e86-4c1b-9fd3-ba722bc8cd14	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd69aa29-1e86-4c1b-9fd3-ba722bc8cd14	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faafb8ce-6955-4de4-8b93-ccc662123b5e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faafb8ce-6955-4de4-8b93-ccc662123b5e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69e66f08-be0b-4120-9a30-333b34ad3507	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69e66f08-be0b-4120-9a30-333b34ad3507	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b247e46-203e-4f5b-b5a7-cbd57341c735	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b247e46-203e-4f5b-b5a7-cbd57341c735	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cb9494c-4d70-4ebd-98ec-0e28021c1fee	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cb9494c-4d70-4ebd-98ec-0e28021c1fee	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b71a2b34-95bf-4430-83a0-1a4d1218ea3c	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b71a2b34-95bf-4430-83a0-1a4d1218ea3c	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b61cdce5-9fb5-4901-a768-4282a684db3f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b61cdce5-9fb5-4901-a768-4282a684db3f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96092977-5514-44a7-be15-51862866c4bf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96092977-5514-44a7-be15-51862866c4bf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7de193c-d730-4f63-aa23-178b5f400967	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7de193c-d730-4f63-aa23-178b5f400967	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa17c22d-32a8-4f48-b7b6-9b8eeeb5a81a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa17c22d-32a8-4f48-b7b6-9b8eeeb5a81a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00722761	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00722761	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c64b8c58-0ef0-4498-a027-2f0a179057b8	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c64b8c58-0ef0-4498-a027-2f0a179057b8	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=843cbef6-cbfb-4a44-bb80-22930753e4c0	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=843cbef6-cbfb-4a44-bb80-22930753e4c0	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT01466673	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT01466673	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	10/03/2004	https://clinicaltrials.gov/study/NCT00280657	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	10/03/2004	https://clinicaltrials.gov/study/NCT00280657	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fd4976d-720c-40ee-8723-a703645d4ff0	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fd4976d-720c-40ee-8723-a703645d4ff0	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9599335c-4a8f-435d-b96c-27d5e5e34c39	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9599335c-4a8f-435d-b96c-27d5e5e34c39	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60f70330-0fac-47fc-b417-5bc1c9451117	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60f70330-0fac-47fc-b417-5bc1c9451117	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00656981	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00656981	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f9d30d9-5553-4cbd-a099-ff045bc85821	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acne	ETHINYL ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f9d30d9-5553-4cbd-a099-ff045bc85821	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ETHINYL ESTRADIOL	targetBased	2	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00344383	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ETHINYL ESTRADIOL	targetBased	2	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00344383	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ETHINYL ESTRADIOL	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00320580	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ETHINYL ESTRADIOL	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00320580	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hidradenitis suppurativa	ETHINYL ESTRADIOL	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00722800	0.2	GoF	protect	Poor recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hidradenitis suppurativa	ETHINYL ESTRADIOL	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00722800	0.2	GoF	protect	Poor recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/02/1989	https://clinicaltrials.gov/study/NCT00191113	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/02/1989	https://clinicaltrials.gov/study/NCT00191113	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00932321	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00932321	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00570440	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00570440	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	2	Completed	05/07/2022	https://clinicaltrials.gov/study/NCT05360550	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	2	Completed	05/07/2022	https://clinicaltrials.gov/study/NCT05360550	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	2	Completed	24/02/2022	https://clinicaltrials.gov/study/NCT05360576	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ETHINYL ESTRADIOL	targetBased	2	Completed	24/02/2022	https://clinicaltrials.gov/study/NCT05360576	0.2	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Spasticity	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	injury	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06333171	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Colonic diverticula	MESALAMINE	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01627262	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Colonic diverticula	MESALAMINE	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01627262	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Colonic diverticula	MESALAMINE	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01627262	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Colonic diverticula	MESALAMINE	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01627262	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Colonic diverticula	MESALAMINE	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01627262	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Colonic diverticula	MESALAMINE	targetBased	2	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT01627262	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	wheezing	ALBUTEROL	targetBased	4	Withdrawn	01/09/2021	https://clinicaltrials.gov/study/NCT04584034	1	GoF	protect	Premature ending of the study due to impossibility of obtaining a suitable placebo-inhaler
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Familial dysautonomia	ALBUTEROL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01987219	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchoconstriction	ALBUTEROL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01791972	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchoconstriction	ALBUTEROL	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00685347	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchoconstriction	ALBUTEROL	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01903785	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchoconstriction	ALBUTEROL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00685425	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	organophosphate poisoning	ALBUTEROL	targetBased	3	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02160548	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Hyperkalemia	ALBUTEROL	targetBased	4	Recruiting	20/12/2019	https://clinicaltrials.gov/study/NCT04012138	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Hyperkalemia	ALBUTEROL	targetBased	4	Recruiting	04/11/2021	https://clinicaltrials.gov/study/NCT05173584	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02755116	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03631004	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	OLANZAPINE	targetBased	2	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05676294	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea	OLANZAPINE	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00124930	0.7	LoF	protect	Study suspended due to low enrollment
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	09/05/2019	https://clinicaltrials.gov/study/NCT03571126	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	17/12/2020	https://clinicaltrials.gov/study/NCT04669132	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	18/08/2020	https://clinicaltrials.gov/study/NCT04535141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02400866	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02097823	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02484911	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02635984	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	03/02/2020	https://clinicaltrials.gov/study/NCT04437017	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	29/04/2019	https://clinicaltrials.gov/study/NCT04075955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02129478	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	23/03/2017	https://clinicaltrials.gov/study/NCT03079219	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05346731	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT05242874	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03219710	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03578081	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT05805800	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02861859	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	OLANZAPINE	targetBased	4	Recruiting	07/12/2022	https://clinicaltrials.gov/study/NCT05590923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	OLANZAPINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03066622	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02116530	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	OLANZAPINE	targetBased	2	Completed	12/07/2017	https://clinicaltrials.gov/study/NCT03137121	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	adverse effect	OLANZAPINE	targetBased	4	Completed	26/02/2024	https://clinicaltrials.gov/study/NCT06357104	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Moderate albuminuria	CARVEDILOL	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00123903	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stage 5 chronic kidney disease	CARVEDILOL	targetBased	3	Recruiting	22/05/2024	https://clinicaltrials.gov/study/NCT05931276	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	kidney disease	CARVEDILOL	targetBased	2	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03867994	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic kidney disease	CARVEDILOL	targetBased	3	Recruiting	22/05/2024	https://clinicaltrials.gov/study/NCT05931276	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	PROCHLORPERAZINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00475085	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	PROCHLORPERAZINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00475085	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	PROCHLORPERAZINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00475085	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	PROCHLORPERAZINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00475085	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	PROCHLORPERAZINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00475085	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	PROCHLORPERAZINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00475085	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03367572	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	PROCHLORPERAZINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	PROCHLORPERAZINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	PROCHLORPERAZINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	PROCHLORPERAZINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	PROCHLORPERAZINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	PROCHLORPERAZINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	2	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01785459	0.2	LoF	protect	Unable to enroll adequate number of patients.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	2	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01785459	0.2	LoF	protect	Unable to enroll adequate number of patients.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	2	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01785459	0.2	LoF	protect	Unable to enroll adequate number of patients.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	2	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01785459	0.2	LoF	protect	Unable to enroll adequate number of patients.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	2	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01785459	0.2	LoF	protect	Unable to enroll adequate number of patients.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	2	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01785459	0.2	LoF	protect	Unable to enroll adequate number of patients.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03185130	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03185130	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03185130	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03185130	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03185130	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03185130	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Headache	PROCHLORPERAZINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00590317	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00590317	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00590317	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00590317	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00590317	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00590317	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00020657	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00020657	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00020657	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00020657	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00020657	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00020657	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d9e8a9-e299-4ee4-9f04-a82a83845594	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d9e8a9-e299-4ee4-9f04-a82a83845594	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d9e8a9-e299-4ee4-9f04-a82a83845594	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d9e8a9-e299-4ee4-9f04-a82a83845594	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d9e8a9-e299-4ee4-9f04-a82a83845594	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d9e8a9-e299-4ee4-9f04-a82a83845594	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		burn	KETAMINE	targetBased	4	Unknown status	27/02/2018	https://clinicaltrials.gov/study/NCT03049930	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Headache	KETAMINE	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02657031	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Headache	KETAMINE	targetBased	3	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02735343	0.7	LoF	protect	study goals met
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Headache	KETAMINE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT03081416	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Headache	KETAMINE	targetBased	3	Recruiting	01/06/2022	https://clinicaltrials.gov/study/NCT05306899	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		post operative nausea and vomiting	KETAMINE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01394406	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		kidney disease	KETAMINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01948336	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		renal colic	KETAMINE	targetBased	3	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT04013958	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	KETAMINE	targetBased	2	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT03336398	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		hypertrophy	KETAMINE	targetBased	2	Completed	02/08/2019	https://clinicaltrials.gov/study/NCT03714919	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Cholecystitis	KETAMINE	targetBased	4	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02493231	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		adverse effect	KETAMINE	targetBased	4	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04490031	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		adverse effect	KETAMINE	targetBased	3	Recruiting	10/09/2023	https://clinicaltrials.gov/study/NCT06122948	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		limb injury	KETAMINE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06464146	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Coma	KETAMINE	targetBased	4	Completed	10/08/2017	https://clinicaltrials.gov/study/NCT03284307	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		post-operative sign or symptom	KETAMINE	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02892916	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		post-operative sign or symptom	KETAMINE	targetBased	4	Completed	10/12/2020	https://clinicaltrials.gov/study/NCT04321746	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		post-operative sign or symptom	KETAMINE	targetBased	2	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02049411	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	2	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00451724	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	4	Unknown status	01/08/2013	https://clinicaltrials.gov/study/NCT01925898	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02432456	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02232347	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	4	Terminated	04/09/2018	https://clinicaltrials.gov/study/NCT03528512	1	LoF	protect	Staffing for study was eliminated
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	3	Not yet recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT03511833	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	2	Completed	16/02/2017	https://clinicaltrials.gov/study/NCT03053947	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	4	Enrolling by invitation	15/12/2021	https://clinicaltrials.gov/study/NCT04933149	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00834730	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	4	Recruiting	06/09/2021	https://clinicaltrials.gov/study/NCT05097261	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT05437575	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	2	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03233035	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE	targetBased	3	Active, not recruiting	03/10/2017	https://clinicaltrials.gov/study/NCT02866071	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cataract	KETAMINE	targetBased	4	Completed	03/05/2016	https://clinicaltrials.gov/study/NCT03054103	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cataract	KETAMINE	targetBased	2	Completed	20/07/2021	https://clinicaltrials.gov/study/NCT05133518	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	diabetic foot	ESMOLOL	targetBased	3	Completed	26/12/2018	https://clinicaltrials.gov/study/NCT03998436	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Tinnitus	ESMOLOL	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02062333	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	ESMOLOL	targetBased	4	Completed	18/12/2018	https://clinicaltrials.gov/study/NCT03549923	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	adverse effect	ESMOLOL	targetBased	2	Completed	05/10/2022	https://clinicaltrials.gov/study/NCT05850832	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	TAMOXIFEN CITRATE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06440967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	TAMOXIFEN CITRATE	targetBased	3	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06440967	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Gynecomastia	TAMOXIFEN CITRATE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00637871	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Gynecomastia	TAMOXIFEN CITRATE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00637871	0.2		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00376675	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00031798	0.7	LoF	protect	low accrual; loss of funding
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE	targetBased	3	Recruiting	03/05/2023	https://clinicaltrials.gov/study/NCT05880342	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE	targetBased	3	Completed	12/10/1999	https://clinicaltrials.gov/study/NCT00003266	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Hypothermia	METHYLPHENIDATE	targetBased	4	Active, not recruiting	15/12/2019	https://clinicaltrials.gov/study/NCT04283877	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	asthenia	METHYLPHENIDATE	targetBased	3	Terminated	01/01/2007	https://clinicaltrials.gov/study/NCT00273741	0.7	LoF	protect	difficulty of recrutement
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	asthenia	METHYLPHENIDATE	targetBased	3	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01773837	0.7	LoF	protect	Slow accrual. 100 patients included
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		essential tremor	MEMANTINE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00439699	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tension-type headache	MEMANTINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00315666	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tremor	MEMANTINE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02466191	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		open-angle glaucoma	MEMANTINE	targetBased	3	Completed	01/03/1999	https://clinicaltrials.gov/study/NCT00141882	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		open-angle glaucoma	MEMANTINE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00168350	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	CARTEOLOL	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00972426	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	CARTEOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED05	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	CARTEOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED55	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	CARTEOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	CARTEOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eccd10e3-ec28-4ab0-887f-fce616cf1bc2	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Eczematoid dermatitis	LOPERAMIDE	targetBased	2	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02517957	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Eczematoid dermatitis	LOPERAMIDE	targetBased	2	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02517957	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b2aa7df-0f38-460e-b1f1-d7473be4ab3c	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01748396	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4	Terminated	01/04/2003	https://clinicaltrials.gov/study/NCT00062699	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1013494-bf62-4e68-9f0c-e6571137f20f	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66a69351-5b09-4368-a9fa-acf81b5ad882	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf62f0f-bd93-43f1-96f2-e4f001ea7328	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01384539	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bebefb2a-7365-48e2-9681-83ed4b41e26e	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c64778c6-3be6-44f5-8387-ebcd82e3eae5	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d755a21-9f42-4d36-aaec-962495ab2f2b	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT01561222	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84262b69-df29-41d0-9e97-6e1188096aeb	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Acute kidney injury	CALCITRIOL	targetBased	2	Completed	03/04/2017	https://clinicaltrials.gov/study/NCT02962102	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	autoimmune thrombocytopenic purpura	CALCITRIOL	targetBased	4	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04094805	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	2	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00623974	0.2	GoF	protect	Terminated due to slow accrual.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1013494-bf62-4e68-9f0c-e6571137f20f	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a86ea01b-51c2-49cb-965a-4659658d0a98	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=406151ad-6c0a-4d66-86fc-e076df9671a3	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b2aa7df-0f38-460e-b1f1-d7473be4ab3c	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d755a21-9f42-4d36-aaec-962495ab2f2b	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bebefb2a-7365-48e2-9681-83ed4b41e26e	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82b2fffd-4a1f-4ea3-b156-b8dc51bfde52	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=045f46c7-c637-443b-8427-c461b3d7ca55	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84262b69-df29-41d0-9e97-6e1188096aeb	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=add1e536-b6ed-4ba1-abd6-084b6845e3a4	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c64778c6-3be6-44f5-8387-ebcd82e3eae5	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d6046c2-4a28-47b1-9bb4-51fadeded2d2	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63d26a82-4b79-44ce-52a4-395e4368acd4	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3b180dd-6c0b-4c15-85d3-bbbb5176d1d1	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf62f0f-bd93-43f1-96f2-e4f001ea7328	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66a69351-5b09-4368-a9fa-acf81b5ad882	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	IGA glomerulonephritis	CALCITRIOL	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00319761	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	glomerulonephritis	CALCITRIOL	targetBased	4	Unknown status	01/03/2009	https://clinicaltrials.gov/study/NCT00862693	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Vertigo	CINNARIZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07CA02	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Vertigo	CINNARIZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07CA52	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	stricture	VINBLASTINE	targetBased	2	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00215046	0.2	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	hematoma	DABIGATRAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01675076	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	injury	DABIGATRAN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01661101	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	NALBUPHINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00323154	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	NALBUPHINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00323154	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	NALBUPHINE	targetBased	3	Recruiting	20/06/2021	https://clinicaltrials.gov/study/NCT04928391	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	NALBUPHINE	targetBased	3	Recruiting	20/06/2021	https://clinicaltrials.gov/study/NCT04928391	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus	NALBUPHINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00323154	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	NALBUPHINE	targetBased	2	Completed	31/07/2019	https://clinicaltrials.gov/study/NCT03470077	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	NALBUPHINE	targetBased	2	Completed	31/07/2019	https://clinicaltrials.gov/study/NCT03470077	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	prurigo nodularis	NALBUPHINE	targetBased	2	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03497975	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prurigo nodularis	NALBUPHINE	targetBased	2	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03497975	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prurigo nodularis	NALBUPHINE	targetBased	2	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03497975	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Cleft palate	NALBUPHINE	targetBased	3	Recruiting	20/06/2021	https://clinicaltrials.gov/study/NCT04928391	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	post-operative sign or symptom	NALBUPHINE	targetBased	2	Completed	31/07/2019	https://clinicaltrials.gov/study/NCT03470077	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	chronic kidney disease	SARPOGRELATE	targetBased	4	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01165567	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	DOBUTAMINE	targetBased	2	Unknown status	01/10/2004	https://clinicaltrials.gov/study/NCT00093301	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	DOBUTAMINE	targetBased	4	Recruiting	05/03/2022	https://clinicaltrials.gov/study/NCT05267886	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Vertigo	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Vertigo	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Vertigo	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Vertigo	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Vertigo	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Meniere disease	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Meniere disease	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Meniere disease	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Meniere disease	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Meniere disease	DIPHENIDOL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01574313	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	nephrogenic fibrosing dermopathy	IMATINIB	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00981942	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	nephrogenic fibrosing dermopathy	IMATINIB	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00677092	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	essential tremor	PRAMIPEXOLE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT01441284	0.7	GoF	protect	Lack of financial support
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aed1e7c1-6197-4152-ae5e-06cf2ec3020f	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1eced33-f9ee-4757-ab94-75f238f9b2a9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	CAPSAICIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=M02AB01	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba11070e-1a36-4d5d-9e48-c37b4e90c037	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2db23534-31bb-4897-b105-95039166f5a7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95910cee-0a43-4ac9-aeb9-6a659757b3ba	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sprain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9475b6c-edd1-4ea7-a22c-243e63c4d0f7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sprain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5dd4fefc-b70a-4850-819c-1cca6f28aa97	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sprain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e3e528-b7cd-e4b7-e053-2995a90a4029	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sprain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db9a695-a41c-4867-8684-161c81abbe00	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	exercise	CAPSAICIN	targetBased	4	Completed	25/05/2022	https://clinicaltrials.gov/study/NCT05298202	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Chemotherapy-induced nausea and vomiting	CAPSAICIN	targetBased	2	Completed	18/10/2019	https://clinicaltrials.gov/study/NCT04918069	0.2		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Hyperkalemia	LEVOSALBUTAMOL	targetBased	4	Recruiting	04/11/2021	https://clinicaltrials.gov/study/NCT05173584	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Tachycardia	REMIFENTANIL	targetBased	4	Completed	09/03/2011	https://clinicaltrials.gov/study/NCT01259648	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Tachycardia	REMIFENTANIL	targetBased	4	Completed	09/03/2011	https://clinicaltrials.gov/study/NCT01259648	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	newborn respiratory distress syndrome	REMIFENTANIL	targetBased	4	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02164734	1	GoF	protect	Slow to impossible recruitment during COVID-19 pandemic
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	newborn respiratory distress syndrome	REMIFENTANIL	targetBased	4	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02164734	1	GoF	protect	Slow to impossible recruitment during COVID-19 pandemic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Myoclonus	REMIFENTANIL	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02518789	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Myoclonus	REMIFENTANIL	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02518789	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	oxidative stress	REMIFENTANIL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02202239	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	oxidative stress	REMIFENTANIL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02202239	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ischemia reperfusion injury	REMIFENTANIL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02405689	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ischemia reperfusion injury	REMIFENTANIL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02405689	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	REMIFENTANIL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01452880	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	REMIFENTANIL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01452880	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	REMIFENTANIL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00667043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	REMIFENTANIL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00667043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	REMIFENTANIL	targetBased	4	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT05215834	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hypothermia	REMIFENTANIL	targetBased	4	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT05215834	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02134093	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02134093	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT02631135	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT02631135	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01627873	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01627873	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02224443	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	REMIFENTANIL	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02224443	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cholecystitis	REMIFENTANIL	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01833819	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cholecystitis	REMIFENTANIL	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01833819	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03022318	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03022318	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03022318	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Terminated	01/07/2018	https://clinicaltrials.gov/study/NCT03451500	0.2	GoF	protect	Lack of funding required for enrollment to reach statistical significance.
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Terminated	01/07/2018	https://clinicaltrials.gov/study/NCT03451500	0.2	GoF	protect	Lack of funding required for enrollment to reach statistical significance.
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Terminated	01/07/2018	https://clinicaltrials.gov/study/NCT03451500	0.2	GoF	protect	Lack of funding required for enrollment to reach statistical significance.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03023059	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03023059	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03023059	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Withdrawn	01/09/2019	https://clinicaltrials.gov/study/NCT02873351	0.2	GoF	protect	Decided to do studies in patients with AMD
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Withdrawn	01/09/2019	https://clinicaltrials.gov/study/NCT02873351	0.2	GoF	protect	Decided to do studies in patients with AMD
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	age-related macular degeneration	LEVODOPA	targetBased	2	Withdrawn	01/09/2019	https://clinicaltrials.gov/study/NCT02873351	0.2	GoF	protect	Decided to do studies in patients with AMD
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM MESYLATE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00286403	0.2	GoF	protect	The study was terminated due to logistics at a local hospital.
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Acute kidney injury	FENOLDOPAM MESYLATE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00286403	0.2	GoF	protect	The study was terminated due to logistics at a local hospital.
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Acute kidney injury	FENOLDOPAM MESYLATE	targetBased	2	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00286403	0.2	GoF	protect	The study was terminated due to logistics at a local hospital.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CALCIFEDIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a95effd-32a5-46b6-a30e-7f4f9bf8cc77	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Acute kidney injury	CALCIFEDIOL	targetBased	2	Completed	03/04/2017	https://clinicaltrials.gov/study/NCT02962102	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CALCIFEDIOL	targetBased	2	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT04735926	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic renal failure syndrome	CALCIFEDIOL	targetBased	4	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01442272	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01675557	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01384539	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	2	Recruiting	01/09/2019	https://clinicaltrials.gov/study/NCT04145492	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01312714	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00749736	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01173848	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	2	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01323712	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	2	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01532349	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01974245	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00798993	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	CHOLECALCIFEROL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00889629	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01263288	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	CHOLECALCIFEROL	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01632514	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01689779	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02783924	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01058720	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01419119	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00610688	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	24/09/2003	https://clinicaltrials.gov/study/NCT00092066	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Recruiting	01/12/2014	https://clinicaltrials.gov/study/NCT02506439	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00412074	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02234544	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02735200	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00886379	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT02069990	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02389179	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	23/10/2014	https://clinicaltrials.gov/study/NCT03233295	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT00933244	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01784029	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01596842	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01924910	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02158598	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	30/09/2019	https://clinicaltrials.gov/study/NCT03920150	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01067898	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00681590	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02192229	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Terminated	01/06/2013	https://clinicaltrials.gov/study/NCT01893385	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Terminated	27/08/2017	https://clinicaltrials.gov/study/NCT02868827	0.2	GoF	protect	The initial plan was 2 years but due to slow recruitment. We were able to screen 635 patients in 4 years and recruited only 127 patients.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02452762	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03038516	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01845142	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00412087	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01896544	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Recruiting	17/06/2019	https://clinicaltrials.gov/study/NCT03742505	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Active, not recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT06054919	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	15/02/2017	https://clinicaltrials.gov/study/NCT03035084	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Terminated	06/05/2021	https://clinicaltrials.gov/study/NCT04629534	1	GoF	protect	low enrollment, lack of funding
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00092079	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02750293	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	05/09/2018	https://clinicaltrials.gov/study/NCT04476511	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	2	Terminated	01/08/2018	https://clinicaltrials.gov/study/NCT03611049	0.2	GoF	protect	Principal Investigator (Dr. Peiris) is retiring
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02443246	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01130181	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Not yet recruiting	01/01/2015	https://clinicaltrials.gov/study/NCT01858051	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01112891	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01506557	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00960232	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01168544	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Recruiting	10/10/2017	https://clinicaltrials.gov/study/NCT03188796	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00292591	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06176157	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	4	Completed	15/10/2015	https://clinicaltrials.gov/study/NCT03648528	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	CHOLECALCIFEROL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01190683	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	premature birth	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03005496	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	urticaria	CHOLECALCIFEROL	targetBased	3	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02873364	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	urticaria	CHOLECALCIFEROL	targetBased	4	Withdrawn	01/02/2016	https://clinicaltrials.gov/study/NCT02742805	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	urticaria	CHOLECALCIFEROL	targetBased	2	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02012387	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	acne	CHOLECALCIFEROL	targetBased	4	Enrolling by invitation	16/02/2023	https://clinicaltrials.gov/study/NCT05758259	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pregnancy	CHOLECALCIFEROL	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT04764955	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pregnancy	CHOLECALCIFEROL	targetBased	2	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01126528	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pregnancy	CHOLECALCIFEROL	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01924013	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	premature birth	RITODRINE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT03040752	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	premature birth	RITODRINE	targetBased	4	Unknown status	25/10/2017	https://clinicaltrials.gov/study/NCT03298191	1	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Myalgia	ZUCAPSAICIN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=M02AB02	0.7	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	dry eye syndrome	ZUCAPSAICIN	targetBased	2	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02116244	0.2	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	autoimmune thrombocytopenic purpura	VINCRISTINE	targetBased	2	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00774202	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	autoimmune thrombocytopenic purpura	VINCRISTINE	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03229746	1	LoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	uveitis	FINGOLIMOD	targetBased	2	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01791192	0.2	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	uveitis	FINGOLIMOD	targetBased	2	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01791192	0.2	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	uveitis	FINGOLIMOD	targetBased	2	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01791192	0.2	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	uveitis	FINGOLIMOD	targetBased	2	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01791192	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	uveitis	FINGOLIMOD	targetBased	2	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01791192	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	uveitis	FINGOLIMOD	targetBased	2	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01791192	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	DROPERIDOL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT04411069	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	DROPERIDOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT01434017	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	DROPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	chronic renal failure syndrome	ARGATROBAN	targetBased	4	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00035178	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE BROMIDE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE BROMIDE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE BROMIDE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE BROMIDE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE BROMIDE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney failure	ISOFLURANE	targetBased	4	Terminated	01/01/2002	https://clinicaltrials.gov/study/NCT00144118	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney failure	ISOFLURANE	targetBased	4	Terminated	01/01/2002	https://clinicaltrials.gov/study/NCT00144118	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	toxicity	ISOFLURANE	targetBased	3	Terminated	01/07/2015	https://clinicaltrials.gov/study/NCT02512809	0.7		protect	PI moving to another institution.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	toxicity	ISOFLURANE	targetBased	3	Terminated	01/07/2015	https://clinicaltrials.gov/study/NCT02512809	0.7		protect	PI moving to another institution.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	ischemia reperfusion injury	ISOFLURANE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01601795	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	ischemia reperfusion injury	ISOFLURANE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01601795	1		protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	kidney disease	LEVETIRACETAM	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01491113	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Torticollis	LEVETIRACETAM	targetBased	2	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00760318	0.2	LoF	protect	Sponsor decided to stop enrollment to review data.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd6b1d1-e967-4a97-aea6-66126d1dffe1	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5ccc096-e0b8-48e7-b10e-8d27e7b3b180	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3edcaae5-81bb-4a18-8bfd-834835187b13	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f691fe85-a3dd-40b8-83ac-c1fa27907e6a	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d0fa6a4-0fca-4114-b5a5-77f9efac7fe2	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f217dbac-8f63-45eb-a871-9fbe2e784711	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf412e94-ca36-4da9-83d7-fb0f1323cf21	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4f7e6ed-992b-4217-82d8-658036d12faa	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77eabc9-9f65-4d4b-8135-0290291e6ee8	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33d82ae-7991-443f-8e48-5832c02ea450	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df661166-325d-4071-9bc1-f7bf992996d2	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2471ee03-d747-4113-86d0-1aa93c8f3eba	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f60b9fb-5305-4488-99b7-a01a693994b4	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=656756de-2404-4845-a8a7-c0ffa2d61c90	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50af33cb-7abd-4e9f-ae5b-953eb2b836d9	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd713e60-478c-43cd-b680-ff594a0b3864	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7932a2c-a3b7-46df-a306-1f17716160a0	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b1d9124-5fde-4f57-9fca-ee061750fcc3	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f05c6158-7d09-46f5-b118-5c5563ac35b5	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80f5349c-3910-4c69-9f56-cb552bf4f336	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9acd365-1b80-4428-bd33-3a5eac814677	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d293d765-e418-4bdf-9955-76a4bdba129b	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d767545-1eb9-45a5-bd16-e8a66e628fea	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1982fbca-fb5f-4e14-b837-e0c59028dad7	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ab30ca8-0695-4789-b258-450d8dd72703	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab24168-058d-496e-9023-da8ee6353eb3	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96bc35a8-eed6-4f0c-b149-1e4c533aa90e	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bc8468f-832c-4e71-95a2-db464d4d54bc	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f65ec19d-b90e-452e-b761-c68b1cf2c892	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe7e0c86-8007-4af5-965c-184c6dbce17d	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7967f8f4-eba8-4849-a176-944fffa2ee53	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8cdad32-9650-48c6-bdd8-3973135c39b7	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70e52e89-3844-4cd9-a406-b29e9520a12c	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12552673-d561-49d7-9402-4100e5a56871	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c4877cc-52bc-4f98-a995-0aa9439da742	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d317020c-0850-4a5b-b344-74ad10b0b089	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f62efa57-b93c-425b-b469-31941762d109	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=746aa1a9-4605-4991-bb80-62685284bb0b	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cb4a1db-f32d-44af-8985-0a94ca506468	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01228747	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d71e14f-8092-444c-afa1-2b79d69d81e6	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed1b74a8-2a9b-4315-b051-673c7941cb13	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1918b4e-2238-4cbd-81be-61cae5481c88	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d57044c1-9222-4127-a491-3328324fb4b2	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f2513f-eb3d-419f-9936-a0cb27b71a6e	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ded90f0c-9b55-4e67-b49e-f029df4bd16e	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc8bf57e-8aa2-4d3c-856d-b19de65e3ba0	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf7c1ce-dfc4-457f-8a8b-365f82aa8512	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08e1bfea-7f3f-42d9-823d-f75080e664ff	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f44e0069-84cf-40e2-a4e8-57494131c65d	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1329893-a8bc-4f31-a31b-76690d111035	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f00d8f59-c333-48ad-aca3-98a49bcd228e	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2177034-e164-453c-be02-1cf91ce27a07	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee03507b-cb35-4fe9-ae7b-85ea89f876f0	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=158d03d1-5c7c-460a-acb0-624069e231ee	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f2642ac-703f-4447-ab2c-2c15511e5a81	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d818ef84-9b3e-434b-92d9-910cfa8af7da	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb8aed34-2f3b-48b1-86ea-84b0d9e2b618	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0081f751-e2e5-4d28-9053-306accab3561	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=483a42b9-c8f3-4f8b-98be-fcac5ab23c7c	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edc3e7ec-81e9-4649-a005-c4382942d459	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63b36274-89f0-42d8-9f09-f9e78e179af4	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aad770b-a342-45c5-8199-21a124060314	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=894a3724-d375-4ab3-a4d9-f5f3ce9721c5	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a70be430-21fa-49a4-84c1-134621ee2f4f	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22de2626-eef5-47a0-a254-10837e5296a3	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc0cbcd4-5400-4b71-a239-39e451b4c7b3	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed654864-5c4c-4299-b331-27666f895fa1	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00510783	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98bae5bb-729b-4a36-b429-5ee25aa80411	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b8a5ff2-d613-46e6-8989-5c1be4893632	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28972d09-9ee7-4027-a9cd-433b5b16b978	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f3c04d9-cccb-06a3-a0f3-f7c9228ee743	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=528c67d0-129d-463f-a160-41f370dead6b	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4317dd71-821c-47cc-95ce-6403804c46c4	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb02779c-acdc-48ed-9d23-ca39ba152d0d	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a987d59-560f-4650-96ec-31aec81953b5	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b14939-7262-40dc-a334-2b3b72c88d47	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90f90650-709f-4d2a-bf94-26aad80e0805	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Bilateral tonic-clonic seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e59f2fec-52d2-428f-a43a-c1d6c0f83f33	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Generalized non-motor (absence) seizure	LEVETIRACETAM	targetBased	2	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00545012	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Focal-onset seizure	LEVETIRACETAM	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00537238	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Focal-onset seizure	LEVETIRACETAM	targetBased	3	Completed	30/11/2017	https://clinicaltrials.gov/study/NCT03340064	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	METIPRANOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED04	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	METIPRANOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED54	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466388	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466388	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466388	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466388	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466388	1	GoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Polyuria	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Urinary incontinence	TERODILINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BD05	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	MODAFINIL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00042848	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	MODAFINIL	targetBased	4	Unknown status	01/03/2013	https://clinicaltrials.gov/study/NCT02385656	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	MODAFINIL	targetBased	2	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00233090	0.2	LoF	protect	Insufficient recruitment
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	MODAFINIL	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00614926	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	chronic kidney disease	AUS-131	targetBased	2	Recruiting	07/03/2023	https://clinicaltrials.gov/study/NCT06128278	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	2	Active, not recruiting	10/01/2018	https://clinicaltrials.gov/study/NCT03369262	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	3	Withdrawn	01/07/2011	https://clinicaltrials.gov/study/NCT01314859	0.7	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT01429545	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	4	Recruiting	01/12/2017	https://clinicaltrials.gov/study/NCT05693688	1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	3	Terminated	16/03/2015	https://clinicaltrials.gov/study/NCT02292771	0.7	LoF	protect	The study was stopped due to the feasibility of recruiting the study in a timely manner
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00599898	1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tractocile	1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	ATOSIBAN	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02292784	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pregnancy	EPHEDRINE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02376192	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pregnancy	EPHEDRINE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01243970	1	GoF	protect	Change in clinical practice since the start of the trial in 2011 (phenylephrine superior)
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pregnancy	EPHEDRINE	targetBased	4	Completed	19/07/2023	https://clinicaltrials.gov/study/NCT05892913	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cycloplegia	EPHEDRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FB02	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	EPHEDRINE	targetBased	4	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT02025426	1	GoF	protect	Significant challenges recruiting a difficult patient population with most surgeries occurring out of hours
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	EPHEDRINE	targetBased	3	Withdrawn	01/06/2011	https://clinicaltrials.gov/study/NCT01451060	0.7	GoF	protect	We didn't have enough financial support
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	chronic kidney disease	DASATINIB	targetBased	2	Enrolling by invitation	01/07/2016	https://clinicaltrials.gov/study/NCT02848131	0.2	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tics	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	premature birth	DOMPERIDONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00238056	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	premature birth	DOMPERIDONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00238056	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	premature birth	DOMPERIDONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00238056	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	premature birth	DOMPERIDONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00238056	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	premature birth	DOMPERIDONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00238056	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	premature birth	DOMPERIDONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00238056	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Vestibular schwannoma	NIMODIPINE	targetBased	2	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04801953	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	poisoning	NIMODIPINE	targetBased	3	Active, not recruiting	11/06/2020	https://clinicaltrials.gov/study/NCT03925025	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Abdominal distention	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b316ff5-b7f8-4509-acc4-fd263d0a1703	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Abdominal distention	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af7b1a71-bc6d-42df-93b3-14be5d3eeb33	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Abdominal distention	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d6cdb9f-f9cd-488e-8c88-bec8606aa4cf	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Abdominal distention	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dab227-b05b-4e72-a59c-6e6f8a80252e	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Abdominal distention	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa461271-91e8-4a83-8435-5f52040ab41b	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Abdominal distention	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd6a0d6e-562a-4364-81a5-c609f3936327	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Acute kidney injury	VASOPRESSIN	targetBased	4	Recruiting	15/10/2020	https://clinicaltrials.gov/study/NCT04602767	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Shock	VASOPRESSIN	targetBased	2	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT03483753	0.2	GoF	protect	no funding for the study
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Shock	VASOPRESSIN	targetBased	4	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02118467	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Shock	VASOPRESSIN	targetBased	3	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01505231	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Shock	VASOPRESSIN	targetBased	2	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01611935	0.2	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa461271-91e8-4a83-8435-5f52040ab41b	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dab227-b05b-4e72-a59c-6e6f8a80252e	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b316ff5-b7f8-4509-acc4-fd263d0a1703	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d6cdb9f-f9cd-488e-8c88-bec8606aa4cf	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd6a0d6e-562a-4364-81a5-c609f3936327	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af7b1a71-bc6d-42df-93b3-14be5d3eeb33	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Polyuria	DESMOPRESSIN	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01435083	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	kidney failure	DESMOPRESSIN	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00748072	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hypothermia	DESMOPRESSIN	targetBased	4	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00902057	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	overactive bladder	DESMOPRESSIN	targetBased	2	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01729819	0.2	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Ecchymosis	DESMOPRESSIN	targetBased	2	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01982760	0.2	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	DESMOPRESSIN	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06020495	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01280188	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	renal colic	DESMOPRESSIN	targetBased	3	Unknown status	01/03/2012	https://clinicaltrials.gov/study/NCT01742689	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	kidney disease	DESMOPRESSIN	targetBased	4	Withdrawn	29/08/2018	https://clinicaltrials.gov/study/NCT03676361	1	GoF	protect	Not initiated
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	head injury	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	head injury	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f040d0-a073-4fa5-8997-b2fecc4a3205	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	TOFACITINIB	targetBased	2	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02299297	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	TOFACITINIB	targetBased	4	Completed	12/01/2019	https://clinicaltrials.gov/study/NCT03800979	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Takayasu arteritis	TOFACITINIB	targetBased	4	Recruiting	01/11/2021	https://clinicaltrials.gov/study/NCT05102448	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Takayasu arteritis	TOFACITINIB	targetBased	4	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04299971	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Takayasu arteritis	TOFACITINIB	targetBased	4	Recruiting	05/01/2022	https://clinicaltrials.gov/study/NCT05151848	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Takayasu arteritis	TOFACITINIB	targetBased	3	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05749666	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Granulomatosis with Polyangiitis	TOFACITINIB	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04944524	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	injury	TOFACITINIB	targetBased	2	Recruiting	03/09/2019	https://clinicaltrials.gov/study/NCT03681275	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Sjogren syndrome	TOFACITINIB	targetBased	2	Recruiting	20/11/2021	https://clinicaltrials.gov/study/NCT05087589	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dry eye syndrome	TOFACITINIB	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01135511	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dry eye syndrome	TOFACITINIB	targetBased	2	Withdrawn	01/12/2010	https://clinicaltrials.gov/study/NCT01226680	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00894621	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	3	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01505231	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	3	Unknown status	15/01/2018	https://clinicaltrials.gov/study/NCT03340779	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	4	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02118467	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	2	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT03483753	0.2	GoF	protect	no funding for the study
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00314704	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	4	Recruiting	15/12/2023	https://clinicaltrials.gov/study/NCT06265259	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shock	NOREPINEPHRINE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01367743	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	toxicity	NOREPINEPHRINE	targetBased	4	Recruiting	21/11/2018	https://clinicaltrials.gov/study/NCT03712111	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	toxicity	NOREPINEPHRINE	targetBased	4	Completed	18/01/2019	https://clinicaltrials.gov/study/NCT03792906	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	HYDROCODONE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	HYDROCODONE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nail disorder	HYDROCODONE	targetBased	4	Completed	10/11/2022	https://clinicaltrials.gov/study/NCT05544734	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nail disorder	HYDROCODONE	targetBased	4	Completed	10/11/2022	https://clinicaltrials.gov/study/NCT05544734	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	nail disorder	HYDROCODONE	targetBased	4	Completed	10/11/2022	https://clinicaltrials.gov/study/NCT05544734	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nausea	HYDROCODONE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nausea	HYDROCODONE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Nausea	HYDROCODONE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	injury	HYDROCODONE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	eye disease	HYDROCODONE	targetBased	2	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03206723	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	eye disease	HYDROCODONE	targetBased	2	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03206723	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	eye disease	HYDROCODONE	targetBased	2	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03206723	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02646566	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02449291	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	post operative nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01510704	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Chemotherapy-induced nausea and vomiting	AMISULPRIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01303978	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	AMISULPRIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		burn	ESKETAMINE	targetBased	4	Recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04682782	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT01934010	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02040207	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00860808	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01270282	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01803646	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02040194	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Coma	ESKETAMINE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02624401	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	ESKETAMINE	targetBased	4	Withdrawn	01/10/2024	https://clinicaltrials.gov/study/NCT05180318	1	LoF	protect	No Participants Enrolled
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	multiple system atrophy	EXENATIDE	targetBased	2	Recruiting	16/09/2020	https://clinicaltrials.gov/study/NCT04431713	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	multiple system atrophy	EXENATIDE	targetBased	2	Recruiting	16/09/2020	https://clinicaltrials.gov/study/NCT04431713	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	multiple system atrophy	EXENATIDE	targetBased	2	Recruiting	16/09/2020	https://clinicaltrials.gov/study/NCT04431713	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Weight loss	EXENATIDE	targetBased	3	Completed	03/03/2009	https://clinicaltrials.gov/study/NCT00856609	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Weight loss	EXENATIDE	targetBased	3	Completed	03/03/2009	https://clinicaltrials.gov/study/NCT00856609	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Weight loss	EXENATIDE	targetBased	3	Completed	03/03/2009	https://clinicaltrials.gov/study/NCT00856609	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	dystocia	OXYTOCIN	targetBased	3	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01397630	0.7	GoF	protect	Due to budgetary concerns, the TSC decided it best to adjust sample size as there was sufficient data to assess feasibility. Recruitment was terminated early.
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	dystocia	OXYTOCIN	targetBased	4	Completed	28/09/2015	https://clinicaltrials.gov/study/NCT02487797	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Atrophy	OXYTOCIN	targetBased	2	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02497547	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Tinnitus	OXYTOCIN	targetBased	3	Terminated	15/01/2020	https://clinicaltrials.gov/study/NCT04210310	0.7	GoF	protect	PI departure from the institution.
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	adverse effect	OXYTOCIN	targetBased	4	Enrolling by invitation	30/11/2021	https://clinicaltrials.gov/study/NCT05110482	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	OXYTOCIN	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02528136	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	OXYTOCIN	targetBased	4	Completed	02/04/2019	https://clinicaltrials.gov/study/NCT03899961	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	OXYTOCIN	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00977769	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NICARDIPINE	targetBased	3	Terminated	01/09/2015	https://clinicaltrials.gov/study/NCT02558023	0.7	LoF	protect	no candidats
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	beta-thalassemia major	AZACITIDINE	targetBased	2	Terminated	01/11/2000	https://clinicaltrials.gov/study/NCT00007072	0.2	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	Beta-thalassemia	AZACITIDINE	targetBased	2	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00005934	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	chronic renal failure syndrome	AMLODIPINE	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00124969	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	kidney disease	AMLODIPINE	targetBased	4	Completed	01/02/2000	https://clinicaltrials.gov/study/NCT00140985	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	beta-thalassemia major	AMLODIPINE	targetBased	2	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT01125254	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	AMLODIPINE	targetBased	4	Completed	09/04/2021	https://clinicaltrials.gov/study/NCT04790279	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	AMLODIPINE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02353806	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	HYDROMORPHONE	targetBased	2	Completed	20/04/2019	https://clinicaltrials.gov/study/NCT03767933	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	HYDROMORPHONE	targetBased	2	Completed	20/04/2019	https://clinicaltrials.gov/study/NCT03767933	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	HYDROMORPHONE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00992576	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	HYDROMORPHONE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00992576	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nausea	HYDROMORPHONE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT02295124	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Nausea	HYDROMORPHONE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT02295124	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Anal fissure	NIFEDIPINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02527109	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02583633	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	2	Unknown status	01/11/2013	https://clinicaltrials.gov/study/NCT01985594	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	2	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04404686	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	3	Terminated	01/05/2003	https://clinicaltrials.gov/study/NCT00137501	0.7	LoF	protect	The trial was terminated because of difficulties in recruitement.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	3	Withdrawn	01/03/2013	https://clinicaltrials.gov/study/NCT01796522	0.7	LoF	protect	have been published new studies that it showed the ineffectiveness of the treatments proposed in this study.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	4	Unknown status	01/04/2014	https://clinicaltrials.gov/study/NCT02068404	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03005496	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	4	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02438371	1	LoF	protect	Study halted due to slow recruitment
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	3	Completed	05/05/2014	https://clinicaltrials.gov/study/NCT02132533	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT03040752	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	3	Withdrawn	01/07/2011	https://clinicaltrials.gov/study/NCT01314859	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	2	Recruiting	01/06/2020	https://clinicaltrials.gov/study/NCT04846621	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT01429545	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00599898	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	premature birth	NIFEDIPINE	targetBased	3	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT01360034	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	chronic kidney disease	NIFEDIPINE	targetBased	2	Completed	09/05/2007	https://clinicaltrials.gov/study/NCT00810732	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	chronic kidney disease	NIFEDIPINE	targetBased	2	Unknown status	01/05/2007	https://clinicaltrials.gov/study/NCT00817037	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	nephrolithiasis	NIFEDIPINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	nephrolithiasis	NIFEDIPINE	targetBased	3	Unknown status	01/01/2008	https://clinicaltrials.gov/study/NCT00713739	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	severe pre-eclampsia	NIFEDIPINE	targetBased	2	Unknown status	23/02/2017	https://clinicaltrials.gov/study/NCT03325348	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	3	Recruiting	17/07/2020	https://clinicaltrials.gov/study/NCT04298034	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02531490	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Completed	11/09/2017	https://clinicaltrials.gov/study/NCT03506724	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Completed	09/04/2021	https://clinicaltrials.gov/study/NCT04790279	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Completed	09/06/2020	https://clinicaltrials.gov/study/NCT04392375	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Active, not recruiting	18/10/2021	https://clinicaltrials.gov/study/NCT05049616	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT01912677	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Completed	24/01/2020	https://clinicaltrials.gov/study/NCT04236258	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Recruiting	20/06/2022	https://clinicaltrials.gov/study/NCT05309460	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	NIFEDIPINE	targetBased	4	Terminated	25/08/2020	https://clinicaltrials.gov/study/NCT04349124	1	LoF	protect	Unable to continue recruiting
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ESTRADIOL VALERATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00307801	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ESTRADIOL VALERATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00307801	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ESTRADIOL VALERATE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00293059	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Metrorrhagia	ESTRADIOL VALERATE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00293059	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Miscarriage	ESTRADIOL VALERATE	targetBased	4	Recruiting	25/05/2019	https://clinicaltrials.gov/study/NCT03976544	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Miscarriage	ESTRADIOL VALERATE	targetBased	4	Recruiting	25/05/2019	https://clinicaltrials.gov/study/NCT03976544	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	tenosynovial giant cell tumor, diffuse type	NILOTINIB	targetBased	2	Active, not recruiting	01/09/2010	https://clinicaltrials.gov/study/NCT01207492	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	tenosynovial giant cell tumor, diffuse type	NILOTINIB	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01261429	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Vestibular schwannoma	NILOTINIB	targetBased	2	Terminated	01/10/2010	https://clinicaltrials.gov/study/NCT01201538	0.2	LoF	protect	Study PI passed away We had trouble recruiting for the drug arm
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Graves ophthalmopathy	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05126147	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	temporal arteritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00430807	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	X-linked Alport syndrome	HYDROXYCHLOROQUINE	targetBased	2	Recruiting	08/09/2021	https://clinicaltrials.gov/study/NCT04937907	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pregnancy	HYDROXYCHLOROQUINE	targetBased	2	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02379650	0.2	LoF	protect	Testing required by FDA for IND approval was too expensive to move forward with conduct of the study.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pregnancy	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	25/01/2018	https://clinicaltrials.gov/study/NCT03305263	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	autoimmune thrombocytopenic purpura	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03229746	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Sjogren syndrome	HYDROXYCHLOROQUINE	targetBased	2	Active, not recruiting	14/07/2022	https://clinicaltrials.gov/study/NCT05016297	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Sjogren syndrome	HYDROXYCHLOROQUINE	targetBased	2	Not yet recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05678335	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Sjogren syndrome	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	14/01/2022	https://clinicaltrials.gov/study/NCT04981145	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Sjogren syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00632866	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Sjogren syndrome	HYDROXYCHLOROQUINE	targetBased	2	Recruiting	20/01/2022	https://clinicaltrials.gov/study/NCT05113004	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	lichen planus	HYDROXYCHLOROQUINE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102557	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	alopecia areata	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00176982	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	IGA glomerulonephritis	HYDROXYCHLOROQUINE	targetBased	4	Unknown status	01/06/2016	https://clinicaltrials.gov/study/NCT02765594	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	IGA glomerulonephritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02351752	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	IGA glomerulonephritis	HYDROXYCHLOROQUINE	targetBased	2	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06350630	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	preeclampsia	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	31/05/2022	https://clinicaltrials.gov/study/NCT05287321	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Disseminated intravascular coagulation	ERGOCALCIFEROL	targetBased	2	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04363840	0.2	GoF	protect	lack of funding
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	calcification	ERGOCALCIFEROL	targetBased	4	Unknown status	01/03/2009	https://clinicaltrials.gov/study/NCT01799317	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Pruritus	ERGOCALCIFEROL	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01114672	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	ERGOCALCIFEROL	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01395823	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	ERGOCALCIFEROL	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01173848	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	ERGOCALCIFEROL	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01675557	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin deficiency	ERGOCALCIFEROL	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01630720	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	burn	ERGOCALCIFEROL	targetBased	3	Withdrawn	01/02/2007	https://clinicaltrials.gov/study/NCT00591604	0.7	GoF	protect	hurricane caused closure of hospital with PI not associated with Shriners Hospital for children
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Neonatal sepsis	ERGOCALCIFEROL	targetBased	3	Completed	14/08/2018	https://clinicaltrials.gov/study/NCT05969327	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Cluster headache	ERGOCALCIFEROL	targetBased	3	Terminated	15/09/2021	https://clinicaltrials.gov/study/NCT04570475	0.7	GoF	protect	Low number met criteria to randomize.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	ERGOCALCIFEROL	targetBased	3	Recruiting	30/06/2021	https://clinicaltrials.gov/study/NCT04775381	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01016184	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	09/10/2017	https://clinicaltrials.gov/study/NCT03141593	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	3	Completed	01/12/2017	https://clinicaltrials.gov/study/NCT03272126	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Recruiting	01/01/2016	https://clinicaltrials.gov/study/NCT02662491	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02186028	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Not yet recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06176157	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00381914	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02451787	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02022475	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01437696	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03228862	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	2	Withdrawn	15/01/2017	https://clinicaltrials.gov/study/NCT03019120	0.2	GoF	protect	Due to administrative reasons, it was not possible to enroll subjects.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01170273	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02008201	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	15/02/2017	https://clinicaltrials.gov/study/NCT03035084	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01633853	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	2	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04363840	0.2	GoF	protect	lack of funding
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01112891	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	vitamin D deficiency	ERGOCALCIFEROL	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01187459	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	acne	ERGOCALCIFEROL	targetBased	4	Enrolling by invitation	16/02/2023	https://clinicaltrials.gov/study/NCT05758259	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pregnancy	ERGOCALCIFEROL	targetBased	3	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01019785	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pregnancy	ERGOCALCIFEROL	targetBased	3	Completed	19/10/2020	https://clinicaltrials.gov/study/NCT04591847	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypophosphatemia	ERGOCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c063ce-5a2c-4ccb-87df-6ec3df0c9fa6	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic renal failure syndrome	ERGOCALCIFEROL	targetBased	4	Terminated	08/07/2019	https://clinicaltrials.gov/study/NCT03710161	1	GoF	protect	Study was stopped due to the COVID pandemic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00259922	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00259922	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00241722	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00241722	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02789111	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02789111	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00101998	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00101998	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00256932	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00256932	0.7	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	RETOSIBAN	targetBased	2	Completed	12/10/2007	https://clinicaltrials.gov/study/NCT00404768	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	RETOSIBAN	targetBased	3	Terminated	29/02/2016	https://clinicaltrials.gov/study/NCT02377466	0.7	LoF	protect	Asset terminated by PIB
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	RETOSIBAN	targetBased	3	Terminated	16/03/2015	https://clinicaltrials.gov/study/NCT02292771	0.7	LoF	protect	The study was stopped due to the feasibility of recruiting the study in a timely manner
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	RETOSIBAN	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02292784	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	pathological myopia	ATROPINE	targetBased	3	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05667454	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	pathological myopia	ATROPINE	targetBased	3	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05667454	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	pathological myopia	ATROPINE	targetBased	3	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05667454	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	pathological myopia	ATROPINE	targetBased	3	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05667454	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pathological myopia	ATROPINE	targetBased	3	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05667454	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	ATROPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	ATROPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	ATROPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	ATROPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	ATROPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00921102	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA01	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA01	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Vitreous floaters	ATROPINE	targetBased	2	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06174935	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Vitreous floaters	ATROPINE	targetBased	2	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06174935	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Vitreous floaters	ATROPINE	targetBased	2	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06174935	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Vitreous floaters	ATROPINE	targetBased	2	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06174935	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Vitreous floaters	ATROPINE	targetBased	2	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06174935	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	3	Completed	01/06/2021	https://clinicaltrials.gov/study/NCT04910477	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	3	Completed	01/06/2021	https://clinicaltrials.gov/study/NCT04910477	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	3	Completed	01/06/2021	https://clinicaltrials.gov/study/NCT04910477	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	3	Completed	01/06/2021	https://clinicaltrials.gov/study/NCT04910477	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE	targetBased	3	Completed	01/06/2021	https://clinicaltrials.gov/study/NCT04910477	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f42a0-1a33-40e8-8221-201767d999e5	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f42a0-1a33-40e8-8221-201767d999e5	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f42a0-1a33-40e8-8221-201767d999e5	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f42a0-1a33-40e8-8221-201767d999e5	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f42a0-1a33-40e8-8221-201767d999e5	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596c7a8f-27cd-4de2-9491-476f43570b8b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596c7a8f-27cd-4de2-9491-476f43570b8b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596c7a8f-27cd-4de2-9491-476f43570b8b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596c7a8f-27cd-4de2-9491-476f43570b8b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596c7a8f-27cd-4de2-9491-476f43570b8b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05006638	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05006638	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05006638	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05006638	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	poisoning	ATROPINE	targetBased	4	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05006638	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	newborn respiratory distress syndrome	ATROPINE	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	newborn respiratory distress syndrome	ATROPINE	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	newborn respiratory distress syndrome	ATROPINE	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	newborn respiratory distress syndrome	ATROPINE	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	newborn respiratory distress syndrome	ATROPINE	targetBased	4	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05065424	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Achalasia	ATROPINE	targetBased	4	Recruiting	17/03/2021	https://clinicaltrials.gov/study/NCT04641702	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Achalasia	ATROPINE	targetBased	4	Recruiting	17/03/2021	https://clinicaltrials.gov/study/NCT04641702	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Achalasia	ATROPINE	targetBased	4	Recruiting	17/03/2021	https://clinicaltrials.gov/study/NCT04641702	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Achalasia	ATROPINE	targetBased	4	Recruiting	17/03/2021	https://clinicaltrials.gov/study/NCT04641702	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Achalasia	ATROPINE	targetBased	4	Recruiting	17/03/2021	https://clinicaltrials.gov/study/NCT04641702	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06111352	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06111352	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06111352	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06111352	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE	targetBased	2	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06111352	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d4307d-da8f-49f5-aac0-02355dd9ffb7	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20491566-e6eb-8d4a-3083-77ea429f7bc4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Anisometropia	ATROPINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00001864	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Anisometropia	ATROPINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00001864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Anisometropia	ATROPINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00001864	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Anisometropia	ATROPINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00001864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Anisometropia	ATROPINE	targetBased	3	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT00001864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	pregnancy	ATROPINE	targetBased	4	Completed	19/07/2023	https://clinicaltrials.gov/study/NCT05892913	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	pregnancy	ATROPINE	targetBased	4	Completed	19/07/2023	https://clinicaltrials.gov/study/NCT05892913	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	pregnancy	ATROPINE	targetBased	4	Completed	19/07/2023	https://clinicaltrials.gov/study/NCT05892913	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	pregnancy	ATROPINE	targetBased	4	Completed	19/07/2023	https://clinicaltrials.gov/study/NCT05892913	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pregnancy	ATROPINE	targetBased	4	Completed	19/07/2023	https://clinicaltrials.gov/study/NCT05892913	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	12/02/2020	https://clinicaltrials.gov/study/NCT04173780	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	12/02/2020	https://clinicaltrials.gov/study/NCT04173780	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	12/02/2020	https://clinicaltrials.gov/study/NCT04173780	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	12/02/2020	https://clinicaltrials.gov/study/NCT04173780	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	12/02/2020	https://clinicaltrials.gov/study/NCT04173780	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05448989	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05448989	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05448989	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05448989	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05448989	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Unknown status	01/04/2007	https://clinicaltrials.gov/study/NCT00541177	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Unknown status	01/04/2007	https://clinicaltrials.gov/study/NCT00541177	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Unknown status	01/04/2007	https://clinicaltrials.gov/study/NCT00541177	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Unknown status	01/04/2007	https://clinicaltrials.gov/study/NCT00541177	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Unknown status	01/04/2007	https://clinicaltrials.gov/study/NCT00541177	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03334253	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03334253	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03334253	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03334253	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03334253	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	30/05/2019	https://clinicaltrials.gov/study/NCT03911271	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	30/05/2019	https://clinicaltrials.gov/study/NCT03911271	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	30/05/2019	https://clinicaltrials.gov/study/NCT03911271	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	30/05/2019	https://clinicaltrials.gov/study/NCT03911271	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	30/05/2019	https://clinicaltrials.gov/study/NCT03911271	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02870478	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02870478	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02870478	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02870478	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02870478	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03544827	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03544827	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03544827	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03544827	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03544827	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Not yet recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05815784	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Not yet recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05815784	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Not yet recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05815784	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Not yet recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05815784	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Not yet recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05815784	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	03/06/2019	https://clinicaltrials.gov/study/NCT03942419	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	03/06/2019	https://clinicaltrials.gov/study/NCT03942419	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	03/06/2019	https://clinicaltrials.gov/study/NCT03942419	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	03/06/2019	https://clinicaltrials.gov/study/NCT03942419	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	03/06/2019	https://clinicaltrials.gov/study/NCT03942419	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Recruiting	19/10/2021	https://clinicaltrials.gov/study/NCT03865160	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Recruiting	19/10/2021	https://clinicaltrials.gov/study/NCT03865160	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Recruiting	19/10/2021	https://clinicaltrials.gov/study/NCT03865160	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Recruiting	19/10/2021	https://clinicaltrials.gov/study/NCT03865160	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Recruiting	19/10/2021	https://clinicaltrials.gov/study/NCT03865160	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00371124	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00371124	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00371124	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00371124	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	2	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00371124	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	renal colic	BUPRENORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01546701	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	BUPRENORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01546701	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	BUPRENORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01546701	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	nephrogenic fibrosing dermopathy	IMATINIB MESYLATE	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00677092	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	nephrogenic fibrosing dermopathy	IMATINIB MESYLATE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00981942	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	mastodynia	TOREMIFENE	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00534846	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	mastodynia	TOREMIFENE	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00534846	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	mastodynia	TOREMIFENE	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00534846	0.7		protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	Hypocalcemia	TERIPARATIDE	targetBased	2	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00623974	0.2	GoF	protect	Terminated due to slow accrual.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pregnancy	PROPRANOLOL HYDROCHLORIDE	targetBased	3	Terminated	14/07/2020	https://clinicaltrials.gov/study/NCT04299438	0.35	LoF	protect	Stopped at interim analysis
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acne	DEZOCINE	targetBased	4	Recruiting	11/02/2023	https://clinicaltrials.gov/study/NCT05861063	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acne	DEZOCINE	targetBased	4	Recruiting	11/02/2023	https://clinicaltrials.gov/study/NCT05861063	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	acne	DEZOCINE	targetBased	4	Recruiting	11/02/2023	https://clinicaltrials.gov/study/NCT05861063	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	X-linked Alport syndrome	HYDROXYCHLOROQUINE SULFATE	targetBased	2	Recruiting	08/09/2021	https://clinicaltrials.gov/study/NCT04937907	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Sjogren syndrome	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Recruiting	14/01/2022	https://clinicaltrials.gov/study/NCT04981145	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	IGA glomerulonephritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Unknown status	01/06/2016	https://clinicaltrials.gov/study/NCT02765594	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	IGA glomerulonephritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02351752	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Anal fissure	DILTIAZEM HYDROCHLORIDE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01217515	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	KETAMINE HYDROCHLORIDE	targetBased	2	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT03336398	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		adverse effect	KETAMINE HYDROCHLORIDE	targetBased	4	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04490031	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE HYDROCHLORIDE	targetBased	3	Active, not recruiting	03/10/2017	https://clinicaltrials.gov/study/NCT02866071	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	KETAMINE HYDROCHLORIDE	targetBased	3	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT05437575	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE HYDROCHLORIDE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE HYDROCHLORIDE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE HYDROCHLORIDE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE HYDROCHLORIDE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE HYDROCHLORIDE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	PIOGLITAZONE HYDROCHLORIDE	targetBased	2	Completed	22/10/2014	https://clinicaltrials.gov/study/NCT02278562	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	31/07/2017	https://clinicaltrials.gov/study/NCT03687268	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	31/07/2017	https://clinicaltrials.gov/study/NCT03687268	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	31/07/2017	https://clinicaltrials.gov/study/NCT03687268	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE HYDROCHLORIDE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00031798	0.7	LoF	protect	low accrual; loss of funding
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE HYDROCHLORIDE	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00376675	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	METHYLPHENIDATE HYDROCHLORIDE	targetBased	3	Completed	12/10/1999	https://clinicaltrials.gov/study/NCT00003266	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	chronic kidney disease	DABIGATRAN ETEXILATE	targetBased	4	Recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05747768	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d705c57-fa98-46e0-97f3-38e1b0ada76b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d705c57-fa98-46e0-97f3-38e1b0ada76b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d705c57-fa98-46e0-97f3-38e1b0ada76b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d705c57-fa98-46e0-97f3-38e1b0ada76b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d705c57-fa98-46e0-97f3-38e1b0ada76b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e5dab9c-755b-460e-afe2-1ddfc4acfd96	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e5dab9c-755b-460e-afe2-1ddfc4acfd96	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e5dab9c-755b-460e-afe2-1ddfc4acfd96	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e5dab9c-755b-460e-afe2-1ddfc4acfd96	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e5dab9c-755b-460e-afe2-1ddfc4acfd96	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	SCOPOLAMINE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA02	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA02	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01FA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD01	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD01	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD51	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD51	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD51	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD51	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Nausea	SCOPOLAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A04AD51	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	14/06/2021	https://clinicaltrials.gov/study/NCT04947423	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	14/06/2021	https://clinicaltrials.gov/study/NCT04947423	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	14/06/2021	https://clinicaltrials.gov/study/NCT04947423	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	14/06/2021	https://clinicaltrials.gov/study/NCT04947423	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	14/06/2021	https://clinicaltrials.gov/study/NCT04947423	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fdc88b-ea00-4694-8f21-b8d15dbb339e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	07/06/2019	https://clinicaltrials.gov/study/NCT03988530	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	07/06/2019	https://clinicaltrials.gov/study/NCT03988530	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	07/06/2019	https://clinicaltrials.gov/study/NCT03988530	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	07/06/2019	https://clinicaltrials.gov/study/NCT03988530	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	07/06/2019	https://clinicaltrials.gov/study/NCT03988530	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	10/08/2021	https://clinicaltrials.gov/study/NCT05852730	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	10/08/2021	https://clinicaltrials.gov/study/NCT05852730	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	10/08/2021	https://clinicaltrials.gov/study/NCT05852730	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	10/08/2021	https://clinicaltrials.gov/study/NCT05852730	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	10/08/2021	https://clinicaltrials.gov/study/NCT05852730	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	09/06/2019	https://clinicaltrials.gov/study/NCT04184115	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	09/06/2019	https://clinicaltrials.gov/study/NCT04184115	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	09/06/2019	https://clinicaltrials.gov/study/NCT04184115	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	09/06/2019	https://clinicaltrials.gov/study/NCT04184115	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	09/06/2019	https://clinicaltrials.gov/study/NCT04184115	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	29/06/2018	https://clinicaltrials.gov/study/NCT04219982	0.2	LoF	protect	Failure to meet enrollment
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	29/06/2018	https://clinicaltrials.gov/study/NCT04219982	0.2	LoF	protect	Failure to meet enrollment
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	29/06/2018	https://clinicaltrials.gov/study/NCT04219982	0.2	LoF	protect	Failure to meet enrollment
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	29/06/2018	https://clinicaltrials.gov/study/NCT04219982	0.2	LoF	protect	Failure to meet enrollment
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	29/06/2018	https://clinicaltrials.gov/study/NCT04219982	0.2	LoF	protect	Failure to meet enrollment
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	23/08/2022	https://clinicaltrials.gov/study/NCT05548270	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	23/08/2022	https://clinicaltrials.gov/study/NCT05548270	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	23/08/2022	https://clinicaltrials.gov/study/NCT05548270	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	23/08/2022	https://clinicaltrials.gov/study/NCT05548270	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	23/08/2022	https://clinicaltrials.gov/study/NCT05548270	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT04272255	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT04272255	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT04272255	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT04272255	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT04272255	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02155309	0.2	LoF	protect	Business reason
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02155309	0.2	LoF	protect	Business reason
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02155309	0.2	LoF	protect	Business reason
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02155309	0.2	LoF	protect	Business reason
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Terminated	01/06/2014	https://clinicaltrials.gov/study/NCT02155309	0.2	LoF	protect	Business reason
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	26/04/2019	https://clinicaltrials.gov/study/NCT03986905	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	26/04/2019	https://clinicaltrials.gov/study/NCT03986905	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	26/04/2019	https://clinicaltrials.gov/study/NCT03986905	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	26/04/2019	https://clinicaltrials.gov/study/NCT03986905	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	3	Completed	26/04/2019	https://clinicaltrials.gov/study/NCT03986905	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05886660	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05886660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05886660	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05886660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Recruiting	21/01/2022	https://clinicaltrials.gov/study/NCT05886660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00374478	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00374478	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00374478	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00374478	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	motion sickness	SCOPOLAMINE	targetBased	2	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00374478	0.2	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	premature birth	DOXAPRAM	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	premature birth	DOXAPRAM	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	3	Withdrawn	01/05/2008	https://clinicaltrials.gov/study/NCT00684164	0.7	LoF	protect	Unable to complete a contract with the Sponsor
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00380575	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	3	Terminated	01/02/2012	https://clinicaltrials.gov/study/NCT01451411	0.7	LoF	protect	Enrollment goals were not met.
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00492037	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00435591	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00379847	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	4	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00727090	1	LoF	protect	Enrollment below goal.
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00478192	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	autoimmune thrombocytopenic purpura	TERBUTALINE	targetBased	2	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05494307	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	nephrolithiasis	PROPANTHELINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT01010048	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02977286	1	LoF	protect	Poor enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02977286	1	LoF	protect	Poor enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01773096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01773096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00366431	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00366431	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Withdrawn	01/03/2009	https://clinicaltrials.gov/study/NCT00858754	1	LoF	protect	Withdrawn [This study was terminated early by Wyeth, prior to dosing any subjects, for business reasons not related to safety.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Withdrawn	01/03/2009	https://clinicaltrials.gov/study/NCT00858754	1	LoF	protect	Withdrawn [This study was terminated early by Wyeth, prior to dosing any subjects, for business reasons not related to safety.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00672477	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00672477	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00672139	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00672139	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547586	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547586	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00936884	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00936884	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02574819	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02574819	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	19/10/2007	https://clinicaltrials.gov/study/NCT00640146	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	19/10/2007	https://clinicaltrials.gov/study/NCT00640146	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00605644	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00605644	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01050595	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01050595	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00804141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00804141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01186770	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01186770	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00529087	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00529087	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT03523520	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	4	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT03523520	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00401362	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00401362	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Tube feeding	METHYLNALTREXONE	targetBased	3	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01360372	0.7	LoF	protect	No eligible subjects identified
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Tube feeding	METHYLNALTREXONE	targetBased	3	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01360372	0.7	LoF	protect	No eligible subjects identified
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	preeclampsia	LABETALOL HYDROCHLORIDE	targetBased	2	Withdrawn	01/06/2015	https://clinicaltrials.gov/study/NCT00293735	0.2	LoF	protect	Lack of funding
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	presbyopia	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	02/09/2021	https://clinicaltrials.gov/study/NCT04983589	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	BUSPIRONE HYDROCHLORIDE	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00895830	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post operative nausea and vomiting	BUSPIRONE HYDROCHLORIDE	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00895830	0.2	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preeclampsia	AMLODIPINE BESYLATE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02353806	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b90d68-bfb6-47f6-aa5b-a6642391ff13	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTRADIOL ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b90d68-bfb6-47f6-aa5b-a6642391ff13	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	kidney failure	DESMOPRESSIN ACETATE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00748072	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Ecchymosis	DESMOPRESSIN ACETATE	targetBased	2	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01982760	0.2	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	DESMOPRESSIN ACETATE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06020495	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	diabetes insipidus	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	head injury	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f040d0-a073-4fa5-8997-b2fecc4a3205	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	head injury	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	2	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01204528	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00497146	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4db985c4-3ba2-4967-898b-35af77f150de	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4	Terminated	01/04/2003	https://clinicaltrials.gov/study/NCT00062699	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00421733	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00048438	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fbaff52-f08f-42b7-8e46-c7214112901a	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00646035	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3638a75b-eeda-4fa4-80c3-a659690ac464	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=508c4846-5c6f-4dad-9e15-fe720a984a77	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b7c7587-2042-0d9c-e054-00144ff88e88	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01136564	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa1a80e9-8778-a03e-5d53-d4b6a6363169	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00048516	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01020487	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01071070	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac3028be-d563-4b0c-86d3-5a7e1c92758c	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c0687e0-de7e-4219-a711-ad75240ca69c	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ea3c966-fe36-4e4d-ac92-f2405437a513	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c233cba2-d645-426c-9e4d-ef616edc7903	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b27c026-2d60-47b4-2a9c-ded1818f21b5	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7da0b-d715-4257-bdb3-d35fd9d02a74	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	2	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00656032	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00048451	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01163162	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01003275	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01820767	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7259652f-81bc-4ad1-bba5-d01f9fac1b80	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f2e6d12-9be9-500d-6ac6-920e0c7c14b1	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	PARICALCITOL	targetBased	2	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00646932	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	kidney disease	PARICALCITOL	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00091975	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	kidney disease	PARICALCITOL	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT02372695	1	GoF	protect	Protocol showed to be inappropriate for the evaluation of the selected patients
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Hypocalcemia	PARICALCITOL	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00053378	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	kidney failure	PARICALCITOL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00294866	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	IGA glomerulonephritis	PARICALCITOL	targetBased	3	Withdrawn	01/01/2008	https://clinicaltrials.gov/study/NCT00599963	0.7	GoF	protect	Funding problem.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic renal failure syndrome	PARICALCITOL	targetBased	4	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00091481	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic renal failure syndrome	PARICALCITOL	targetBased	4	Unknown status	01/01/2012	https://clinicaltrials.gov/study/NCT01442272	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Myalgia	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Spasticity	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Spasticity	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Eczematoid dermatitis	CALCIPOTRIENE	targetBased	2	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00404196	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	skin disease	CALCIPOTRIENE	targetBased	2	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02416258	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	skin disease	CALCIPOTRIENE	targetBased	2	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02518048	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	acne	CALCIPOTRIENE	targetBased	2	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01694433	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	radiodermatitis	CALCIPOTRIENE	targetBased	2	Unknown status		https://clinicaltrials.gov/study/NCT00445250	0.2	GoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Skin ulcer	SEVOFLURANE	targetBased	4	Recruiting	02/05/2022	https://clinicaltrials.gov/study/NCT05303805	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	oxidative stress	SEVOFLURANE	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02202239	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Coma	SEVOFLURANE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02624401	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	fluoride poisoning	SEVOFLURANE	targetBased	3	Withdrawn	01/03/2013	https://clinicaltrials.gov/study/NCT01802255	0.7		protect	Lack of recruitment in the Centres
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	oxidative stress	SEVOFLURANE	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02202239	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	tonsillitis	SEVOFLURANE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01691690	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney failure	SEVOFLURANE	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03917186	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney failure	SEVOFLURANE	targetBased	2	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02559297	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney failure	SEVOFLURANE	targetBased	4	Terminated	01/01/2002	https://clinicaltrials.gov/study/NCT00144118	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	post-operative sign or symptom	SEVOFLURANE	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02224443	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	post-operative sign or symptom	SEVOFLURANE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02931877	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	energy expenditure	SEVOFLURANE	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02272166	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	post operative nausea and vomiting	SEVOFLURANE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00793663	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	post operative nausea and vomiting	SEVOFLURANE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney failure	SEVOFLURANE	targetBased	2	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02559297	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney failure	SEVOFLURANE	targetBased	4	Terminated	01/01/2002	https://clinicaltrials.gov/study/NCT00144118	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney failure	SEVOFLURANE	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03917186	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Acute kidney injury	SEVOFLURANE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02042599	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Acute kidney injury	SEVOFLURANE	targetBased	4	Completed	01/09/2017	https://clinicaltrials.gov/study/NCT03336801	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Coma	SEVOFLURANE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02624401	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	post operative nausea and vomiting	SEVOFLURANE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00793663	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	post operative nausea and vomiting	SEVOFLURANE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	energy expenditure	SEVOFLURANE	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02272166	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	post-operative sign or symptom	SEVOFLURANE	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02224443	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	post-operative sign or symptom	SEVOFLURANE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02931877	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	ischemia reperfusion injury	SEVOFLURANE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01601795	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	ischemia reperfusion injury	SEVOFLURANE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00337051	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	ischemia reperfusion injury	SEVOFLURANE	targetBased	4	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00526695	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	ischemia reperfusion injury	SEVOFLURANE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02405689	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	tonsillitis	SEVOFLURANE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01691690	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Skin ulcer	SEVOFLURANE	targetBased	4	Recruiting	02/05/2022	https://clinicaltrials.gov/study/NCT05303805	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	fluoride poisoning	SEVOFLURANE	targetBased	3	Withdrawn	01/03/2013	https://clinicaltrials.gov/study/NCT01802255	0.7		protect	Lack of recruitment in the Centres
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Acute kidney injury	SEVOFLURANE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02042599	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Acute kidney injury	SEVOFLURANE	targetBased	4	Completed	01/09/2017	https://clinicaltrials.gov/study/NCT03336801	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	ischemia reperfusion injury	SEVOFLURANE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00337051	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	ischemia reperfusion injury	SEVOFLURANE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01601795	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	ischemia reperfusion injury	SEVOFLURANE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02405689	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	ischemia reperfusion injury	SEVOFLURANE	targetBased	4	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00526695	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	oxidative stress	DESFLURANE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02149628	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	chronic kidney disease	DESFLURANE	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01132157	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	chronic kidney disease	DESFLURANE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01870011	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	oxidative stress	DESFLURANE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02149628	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney failure	DESFLURANE	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03917186	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	kidney failure	DESFLURANE	targetBased	2	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02559297	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	post operative nausea and vomiting	DESFLURANE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney failure	DESFLURANE	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03917186	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	kidney failure	DESFLURANE	targetBased	2	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02559297	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	chronic kidney disease	DESFLURANE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01870011	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	chronic kidney disease	DESFLURANE	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01132157	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	post operative nausea and vomiting	DESFLURANE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1		protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00889629	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00749736	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253367e2-ae31-4196-9571-71f560283cf3	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e28403e8-443e-40de-a823-db22ff9f8c99	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7efc3d9c-12f5-43f6-9a22-88d66cbe6f62	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1724c79c-3d32-4e41-a961-9795500a17cd	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a43afaad-1862-4885-9b47-ddc2302160a3	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	DOXERCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e99a1d29-3989-4437-999e-4e9cab8b9b1e	1	GoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	Acute kidney injury	LITHIUM CARBONATE	targetBased	4	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03056248	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	Acute kidney injury	LITHIUM CARBONATE	targetBased	4	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03056248	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00108017	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550f843b-4069-42c1-ae5c-09bac19d95ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6ab3f6-3644-434c-b6cf-e4f111d18962	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72b0d0ec-832a-4c25-b845-2537ab506354	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0c28b92-898a-4755-9eaf-58f790a189ab	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a236f05-1ee1-4180-9d80-31518d2204c7	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=258bbc8d-00ee-45b0-ac35-6f16c4e8d45f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0972bed1-fb7f-583c-dfab-5db701c7c4a6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ae5ed44-8e5a-41ed-a223-988b4c1436ac	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3206f5f4-103f-4f04-9c95-35cf17e7a3eb	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f39126-3e3b-4633-a4e0-c1f09a794eec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00293787	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00311389	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa1986-1c24-4733-96b3-e6d8e1d44558	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e7427c3-0195-4212-9839-ab5629906ffc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167c5ae9-c354-4658-98ca-8b5b0939c841	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e3bbcd-01d4-4dba-be22-308dffecf236	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ocular hypertension	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c062ca-add7-4ddf-ba7c-7b5dd531e9ec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e3bbcd-01d4-4dba-be22-308dffecf236	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01514734	1	LoF	protect	Low recruitment rate
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811850	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00519753	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01336569	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4	Terminated	01/06/2012	https://clinicaltrials.gov/study/NCT01514721	1	LoF	protect	low enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01518244	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	3	Completed	12/03/2007	https://clinicaltrials.gov/study/NCT00449956	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00108017	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c641b6c-3335-4ec3-89b9-2d97a8901062	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbba38a-dbd6-4d3b-8788-cadb7d5246ee	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ae5ed44-8e5a-41ed-a223-988b4c1436ac	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c33fd-aa86-49ad-a767-c79ade4a62c7	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63f36fa6-bd5a-49b2-b7bf-28ce0db3c6dc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00311389	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75b3b776-5eb8-4381-ade1-5cf0e942d5ed	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f949fa34-6a9a-40d5-91ab-ff1cbb79b9ea	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4386a2d5-f577-4768-9efe-7d11a8938644	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0c28b92-898a-4755-9eaf-58f790a189ab	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d83efec-cd72-4093-a8d4-4dd5021e151e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c57114-5f79-4d70-9423-7b87fb554971	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f39126-3e3b-4633-a4e0-c1f09a794eec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85724f95-6fc9-4f0c-b69d-05a23b093e2b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00273455	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550f843b-4069-42c1-ae5c-09bac19d95ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00293787	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98d81fc6-4482-45e5-8106-4dfd56f3433b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72b0d0ec-832a-4c25-b845-2537ab506354	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9726422-f794-4d39-a437-17dcb8c0f3b5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3206f5f4-103f-4f04-9c95-35cf17e7a3eb	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e7427c3-0195-4212-9839-ab5629906ffc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d58ead9-dec9-448b-9f46-07b48c1f636c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a236f05-1ee1-4180-9d80-31518d2204c7	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23b61c26-75fb-4d2a-9282-b7af27cbc6cb	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167c5ae9-c354-4658-98ca-8b5b0939c841	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0972bed1-fb7f-583c-dfab-5db701c7c4a6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6ab3f6-3644-434c-b6cf-e4f111d18962	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32e96044-2713-40f2-b6f7-c342a31382d8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ed21930-1e05-46de-8acd-cb6f4798a7fa	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2832de-114f-49e1-8851-99d01c4361ff	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c062ca-add7-4ddf-ba7c-7b5dd531e9ec	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fa20dc-b181-48be-83ce-d66a83753878	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e3bbcd-01d4-4dba-be22-308dffecf236	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11268176-a549-43d4-a683-beab6dec0d0a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	2	Completed	29/03/2016	https://clinicaltrials.gov/study/NCT02754596	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=258bbc8d-00ee-45b0-ac35-6f16c4e8d45f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa1986-1c24-4733-96b3-e6d8e1d44558	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	TIMOLOL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15732de7-64b9-4c42-897d-89ae1b330192	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	corneal edema	TIMOLOL MALEATE	targetBased	3	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00800423	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475306	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	kidney failure	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78499dc-4d24-4226-be97-dc618d9da0cf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=917494a9-cff1-4ee6-9523-e112120373c5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT03435003	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post operative nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373ba08b-33ad-49fc-28a7-928e89a65314	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00003213	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Nausea and vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	CARTEOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	open-angle glaucoma	CARTEOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eccd10e3-ec28-4ab0-887f-fce616cf1bc2	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRROLATE	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRROLATE	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRROLATE	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRROLATE	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRROLATE	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRROLATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRROLATE	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRROLATE	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRROLATE	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRROLATE	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRROLATE	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRROLATE	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRROLATE	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRROLATE	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRROLATE	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRROLATE	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	CODEINE PHOSPHATE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00386269	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	CODEINE PHOSPHATE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00386269	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	CODEINE PHOSPHATE	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	CODEINE PHOSPHATE	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Cleft palate	CODEINE PHOSPHATE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00386269	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Constipation	CODEINE PHOSPHATE	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN HYDROCHLORIDE	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00380575	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN HYDROCHLORIDE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00492037	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Hyponatremia	CONIVAPTAN HYDROCHLORIDE	targetBased	3	Terminated	01/02/2012	https://clinicaltrials.gov/study/NCT01451411	0.7	LoF	protect	Enrollment goals were not met.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	diabetic foot	ESMOLOL HYDROCHLORIDE	targetBased	3	Completed	26/12/2018	https://clinicaltrials.gov/study/NCT03998436	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	autoimmune thrombocytopenic purpura	DECITABINE	targetBased	3	Not yet recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03252457	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	autoimmune thrombocytopenic purpura	DECITABINE	targetBased	2	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT01568333	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00323154	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00323154	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	NALBUPHINE HYDROCHLORIDE	targetBased	3	Recruiting	20/06/2021	https://clinicaltrials.gov/study/NCT04928391	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cleft palate	NALBUPHINE HYDROCHLORIDE	targetBased	3	Recruiting	20/06/2021	https://clinicaltrials.gov/study/NCT04928391	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus	NALBUPHINE HYDROCHLORIDE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00323154	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	NALBUPHINE HYDROCHLORIDE	targetBased	2	Completed	31/07/2019	https://clinicaltrials.gov/study/NCT03470077	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-operative sign or symptom	NALBUPHINE HYDROCHLORIDE	targetBased	2	Completed	31/07/2019	https://clinicaltrials.gov/study/NCT03470077	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	prurigo nodularis	NALBUPHINE HYDROCHLORIDE	targetBased	2	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03497975	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prurigo nodularis	NALBUPHINE HYDROCHLORIDE	targetBased	2	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03497975	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	prurigo nodularis	NALBUPHINE HYDROCHLORIDE	targetBased	2	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03497975	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Cleft palate	NALBUPHINE HYDROCHLORIDE	targetBased	3	Recruiting	20/06/2021	https://clinicaltrials.gov/study/NCT04928391	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	post-operative sign or symptom	NALBUPHINE HYDROCHLORIDE	targetBased	2	Completed	31/07/2019	https://clinicaltrials.gov/study/NCT03470077	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	LEVOBUNOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a32c0e8-7d10-447e-a7c4-252c98b629bd	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	glaucoma	LISDEXAMFETAMINE DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	ARMODAFINIL	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00825227	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Fatigue	ARMODAFINIL	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01781468	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	glaucoma	LISDEXAMFETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	LEVOBUNOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01ED03	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	LEVOBUNOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a32c0e8-7d10-447e-a7c4-252c98b629bd	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	glaucoma	DIPIVEFRIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01EA02	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		essential tremor	ACAMPROSATE	targetBased	2	Withdrawn	01/03/2016	https://clinicaltrials.gov/study/NCT06312800	0.2	LoF	protect	Study was never initiated.
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2022	https://clinicaltrials.gov/study/NCT05331651	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	post operative nausea and vomiting	GLYCOPYRRONIUM	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05265507	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Drooling	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02553798	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02530294	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02530281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	27/09/2021	https://clinicaltrials.gov/study/NCT04924036	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	07/03/2023	https://clinicaltrials.gov/study/NCT05863104	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02016885	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04159610	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02129660	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM	targetBased	2	Completed	22/02/2019	https://clinicaltrials.gov/study/NCT03880266	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Urinary retention	GLYCOPYRRONIUM	targetBased	4	Enrolling by invitation	03/08/2023	https://clinicaltrials.gov/study/NCT05887375	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	burn	GLYCOPYRRONIUM	targetBased	3	Completed	15/03/2018	https://clinicaltrials.gov/study/NCT03513406	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Headache	GLYCOPYRRONIUM	targetBased	2	Recruiting	19/11/2021	https://clinicaltrials.gov/study/NCT05116930	0.2	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Disseminated intravascular coagulation	ANTITHROMBIN ALFA	targetBased	3	Terminated	01/02/2012	https://clinicaltrials.gov/study/NCT01384409	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Disseminated intravascular coagulation	ANTITHROMBIN ALFA	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01384396	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Disseminated intravascular coagulation	ANTITHROMBIN ALFA	targetBased	2	Terminated	01/07/2007	https://clinicaltrials.gov/study/NCT00506519	0.2	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Disseminated intravascular coagulation	ANTITHROMBIN ALFA	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01384903	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Reduced antithrombin III activity	ANTITHROMBIN ALFA	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/atryn	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	preeclampsia	ANTITHROMBIN ALFA	targetBased	3	Completed	11/07/2014	https://clinicaltrials.gov/study/NCT02059135	0.7	LoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	kidney disease	NESIRITIDE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00170183	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	Acute kidney injury	NESIRITIDE	targetBased	3	Unknown status	01/03/2005	https://clinicaltrials.gov/study/NCT00110201	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	Dyspnea	NESIRITIDE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00270387	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	kidney failure	NESIRITIDE	targetBased	2	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01440881	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, CONJUGATED SYNTHETIC A	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd07b54-f66f-4040-9058-462324267196	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, CONJUGATED SYNTHETIC A	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd07b54-f66f-4040-9058-462324267196	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	ESTROGENS, CONJUGATED SYNTHETIC A	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd07b54-f66f-4040-9058-462324267196	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Dyspareunia	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00272935	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00272935	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTROGENS, CONJUGATED	targetBased	3	Completed	28/11/2000	https://clinicaltrials.gov/study/NCT00026286	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ESTROGENS, CONJUGATED	targetBased	3	Completed	28/11/2000	https://clinicaltrials.gov/study/NCT00026286	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Hot flashes	ESTROGENS, CONJUGATED	targetBased	3	Completed	28/11/2000	https://clinicaltrials.gov/study/NCT00026286	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Hot flashes	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00272935	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Shock	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00973102	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Shock	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00973102	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Turner syndrome	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/11/1989	https://clinicaltrials.gov/study/NCT01518062	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Turner syndrome	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/11/1992	https://clinicaltrials.gov/study/NCT00029159	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	overactive bladder	ESTROGENS, CONJUGATED	targetBased	4	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05221021	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	overactive bladder	ESTROGENS, CONJUGATED	targetBased	4	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05221021	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	overactive bladder	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00648310	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	overactive bladder	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00648310	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	overactive bladder	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01613170	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	overactive bladder	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01613170	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/11/1992	https://clinicaltrials.gov/study/NCT00029159	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/11/1992	https://clinicaltrials.gov/study/NCT00029159	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/11/1989	https://clinicaltrials.gov/study/NCT01518062	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Turner syndrome	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/11/1989	https://clinicaltrials.gov/study/NCT01518062	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Shock	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00973102	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	overactive bladder	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00648310	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	overactive bladder	ESTROGENS, CONJUGATED	targetBased	4	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05221021	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	overactive bladder	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01613170	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547586	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547586	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00605644	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00605644	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	19/10/2007	https://clinicaltrials.gov/study/NCT00640146	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	19/10/2007	https://clinicaltrials.gov/study/NCT00640146	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00529087	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00529087	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00672139	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00672139	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	3	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00804141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	3	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00804141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00366431	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00366431	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	3	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01050595	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	3	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01050595	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT03523520	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLNALTREXONE BROMIDE	targetBased	4	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT03523520	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	TAPENTADOL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01516008	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	TAPENTADOL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01516008	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	TAPENTADOL	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01813890	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	TAPENTADOL	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01813890	0.7	GoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	cold urticaria	RILONACEPT	pathwayBased	2	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02171416	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	chronic kidney disease	RILONACEPT	pathwayBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01663103	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	dry eye syndrome	CANAKINUMAB	pathwayBased	2	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01250171	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Behcet's syndrome	CANAKINUMAB	pathwayBased	2	Completed	23/06/2016	https://clinicaltrials.gov/study/NCT02756650	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	chronic idiopathic urticaria	CANAKINUMAB	pathwayBased	2	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01635127	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Pyoderma	CANAKINUMAB	pathwayBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01302795	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Fever	CANAKINUMAB	pathwayBased	3	Completed	27/06/2014	https://clinicaltrials.gov/study/NCT02059291	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	pregnancy	ESTETROL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ESTETROL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	ESTETROL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	TRAMADOL	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	TRAMADOL	targetBased	2	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT03383315	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	TRAMADOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00310908	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	TRAMADOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00310908	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	TRAMADOL	targetBased	2	Not yet recruiting	10/04/2024	https://clinicaltrials.gov/study/NCT06345716	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	TRAMADOL	targetBased	2	Not yet recruiting	10/04/2024	https://clinicaltrials.gov/study/NCT06345716	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	TRAMADOL	targetBased	4	Completed	27/04/2022	https://clinicaltrials.gov/study/NCT06231043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	renal colic	TRAMADOL	targetBased	4	Completed	27/04/2022	https://clinicaltrials.gov/study/NCT06231043	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00310908	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nephrolithiasis	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00310908	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	NOLASIBAN	targetBased	2	Terminated	01/03/2015	https://clinicaltrials.gov/study/NCT02326142	0.2	LoF	protect	Enrolment difficulties.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Myelofibrosis	FEDRATINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7	1	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	calcification	ALFACALCIDOL	targetBased	2	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01364688	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic kidney disease	ALFACALCIDOL	targetBased	4	Withdrawn	01/06/2007	https://clinicaltrials.gov/study/NCT00483275	1	GoF	protect	No final agreement with sponsor
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	kidney failure	ALFACALCIDOL	targetBased	2	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01231438	0.2	GoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	essential tremor	SUVECALTAMIDE	targetBased	2	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT03101241	0.2		protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	essential tremor	SUVECALTAMIDE	targetBased	2	Active, not recruiting	06/12/2021	https://clinicaltrials.gov/study/NCT05122650	0.2		protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	focal segmental glomerulosclerosis	FRESOLIMUMAB	pathwayBased	2	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01665391	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Behcet's syndrome	GEVOKIZUMAB	pathwayBased	3	Terminated	01/11/2014	https://clinicaltrials.gov/study/NCT02258867	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	acne	GEVOKIZUMAB	pathwayBased	2	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01498874	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Pyoderma	GEVOKIZUMAB	pathwayBased	3	Terminated	01/11/2014	https://clinicaltrials.gov/study/NCT02315417	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Pyoderma	GEVOKIZUMAB	pathwayBased	2	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01882504	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Pyoderma	GEVOKIZUMAB	pathwayBased	3	Terminated	01/11/2014	https://clinicaltrials.gov/study/NCT02318914	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Pyoderma	GEVOKIZUMAB	pathwayBased	3	Terminated	01/12/2014	https://clinicaltrials.gov/study/NCT02326740	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	uveitis	GEVOKIZUMAB	pathwayBased	3	Terminated	01/10/2012	https://clinicaltrials.gov/study/NCT01747538	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	uveitis	GEVOKIZUMAB	pathwayBased	3	Terminated	01/08/2012	https://clinicaltrials.gov/study/NCT01684345	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	uveitis	GEVOKIZUMAB	pathwayBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02258854	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	uveitis	GEVOKIZUMAB	pathwayBased	3	Terminated	01/08/2014	https://clinicaltrials.gov/study/NCT02375685	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	uveitis	GEVOKIZUMAB	pathwayBased	3	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01965145	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	autoimmune inner ear disease	GEVOKIZUMAB	pathwayBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01950312	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	Nuclear factor erythroid 2-related factor 2	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2	Alport syndrome	BARDOXOLONE METHYL	pathwayBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	Nuclear factor erythroid 2-related factor 2	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2	chronic kidney disease	BARDOXOLONE METHYL	pathwayBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	chronic kidney disease	BARDOXOLONE METHYL	targetBased	2	Completed	09/02/2021	https://clinicaltrials.gov/study/NCT04702997	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alport syndrome	BARDOXOLONE METHYL	targetBased	2	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03019185	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	prurigo	RUXOLITINIB	targetBased	3	Recruiting	10/03/2023	https://clinicaltrials.gov/study/NCT05755438	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	3	Completed	10/06/2021	https://clinicaltrials.gov/study/NCT04797650	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	2	Completed	09/08/2017	https://clinicaltrials.gov/study/NCT03137381	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	2	Completed	26/02/2021	https://clinicaltrials.gov/study/NCT04784533	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	2	Completed	24/05/2019	https://clinicaltrials.gov/study/NCT03941548	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	2	Completed	21/03/2019	https://clinicaltrials.gov/study/NCT03811912	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01950780	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	2	Active, not recruiting	04/04/2019	https://clinicaltrials.gov/study/NCT03898479	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	3	Completed	23/11/2020	https://clinicaltrials.gov/study/NCT04518995	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	RUXOLITINIB	targetBased	3	Active, not recruiting	19/10/2021	https://clinicaltrials.gov/study/NCT05041803	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	RUXOLITINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=D11AH09	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	RUXOLITINIB	targetBased	3	Withdrawn	31/01/2023	https://clinicaltrials.gov/study/NCT05233410	0.7	LoF	protect	Business decision; no safety concerns
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	RUXOLITINIB	targetBased	2	Active, not recruiting	31/07/2023	https://clinicaltrials.gov/study/NCT05906628	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	RUXOLITINIB	targetBased	3	Withdrawn	31/01/2023	https://clinicaltrials.gov/study/NCT05219864	0.7	LoF	protect	Business decision; no safety concerns.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	lichen planus	RUXOLITINIB	targetBased	2	Completed	30/08/2018	https://clinicaltrials.gov/study/NCT03697460	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	lichen planus	RUXOLITINIB	targetBased	2	Completed	23/11/2022	https://clinicaltrials.gov/study/NCT05593432	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Myelofibrosis	RUXOLITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	prurigo nodularis	RUXOLITINIB	targetBased	3	Recruiting	12/06/2023	https://clinicaltrials.gov/study/NCT05764161	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	lichen disease	RUXOLITINIB	targetBased	2	Completed	18/11/2022	https://clinicaltrials.gov/study/NCT05593445	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	beta-thalassemia major	RUXOLITINIB	targetBased	4	Recruiting	01/06/2019	https://clinicaltrials.gov/study/NCT04009525	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	beta-thalassemia major	RUXOLITINIB	targetBased	2	Completed	28/05/2014	https://clinicaltrials.gov/study/NCT02049450	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	necrobiosis lipoidica	RUXOLITINIB	targetBased	2	Completed	29/09/2020	https://clinicaltrials.gov/study/NCT04492618	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	hidradenitis suppurativa	RUXOLITINIB	targetBased	2	Completed	07/12/2022	https://clinicaltrials.gov/study/NCT05635838	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	hidradenitis suppurativa	RUXOLITINIB	targetBased	2	Recruiting	13/10/2022	https://clinicaltrials.gov/study/NCT04414514	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	seborrheic dermatitis	RUXOLITINIB	targetBased	2	Completed	15/11/2022	https://clinicaltrials.gov/study/NCT05787860	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Histiocytosis	RUXOLITINIB	targetBased	2	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT05762640	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Myelofibrosis	RUXOLITINIB PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	corneal disease	LIFITEGRAST	targetBased	4	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT05045053	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	12/12/2016	https://clinicaltrials.gov/study/NCT03451396	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Withdrawn	01/11/2018	https://clinicaltrials.gov/study/NCT03431272	1	LoF	protect	no longer interest / resources to start study
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	06/11/2014	https://clinicaltrials.gov/study/NCT02284516	0.7	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	07/12/2012	https://clinicaltrials.gov/study/NCT01743729	0.7	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	07/07/2021	https://clinicaltrials.gov/study/NCT04297618	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	17/03/2021	https://clinicaltrials.gov/study/NCT04669561	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	09/09/2021	https://clinicaltrials.gov/study/NCT05102409	0.2	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	22/09/2022	https://clinicaltrials.gov/study/NCT05505292	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04734197	0.2	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Terminated	01/08/2020	https://clinicaltrials.gov/study/NCT04413253	1	LoF	protect	Unable to recruit
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	04/03/2020	https://clinicaltrials.gov/study/NCT04030962	0.2	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Recruiting	01/02/2020	https://clinicaltrials.gov/study/NCT04172961	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	29/08/2011	https://clinicaltrials.gov/study/NCT01421498	0.7	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	02/03/2021	https://clinicaltrials.gov/study/NCT05594745	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	4	Withdrawn	31/05/2021	https://clinicaltrials.gov/study/NCT04120987	1	LoF	protect	Administrative
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	16/10/2012	https://clinicaltrials.gov/study/NCT01636206	0.7	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	03/08/2009	https://clinicaltrials.gov/study/NCT00926185	0.2	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	eye disease	LIFITEGRAST	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01XA25	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	corneal disease	LIFITEGRAST	targetBased	4	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT05045053	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	29/08/2011	https://clinicaltrials.gov/study/NCT01421498	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	04/03/2020	https://clinicaltrials.gov/study/NCT04030962	0.2	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Withdrawn	01/11/2018	https://clinicaltrials.gov/study/NCT03431272	1	LoF	protect	no longer interest / resources to start study
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04734197	0.2	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	16/10/2012	https://clinicaltrials.gov/study/NCT01636206	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	06/11/2014	https://clinicaltrials.gov/study/NCT02284516	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	03/08/2009	https://clinicaltrials.gov/study/NCT00926185	0.2	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	12/12/2016	https://clinicaltrials.gov/study/NCT03451396	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	07/07/2021	https://clinicaltrials.gov/study/NCT04297618	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Withdrawn	31/05/2021	https://clinicaltrials.gov/study/NCT04120987	1	LoF	protect	Administrative
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	2	Completed	09/09/2021	https://clinicaltrials.gov/study/NCT05102409	0.2	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	3	Completed	07/12/2012	https://clinicaltrials.gov/study/NCT01743729	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	22/09/2022	https://clinicaltrials.gov/study/NCT05505292	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Recruiting	01/02/2020	https://clinicaltrials.gov/study/NCT04172961	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Terminated	01/08/2020	https://clinicaltrials.gov/study/NCT04413253	1	LoF	protect	Unable to recruit
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	02/03/2021	https://clinicaltrials.gov/study/NCT05594745	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dry eye syndrome	LIFITEGRAST	targetBased	4	Completed	17/03/2021	https://clinicaltrials.gov/study/NCT04669561	1	LoF	protect
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	ITGB2	Integrin beta-2	eye disease	LIFITEGRAST	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=S01XA25	1	LoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Acute kidney injury	LEVOSIMENDAN	targetBased	2	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT01720030	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Acute kidney injury	LEVOSIMENDAN	targetBased	2	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT01720030	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Acute kidney injury	LEVOSIMENDAN	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02531724	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Acute kidney injury	LEVOSIMENDAN	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02531724	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Shock	LEVOSIMENDAN	targetBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT04728932	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Shock	LEVOSIMENDAN	targetBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT04728932	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Shock	LEVOSIMENDAN	targetBased	2	Unknown status	01/10/2004	https://clinicaltrials.gov/study/NCT00093301	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Shock	LEVOSIMENDAN	targetBased	2	Unknown status	01/10/2004	https://clinicaltrials.gov/study/NCT00093301	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	kidney disease	BREMELANOTIDE	targetBased	2	Recruiting	26/12/2022	https://clinicaltrials.gov/study/NCT05709444	0.2	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	kidney disease	BREMELANOTIDE	targetBased	2	Recruiting	26/12/2022	https://clinicaltrials.gov/study/NCT05709444	0.2	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	chronic kidney disease	BENIDIPINE	targetBased	4	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02646397	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE SULFATE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT02277678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE SULFATE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT02277678	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE SULFATE	targetBased	2	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03483870	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Pruritus	MORPHINE SULFATE	targetBased	2	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03483870	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	MORPHINE SULFATE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00388011	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Hallux valgus	MORPHINE SULFATE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00388011	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	iris melanoma	AGATOLIMOD	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00085189	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	iris melanoma	AGATOLIMOD SODIUM	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00085189	0.2	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	progressive supranuclear palsy	DAVUNETIDE	targetBased	2	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01110720	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	multiple system atrophy	DROXIDOPA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	multiple system atrophy	DROXIDOPA	targetBased	2	Completed	21/01/2014	https://clinicaltrials.gov/study/NCT02071459	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	dry eye syndrome	RIVOGLITAZONE	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01468168	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	dry eye syndrome	RIVOGLITAZONE	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01468168	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	dry eye syndrome	RIVOGLITAZONE	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01468168	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	dry eye syndrome	RIVOGLITAZONE	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01468168	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	dry eye syndrome	RIVOGLITAZONE	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01468168	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	dry eye syndrome	RIVOGLITAZONE	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01468168	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Dyspareunia	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	OSPEMIFENE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00276094	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	OSPEMIFENE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00276094	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	OSPEMIFENE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00729469	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophy	OSPEMIFENE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00729469	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	OSPEMIFENE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00276094	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophy	OSPEMIFENE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00729469	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dyspareunia	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	stage 5 chronic kidney disease	LUNACALCIPOL	targetBased	2	Withdrawn	01/01/2013	https://clinicaltrials.gov/study/NCT01453634	0.2	GoF	protect	The company is no longer pursuing this study.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic renal failure syndrome	LUNACALCIPOL	targetBased	2	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00742716	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	3	Completed	29/08/2013	https://clinicaltrials.gov/study/NCT01965158	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	3	Completed	29/08/2013	https://clinicaltrials.gov/study/NCT01965158	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	3	Completed	04/11/2013	https://clinicaltrials.gov/study/NCT01993940	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	3	Completed	04/11/2013	https://clinicaltrials.gov/study/NCT01993940	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	3	Completed	24/09/2013	https://clinicaltrials.gov/study/NCT01965652	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	3	Completed	24/09/2013	https://clinicaltrials.gov/study/NCT01965652	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	2	Completed	17/08/2011	https://clinicaltrials.gov/study/NCT01443403	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	2	Completed	17/08/2011	https://clinicaltrials.gov/study/NCT01443403	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	frontal fibrosing alopecia	BARICITINIB	targetBased	4	Recruiting	22/04/2024	https://clinicaltrials.gov/study/NCT06240351	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	BARICITINIB	targetBased	3	Active, not recruiting	08/07/2019	https://clinicaltrials.gov/study/NCT03899259	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	BARICITINIB	targetBased	2	Active, not recruiting	24/09/2018	https://clinicaltrials.gov/study/NCT03570749	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	temporal arteritis	BARICITINIB	targetBased	2	Completed	09/03/2017	https://clinicaltrials.gov/study/NCT03026504	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	autoimmune thrombocytopenic purpura	BARICITINIB	targetBased	2	Recruiting	07/07/2023	https://clinicaltrials.gov/study/NCT05932524	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	autoimmune thrombocytopenic purpura	BARICITINIB	targetBased	2	Recruiting	16/05/2023	https://clinicaltrials.gov/study/NCT05852847	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	autoimmune thrombocytopenic purpura	BARICITINIB	targetBased	2	Recruiting	13/07/2022	https://clinicaltrials.gov/study/NCT05446831	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	chronic kidney disease	BARICITINIB	targetBased	2	Recruiting	20/04/2023	https://clinicaltrials.gov/study/NCT05237388	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	lichen planus	BARICITINIB	targetBased	2	Completed	11/01/2022	https://clinicaltrials.gov/study/NCT05188521	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	uveitis	BARICITINIB	targetBased	3	Active, not recruiting	16/10/2019	https://clinicaltrials.gov/study/NCT04088409	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	uveitis	BARICITINIB	targetBased	3	Not yet recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05651880	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Myalgia	BARICITINIB	targetBased	2	Completed	01/12/2020	https://clinicaltrials.gov/study/NCT04027101	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Sjogren syndrome	BARICITINIB	targetBased	2	Active, not recruiting	14/07/2022	https://clinicaltrials.gov/study/NCT05016297	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE MESYLATE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00772980	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00739635	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE MESYLATE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00955799	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE MESYLATE	targetBased	3	Terminated	01/01/2009	https://clinicaltrials.gov/study/NCT00827008	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	age-related macular degeneration	DIMETHYL FUMARATE	targetBased	2	Recruiting	07/02/2022	https://clinicaltrials.gov/study/NCT04292080	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Constipation	ITOPRIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01513811	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Constipation	ITOPRIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01513811	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Constipation	ITOPRIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01513811	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Constipation	ITOPRIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01513811	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Constipation	ITOPRIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01513811	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Constipation	ITOPRIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01513811	0.2	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Polydipsia	DULAGLUTIDE	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02770885	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Polydipsia	DULAGLUTIDE	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02770885	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Polydipsia	DULAGLUTIDE	targetBased	2	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02770885	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic kidney disease	DULAGLUTIDE	targetBased	2	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05254418	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic kidney disease	DULAGLUTIDE	targetBased	2	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05254418	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic kidney disease	DULAGLUTIDE	targetBased	2	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05254418	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	Hypocalcemia	PARATHYROID HORMONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11fba31-0a6c-11e3-8ffd-0800200c9a66	1	GoF	protect
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	RXFP1	Relaxin receptor 1	preeclampsia	SERELAXIN	targetBased	2	Terminated	01/05/2013	https://clinicaltrials.gov/study/NCT01566630	0.2	GoF	protect	Novartis terminated this study due to internal, strategic decisions.
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	RXFP1	Relaxin receptor 1	preeclampsia	SERELAXIN	targetBased	2	Terminated	01/05/2013	https://clinicaltrials.gov/study/NCT01566630	0.2	GoF	protect	Novartis terminated this study due to internal, strategic decisions.
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	RXFP1	Relaxin receptor 1	preeclampsia	SERELAXIN	targetBased	2	Terminated	01/05/2013	https://clinicaltrials.gov/study/NCT01566630	0.2	GoF	protect	Novartis terminated this study due to internal, strategic decisions.
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	injury	FIBRINOGEN, HUMAN	targetBased	3	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01545635	0.35		protect	The Interim analysis (100 patients) revealed a possible harm to patients randomised to the fresh frozen plasma (FFP) treatment arm.
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	injury	FIBRINOGEN, HUMAN	targetBased	3	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01545635	0.35		protect	The Interim analysis (100 patients) revealed a possible harm to patients randomised to the fresh frozen plasma (FFP) treatment arm.
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	Shock	FIBRINOGEN, HUMAN	targetBased	3	Completed	26/09/2018	https://clinicaltrials.gov/study/NCT04149171	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	Shock	FIBRINOGEN, HUMAN	targetBased	3	Completed	26/09/2018	https://clinicaltrials.gov/study/NCT04149171	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	Aortic dissection	FIBRINOGEN, HUMAN	targetBased	2	Unknown status	01/07/2013	https://clinicaltrials.gov/study/NCT02542306	0.2		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	Aortic dissection	FIBRINOGEN, HUMAN	targetBased	2	Unknown status	01/07/2013	https://clinicaltrials.gov/study/NCT02542306	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	atrophic macular degeneration	GSK933776	pathwayBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01342926	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	atrophic macular degeneration	GSK933776	pathwayBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01342926	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	atrophic macular degeneration	GSK933776	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01342926	0.2		protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE	targetBased	3	Terminated	01/01/2009	https://clinicaltrials.gov/study/NCT00827008	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE	targetBased	2	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00405886	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00739635	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00772980	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	NERAMEXANE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00955799	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00370253	0.7		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02489864	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	3	Active, not recruiting	11/12/2020	https://clinicaltrials.gov/study/NCT04460560	0.7		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00089570	0.7		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	3	Completed	11/10/2010	https://clinicaltrials.gov/study/NCT01143246	0.7		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	hepatorenal syndrome	TERLIPRESSIN	targetBased	3	Completed	13/07/2016	https://clinicaltrials.gov/study/NCT02770716	0.7		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	kidney failure	TERLIPRESSIN	targetBased	2	Withdrawn	01/01/2020	https://clinicaltrials.gov/study/NCT02368249	0.2		protect	no focus on this topic
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Acute kidney injury	TERLIPRESSIN	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02059460	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Acute kidney injury	TERLIPRESSIN	targetBased	4	Recruiting	18/08/2023	https://clinicaltrials.gov/study/NCT06108362	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Renal insufficiency	TERLIPRESSIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	kidney disease	TERLIPRESSIN	targetBased	4	Recruiting	16/07/2019	https://clinicaltrials.gov/study/NCT04028323	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	liver failure	TERLIPRESSIN	targetBased	2	Terminated	01/11/2013	https://clinicaltrials.gov/study/NCT01921985	0.2		protect	Interim analysis revealed that no statistical difference will be identified after inclusion of the patient cohort as foreseen in the sample size calculation
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cycloplegia	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE SULFATE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE SULFATE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE SULFATE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE SULFATE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Headache	ATROPINE SULFATE	targetBased	4	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT03997006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE SULFATE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE SULFATE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE SULFATE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE SULFATE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	organophosphate poisoning	ATROPINE SULFATE	targetBased	2	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT04393103	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590a4e7b-565f-415f-a8e4-499a382c9a3b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e608aa-f552-4c49-bf12-7da0963c62b1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Mydriasis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	24/04/2019	https://clinicaltrials.gov/study/NCT03918915	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	21/04/2017	https://clinicaltrials.gov/study/NCT03140358	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Enrolling by invitation	08/05/2019	https://clinicaltrials.gov/study/NCT03949101	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05529056	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	2	Active, not recruiting	03/04/2019	https://clinicaltrials.gov/study/NCT03690089	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	13/05/2022	https://clinicaltrials.gov/study/NCT06209281	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT06209320	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT05357326	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	3	Recruiting	17/02/2020	https://clinicaltrials.gov/study/NCT04338373	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Myopia	ATROPINE SULFATE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03158142	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	xerostomia	CEVIMELINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0679dd4c-fece-4c6d-b273-2c62237e8973	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL OXALATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL OXALATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00600119	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00600119	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01309841	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01309841	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01323790	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01323790	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01395524	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01395524	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02946580	1	LoF	protect	Slow recruitment and inability to extend funding.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02946580	1	LoF	protect	Slow recruitment and inability to extend funding.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	2	Recruiting	06/11/2017	https://clinicaltrials.gov/study/NCT03316859	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	2	Recruiting	06/11/2017	https://clinicaltrials.gov/study/NCT03316859	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A06AH03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01336205	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01336205	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02977286	1	LoF	protect	Poor enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Terminated	01/01/2017	https://clinicaltrials.gov/study/NCT02977286	1	LoF	protect	Poor enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Terminated	01/06/2011	https://clinicaltrials.gov/study/NCT01384292	0.7	LoF	protect	The study was stopped early due to recruitment challenges
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Terminated	01/06/2011	https://clinicaltrials.gov/study/NCT01384292	0.7	LoF	protect	The study was stopped early due to recruitment challenges
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	2	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02745353	0.2	LoF	protect	Couldn't enough accrue patients
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	2	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02745353	0.2	LoF	protect	Couldn't enough accrue patients
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Withdrawn	01/05/2017	https://clinicaltrials.gov/study/NCT02705378	0.7	LoF	protect	PI left institution. Protocol never submitted to the IRB, no contract executed only Confidentiality Agreement, and study not done.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	3	Withdrawn	01/05/2017	https://clinicaltrials.gov/study/NCT02705378	0.7	LoF	protect	PI left institution. Protocol never submitted to the IRB, no contract executed only Confidentiality Agreement, and study not done.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT03523520	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Completed	23/12/2020	https://clinicaltrials.gov/study/NCT03523520	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALOXEGOL	targetBased	4	Completed	27/06/2018	https://clinicaltrials.gov/study/NCT05770960	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	CLOMIPHENE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT02638285	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	CLOMIPHENE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT02638285	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	CLOMIPHENE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01213147	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	CLOMIPHENE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01213147	1		protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE HYDROCHLORIDE	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01803646	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE HYDROCHLORIDE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00860808	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE HYDROCHLORIDE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT01934010	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE HYDROCHLORIDE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02040207	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE HYDROCHLORIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01270282	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Tinnitus	ESKETAMINE HYDROCHLORIDE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02040194	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		injury	ESKETAMINE HYDROCHLORIDE	targetBased	4	Withdrawn	01/10/2024	https://clinicaltrials.gov/study/NCT05180318	1	LoF	protect	No Participants Enrolled
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLSAMIDORPHAN	targetBased	2	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01382797	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLSAMIDORPHAN	targetBased	2	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01382797	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLSAMIDORPHAN	targetBased	2	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01100151	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	METHYLSAMIDORPHAN	targetBased	2	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01100151	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	OLICERIDINE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06411665	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post operative nausea and vomiting	OLICERIDINE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06411665	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE TOSYLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE TOSYLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	NALDEMEDINE TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	07/04/2013	https://clinicaltrials.gov/study/NCT01901328	0.7	LoF	protect	Sponsor decision due to lack of enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	07/04/2013	https://clinicaltrials.gov/study/NCT01901328	0.7	LoF	protect	Sponsor decision due to lack of enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	2	Completed	19/01/2011	https://clinicaltrials.gov/study/NCT01275755	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	2	Completed	19/01/2011	https://clinicaltrials.gov/study/NCT01275755	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	20/05/2013	https://clinicaltrials.gov/study/NCT01901302	0.7	LoF	protect	Sponsor decision due to lack of enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	20/05/2013	https://clinicaltrials.gov/study/NCT01901302	0.7	LoF	protect	Sponsor decision due to lack of enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	2	Completed	14/10/2010	https://clinicaltrials.gov/study/NCT01207427	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	2	Completed	14/10/2010	https://clinicaltrials.gov/study/NCT01207427	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	12/10/2012	https://clinicaltrials.gov/study/NCT01696643	0.7	LoF	protect	A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	12/10/2012	https://clinicaltrials.gov/study/NCT01696643	0.7	LoF	protect	A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	02/07/2013	https://clinicaltrials.gov/study/NCT01901341	0.7	LoF	protect	Due to difficulties with enrollment, the study was terminated early.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	BEVENOPRAN	targetBased	3	Terminated	02/07/2013	https://clinicaltrials.gov/study/NCT01901341	0.7	LoF	protect	Due to difficulties with enrollment, the study was terminated early.
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	2	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02268409	0.2	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	3	Completed	02/05/2016	https://clinicaltrials.gov/study/NCT02604433	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	2	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01749540	0.2	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	2	Recruiting	07/11/2019	https://clinicaltrials.gov/study/NCT04143724	0.2	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	2	Recruiting	17/10/2022	https://clinicaltrials.gov/study/NCT05567458	0.2	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	3	Recruiting	12/08/2019	https://clinicaltrials.gov/study/NCT04064060	0.7	LoF	protect
qHTS for Inhibitors of TGF-b	TGFB1	TGFB1	HSPC193, Mothers against decapentaplegic homolog 3	Beta-thalassemia	LUSPATERCEPT	pathwayBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	AXELOPRAN	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01401985	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	AXELOPRAN	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01401985	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	AXELOPRAN	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333540	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	AXELOPRAN	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333540	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	AXELOPRAN	targetBased	2	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01459926	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Constipation	AXELOPRAN	targetBased	2	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01459926	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	CLOMIPHENE CITRATE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01213147	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pregnancy	CLOMIPHENE CITRATE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01213147	1		protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	uveitis	FILGOTINIB	targetBased	2	Terminated	26/07/2017	https://clinicaltrials.gov/study/NCT03207815	0.2	LoF	protect	Development program terminated
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Sjogren syndrome	FILGOTINIB	targetBased	2	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT03100942	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	adverse effect	CARBETOCIN	targetBased	4	Enrolling by invitation	30/11/2021	https://clinicaltrials.gov/study/NCT05110482	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	severe pre-eclampsia	CARBETOCIN	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT02086994	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	CARBETOCIN	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02636816	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	CARBETOCIN	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00977769	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	CARBETOCIN	targetBased	4	Completed	02/04/2019	https://clinicaltrials.gov/study/NCT03899961	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pregnancy	CARBETOCIN	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02528136	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	alopecia areata	ETRASIMOD	targetBased	2	Completed	29/07/2020	https://clinicaltrials.gov/study/NCT04556734	0.2		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	alopecia areata	ETRASIMOD	targetBased	2	Completed	29/07/2020	https://clinicaltrials.gov/study/NCT04556734	0.2		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Pyoderma	ETRASIMOD	targetBased	2	Terminated	07/06/2017	https://clinicaltrials.gov/study/NCT03072953	0.2	GoF	protect	Terminated [Sponsor decision to terminate the study]
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	alopecia areata	ETRASIMOD	targetBased	2	Completed	29/07/2020	https://clinicaltrials.gov/study/NCT04556734	0.2	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	Pyoderma	ETRASIMOD	targetBased	2	Terminated	07/06/2017	https://clinicaltrials.gov/study/NCT03072953	0.2		protect	Terminated [Sponsor decision to terminate the study]
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	Pyoderma	ETRASIMOD	targetBased	2	Terminated	07/06/2017	https://clinicaltrials.gov/study/NCT03072953	0.2		protect	Terminated [Sponsor decision to terminate the study]
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs endothelial corneal dystrophy	RIPASUDIL	targetBased	4	Recruiting	06/12/2017	https://clinicaltrials.gov/study/NCT03249337	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs endothelial corneal dystrophy	RIPASUDIL	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05795699	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs endothelial corneal dystrophy	RIPASUDIL	targetBased	3	Recruiting	11/05/2023	https://clinicaltrials.gov/study/NCT05826353	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	corneal edema	RIPASUDIL	targetBased	3	Completed	04/08/2022	https://clinicaltrials.gov/study/NCT05528172	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs' endothelial dystrophy	RIPASUDIL	targetBased	3	Recruiting	23/01/2023	https://clinicaltrials.gov/study/NCT05275972	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs' endothelial dystrophy	RIPASUDIL	targetBased	2	Recruiting	25/03/2019	https://clinicaltrials.gov/study/NCT03813056	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	glaucoma	RIPASUDIL	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=S01EX07	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	VEROSUDIL	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902200	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	glaucoma	VEROSUDIL	targetBased	2	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02174991	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	glaucoma	VEROSUDIL	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01060579	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	eye disease	AMA0076	targetBased	2	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01693315	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	AMA0076	targetBased	2	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01693315	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	AMA0076	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02136940	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	glaucoma	AMA0076	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02136940	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	glaucoma	AMA0076	targetBased	2	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01693315	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	DE-104	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00656240	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	DE-104	targetBased	2	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00650338	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	DE-104	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00657579	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	DE-104	targetBased	2	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00650338	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	DE-104	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00656240	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	DE-104	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00657579	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	overactive bladder	AFACIFENACIN	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00409539	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth	FE 202767	targetBased	2	Terminated	28/05/2021	https://clinicaltrials.gov/study/NCT02545127	0.2	GoF	protect	The trial was prematurely terminated. Termination was not because of safety concerns but due to slow recruitment.
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Hot flashes	MF101	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00119665	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	UPADACITINIB	targetBased	3	Recruiting	11/10/2023	https://clinicaltrials.gov/study/NCT06012240	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Takayasu arteritis	UPADACITINIB	targetBased	3	Active, not recruiting	04/02/2020	https://clinicaltrials.gov/study/NCT04161898	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	temporal arteritis	UPADACITINIB	targetBased	3	Active, not recruiting	24/01/2019	https://clinicaltrials.gov/study/NCT03725202	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	hidradenitis suppurativa	UPADACITINIB	targetBased	3	Recruiting	21/06/2023	https://clinicaltrials.gov/study/NCT05889182	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	hidradenitis suppurativa	UPADACITINIB	targetBased	2	Completed	14/07/2020	https://clinicaltrials.gov/study/NCT04430855	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM BROMIDE	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT03836287	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	10/03/2015	https://clinicaltrials.gov/study/NCT02336503	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	3	Completed	04/12/2020	https://clinicaltrials.gov/study/NCT03948646	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	22/12/2016	https://clinicaltrials.gov/study/NCT03024255	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02682238	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	SOFPIRONIUM	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03785587	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Hyperhidrosis	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b985380-1256-4fb3-b89a-6df2c6a6d12e	1	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	glaucoma	OMIDENEPAG	targetBased	2			https://www.whocc.no/atc_ddd_index/?code=S01EX06	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	glaucoma	OMIDENEPAG	targetBased	2			https://www.whocc.no/atc_ddd_index/?code=S01EX06	0.2	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	dry eye syndrome	SYL-1001	targetBased	3	Completed	18/05/2017	https://clinicaltrials.gov/study/NCT03108664	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	dry eye syndrome	SYL-1001	targetBased	3	Completed	24/03/2022	https://clinicaltrials.gov/study/NCT05310422	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	dry eye syndrome	SYL-1001	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02455999	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	dry eye syndrome	SYL-1001	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04819269	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	seborrheic dermatitis	PAC-14028	targetBased	2	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02749383	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rosacea	PAC-14028	targetBased	2	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02052999	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rosacea	PAC-14028	targetBased	2	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02583009	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Pruritus	PAC-14028	targetBased	2	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02052531	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Pruritus	PAC-14028	targetBased	2	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02565134	0.2	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	premature birth	DOXAPRAM HYDROCHLORIDE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	premature birth	DOXAPRAM HYDROCHLORIDE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	HYDROCODONE BITARTRATE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	injury	HYDROCODONE BITARTRATE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	injury	HYDROCODONE BITARTRATE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818932	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus	DIFELIKEFALIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus	DIFELIKEFALIN	targetBased	2	Terminated	25/06/2019	https://clinicaltrials.gov/study/NCT03995212	0.2	GoF	protect	Slow enrollment due primarily to Covid-19
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus	DIFELIKEFALIN	targetBased	2	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04706975	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	chronic kidney disease	DIFELIKEFALIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	overweight body mass index status	LIRAGLUTIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	overweight body mass index status	LIRAGLUTIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	overweight body mass index status	LIRAGLUTIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Malabsorption	LIRAGLUTIDE	targetBased	4	Completed	07/03/2019	https://clinicaltrials.gov/study/NCT03955575	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Malabsorption	LIRAGLUTIDE	targetBased	4	Completed	07/03/2019	https://clinicaltrials.gov/study/NCT03955575	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Malabsorption	LIRAGLUTIDE	targetBased	4	Completed	07/03/2019	https://clinicaltrials.gov/study/NCT03955575	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Weight loss	LIRAGLUTIDE	targetBased	3	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT04325581	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Weight loss	LIRAGLUTIDE	targetBased	3	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT04325581	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Weight loss	LIRAGLUTIDE	targetBased	3	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT04325581	0.7	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Myelofibrosis	FEDRATINIB HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7	1	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Secretory diarrhea	IOWH-032	targetBased	2	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT02111304	0.2	LoF	protect	Trial was never initiated due to PATH executive decision.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Secretory diarrhea	IOWH-032	targetBased	2	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT02111304	0.2	LoF	protect	Trial was never initiated due to PATH executive decision.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	frontal fibrosing alopecia	DELGOCITINIB	targetBased	2	Completed	19/04/2022	https://clinicaltrials.gov/study/NCT05332366	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	alopecia areata	DELGOCITINIB	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02561585	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	3	Recruiting	05/09/2023	https://clinicaltrials.gov/study/NCT06004050	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	3	Completed	23/08/2021	https://clinicaltrials.gov/study/NCT04949841	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	3	Completed	10/05/2021	https://clinicaltrials.gov/study/NCT04871711	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	2	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02664805	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	2	Completed	28/11/2018	https://clinicaltrials.gov/study/NCT03683719	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04872101	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	3	Recruiting	14/07/2022	https://clinicaltrials.gov/study/NCT05355818	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Eczematoid dermatitis	DELGOCITINIB	targetBased	3	Completed	15/06/2022	https://clinicaltrials.gov/study/NCT05259722	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ELACESTRANT	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00875420	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ELACESTRANT	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00875420	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ELACESTRANT	targetBased	2	Terminated	01/12/2015	https://clinicaltrials.gov/study/NCT02653417	0.2	LoF	protect	Sponsor's Decision
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Hot flashes	ELACESTRANT	targetBased	2	Terminated	01/12/2015	https://clinicaltrials.gov/study/NCT02653417	0.2	LoF	protect	Sponsor's Decision
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	SAROGLITAZAR	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	SAROGLITAZAR	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	SAROGLITAZAR	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	SAROGLITAZAR	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	SAROGLITAZAR	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Hepatic steatosis	SAROGLITAZAR	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02265276	0.7	GoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01843530	0.7	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	2	Completed	02/06/2010	https://clinicaltrials.gov/study/NCT01095510	0.2	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze	1	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01467947	1	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	2	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04898309	0.2	LoF	protect	Company pipeline revision
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	2	Completed	07/06/2010	https://clinicaltrials.gov/study/NCT01095497	0.2	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	3	Completed	08/09/2016	https://clinicaltrials.gov/study/NCT02865720	0.7	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	3	Completed	20/03/2014	https://clinicaltrials.gov/study/NCT02052141	0.7	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=B06AC01	1	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=B06AC01	1	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01467947	1	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	2	Completed	07/06/2010	https://clinicaltrials.gov/study/NCT01095497	0.2	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze	1	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	3	Completed	20/03/2014	https://clinicaltrials.gov/study/NCT02052141	0.7	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	2	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04898309	0.2	LoF	protect	Company pipeline revision
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	2	Completed	02/06/2010	https://clinicaltrials.gov/study/NCT01095510	0.2	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	hereditary angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	3	Completed	08/09/2016	https://clinicaltrials.gov/study/NCT02865720	0.7	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	angioedema	HUMAN C1-ESTERASE INHIBITOR	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01843530	0.7	LoF	protect
qHTS assay for re-activators of p53 using a Luc reporter	TP53	TP53	Cellular tumor antigen p53, Cellular tumor antigen p53	Acute kidney injury	TEPRASIRAN	pathwayBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02610283	0.2	LoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	Acute kidney injury	TEPRASIRAN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02610283	0.2	LoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	Acute kidney injury	TEPRASIRAN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02610283	0.2	LoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	Acute kidney injury	TEPRASIRAN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02610283	0.2	LoF	protect
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	TP53	Cellular tumor antigen p53	Acute kidney injury	TEPRASIRAN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02610283	0.2	LoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	TRHR	Thyrotropin-releasing hormone receptor	Schnyder corneal dystrophy	ROVATIRELIN	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT01384435	0.2	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	TRHR	Thyrotropin-releasing hormone receptor	Schnyder corneal dystrophy	ROVATIRELIN	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT01384435	0.2	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	glaucoma	OMIDENEPAG ISOPROPYL	targetBased	3	Completed	27/09/2018	https://clinicaltrials.gov/study/NCT03697811	0.7	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	glaucoma	OMIDENEPAG ISOPROPYL	targetBased	3	Completed	27/09/2018	https://clinicaltrials.gov/study/NCT03697811	0.7	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	glaucoma	OMIDENEPAG ISOPROPYL	targetBased	2	Completed	28/01/2019	https://clinicaltrials.gov/study/NCT03858894	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	glaucoma	OMIDENEPAG ISOPROPYL	targetBased	2	Completed	28/01/2019	https://clinicaltrials.gov/study/NCT03858894	0.2	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	ocular hypertension	OMIDENEPAG ISOPROPYL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	ocular hypertension	OMIDENEPAG ISOPROPYL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	open-angle glaucoma	OMIDENEPAG ISOPROPYL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	open-angle glaucoma	OMIDENEPAG ISOPROPYL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic kidney disease	TIRZEPATIDE	targetBased	2	Recruiting	08/02/2023	https://clinicaltrials.gov/study/NCT05536804	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic kidney disease	TIRZEPATIDE	targetBased	2	Recruiting	08/02/2023	https://clinicaltrials.gov/study/NCT05536804	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic kidney disease	TIRZEPATIDE	targetBased	2	Recruiting	08/02/2023	https://clinicaltrials.gov/study/NCT05536804	0.2	GoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	progressive supranuclear palsy	TILAVONEMAB	pathwayBased	2	Terminated	24/01/2018	https://clinicaltrials.gov/study/NCT03391765	0.2	LoF	protect	This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.
qHTS Assay for Tau Filament Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	progressive supranuclear palsy	TILAVONEMAB	targetBased	2	Terminated	24/01/2018	https://clinicaltrials.gov/study/NCT03391765	0.2	LoF	protect	This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	progressive supranuclear palsy	TILAVONEMAB	pathwayBased	2	Terminated	24/01/2018	https://clinicaltrials.gov/study/NCT03391765	0.2	LoF	protect	This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Fever	ZICONOTIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02BG08	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	NETARSUDIL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	NETARSUDIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d4f0e3a-5b86-4c43-982a-813b22ae7e22	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	NETARSUDIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1d71f41-be06-4a08-94d4-e352198f09c2	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs endothelial corneal dystrophy	NETARSUDIL	targetBased	3	Completed	05/09/2017	https://clinicaltrials.gov/study/NCT03248037	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	corneal edema	NETARSUDIL	targetBased	2	Completed	17/09/2020	https://clinicaltrials.gov/study/NCT04498169	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	NETARSUDIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d4f0e3a-5b86-4c43-982a-813b22ae7e22	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	NETARSUDIL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	NETARSUDIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1d71f41-be06-4a08-94d4-e352198f09c2	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs' endothelial dystrophy	NETARSUDIL	targetBased	2	Completed	05/08/2019	https://clinicaltrials.gov/study/NCT04051463	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	glaucoma	NETARSUDIL	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=S01EX05	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	NETARSUDIL DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d4f0e3a-5b86-4c43-982a-813b22ae7e22	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	NETARSUDIL DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1d71f41-be06-4a08-94d4-e352198f09c2	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	open-angle glaucoma	NETARSUDIL DIMESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	NETARSUDIL DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d4f0e3a-5b86-4c43-982a-813b22ae7e22	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	NETARSUDIL DIMESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	ocular hypertension	NETARSUDIL DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1d71f41-be06-4a08-94d4-e352198f09c2	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dermatitis	GUSACITINIB	targetBased	2	Completed	03/01/2019	https://clinicaltrials.gov/study/NCT03728504	0.2	LoF	protect
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	LDHA	lactate dehydrogenase	primary hyperoxaluria	NEDOSIRAN SODIUM	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf	1	LoF	protect
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	LDHA	lactate dehydrogenase	primary hyperoxaluria type 2	NEDOSIRAN SODIUM	targetBased	2	Completed	28/10/2019	https://clinicaltrials.gov/study/NCT03847909	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Fuchs' endothelial dystrophy	RIPASUDIL HYDROCHLORIDE DIHYDRATE	targetBased	2	Recruiting	25/03/2019	https://clinicaltrials.gov/study/NCT03813056	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	hidradenitis suppurativa	LUTIKIZUMAB	pathwayBased	3	Recruiting	27/06/2024	https://clinicaltrials.gov/study/NCT06468228	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	hidradenitis suppurativa	LUTIKIZUMAB	pathwayBased	2	Recruiting	28/12/2021	https://clinicaltrials.gov/study/NCT05139602	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature birth		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tractocile	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Pruritus		targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	chronic kidney disease		targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Impotence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/uprima	1	GoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.